{"meta":{"query_hash":"a3fa8339d393","filters":{"venue":"International Clinical Psychopharmacology"},"cohort_total":107,"direct_labels_cover":0,"predictions_cover":107,"exported":107,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a3fa8339d393","api":"https://metacan.xera.ac/api/v1/cohort?venue=International+Clinical+Psychopharmacology"},"results":[{"id":"W1601971109","doi":"10.1097/yic.0b013e3283597678","title":"Adherence to escitalopram treatment in depression","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"National Institute of Mental Health","keywords":"Escitalopram; Dosing; Discontinuation; Regimen; Interpersonal psychotherapy; Pharmacotherapy; Depression (economics); Medicine; Psychiatry; Citalopram; Pill; Psychology; Internal medicine; Randomized controlled trial; Pharmacology; Anxiety; Antidepressant","score_opus":0.09389593227981391,"score_gpt":0.5073609288943141,"score_spread":0.41346499661450015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1601971109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965724,0.0021057853,0.00013414143,0.00026521177,0.00001073485,0.000018445704,0.00007853758,0.000003165116,0.0008115999],"genre_scores_gemma":[0.99873585,0.00075620203,0.00014242083,0.00009397978,0.000016280806,0.000010656491,0.000075575685,0.0000010240798,0.00016804448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984602,0.0005482679,0.00024092702,0.000098259974,0.0005254166,0.00012700746],"domain_scores_gemma":[0.9972314,0.0007514277,0.0014559842,0.00008677846,0.00026771004,0.00020663407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013776171,0.00009516222,0.00033653562,0.00043369085,0.0003970891,0.00044724785,0.00019885978,0.00041998268,0.0009073301],"category_scores_gemma":[0.0072354693,0.00014675867,0.00031590217,0.00066774455,0.0001326495,0.00027478326,0.00029782896,0.0005253344,0.00011867407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015777843,0.00016556244,0.9618753,0.00006814104,0.00010563245,0.00008791495,0.00028672363,0.00005133901,0.0001707295,0.00003112423,0.0001998739,0.03679984],"study_design_scores_gemma":[0.0000065247273,0.00016466365,0.99896824,0.000034197008,0.000027947593,0.00020939678,0.00011987216,0.00018015943,0.00003852184,0.00004097724,0.00020687297,0.0000026318573],"about_ca_topic_score_codex":0.004493388,"about_ca_topic_score_gemma":0.006156381,"teacher_disagreement_score":0.004493388,"about_ca_system_score_codex":0.0003936546,"about_ca_system_score_gemma":0.0003189803,"threshold_uncertainty_score":0.008934438},"labels":[],"label_agreement":null},{"id":"W1969712323","doi":"10.1097/yic.0b013e32830cebed","title":"Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial","year":2008,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Tolerability; Placebo; Internal medicine; Hamilton Anxiety Rating Scale; Major depressive disorder; Nausea; Medicine; Hamilton Rating Scale for Depression; Adverse effect; Population; Psychiatry; Anxiety","score_opus":0.04528260503552192,"score_gpt":0.4316187127020481,"score_spread":0.38633610766652615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969712323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859037,0.008684963,0.000791453,0.00038170617,0.00036274706,0.0021425716,0.000489801,0.00010832359,0.001134748],"genre_scores_gemma":[0.98813754,0.0042724838,0.001858517,0.0007731509,0.00038783927,0.0025483207,0.0005474694,0.000017068882,0.0014576709],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99913675,0.0005062453,0.00008241017,0.00012111259,0.00007978523,0.000073700096],"domain_scores_gemma":[0.99936813,0.00022404887,0.00016767369,0.000043873857,0.000045063345,0.00015135897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022488846,0.0008867254,0.002659129,0.00041748647,0.00037198162,0.0007273473,0.00081027765,0.0014622716,0.003539882],"category_scores_gemma":[0.0017988544,0.0005461567,0.0012934641,0.00032439968,0.00070611545,0.0005400376,0.00019893012,0.0013973196,0.00045382572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.958933,0.0062235342,0.0006790504,0.0008853836,0.0010376102,0.000059277525,0.000036402573,0.00024141964,0.0076028244,0.000092710834,0.00041323644,0.023795461],"study_design_scores_gemma":[0.92682105,0.06904032,0.0024311417,0.00003657091,0.0003716225,0.00004141621,0.000012333651,0.00025121437,0.00051011285,0.000058384943,0.0004143717,0.00001144883],"about_ca_topic_score_codex":0.00042864258,"about_ca_topic_score_gemma":0.0012851041,"teacher_disagreement_score":0.003539882,"about_ca_system_score_codex":0.0005067028,"about_ca_system_score_gemma":0.0006334734,"threshold_uncertainty_score":0.011893392},"labels":[],"label_agreement":null},{"id":"W1971130967","doi":"10.1097/yic.0b013e3281c61b28","title":"Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting","year":2007,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Discontinuation; Encephalopathy; Medicine; Adverse effect; Pediatrics; Urea cycle; Psychiatry; Delirium; Internal medicine","score_opus":0.22630111614812712,"score_gpt":0.5704658701246423,"score_spread":0.34416475397651525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971130967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018219503,0.99724555,0.000068615605,0.00009827738,0.00006358161,0.000021148591,0.000050912357,0.00000812124,0.00062183803],"genre_scores_gemma":[0.007068081,0.9921644,0.00025373738,0.00015402329,0.00007562981,0.000020755855,0.00008242998,0.0000021836468,0.00017883514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99934596,0.00010768449,0.00031609842,0.00006511518,0.00012830862,0.000036925227],"domain_scores_gemma":[0.99891996,0.0005546335,0.00030258027,0.000029086805,0.0001486939,0.000045029217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006033145,0.0010152062,0.0017908564,0.007402229,0.00040297338,0.00070715055,0.0010383846,0.0008507886,0.0031363487],"category_scores_gemma":[0.0016964951,0.00037201497,0.00093885866,0.009183635,0.00041785557,0.0012484542,0.00054592226,0.00036479416,0.00079344324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002817947,0.00013106756,0.00583093,0.20615944,0.001168783,0.02535568,0.0007485325,0.00030595466,0.0024881246,0.00050419517,0.016712517,0.740313],"study_design_scores_gemma":[0.000285299,0.0010691277,0.05999623,0.15284374,0.010840834,0.24007116,0.0026111924,0.00035391175,0.0036331487,0.0013895454,0.5267317,0.00017418692],"about_ca_topic_score_codex":0.0019070731,"about_ca_topic_score_gemma":0.0038988502,"teacher_disagreement_score":0.007402229,"about_ca_system_score_codex":0.00063621363,"about_ca_system_score_gemma":0.0017974499,"threshold_uncertainty_score":0.010492086},"labels":[],"label_agreement":null},{"id":"W1977708183","doi":"10.1097/01.yic.0000137184.64610.c8","title":"Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study","year":2004,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Discontinuation; Agomelatine; Paroxetine; Placebo; Medicine; Double blind; Randomized controlled trial; Internal medicine; Psychiatry; Psychology; Antidepressant; Alternative medicine; Anxiety","score_opus":0.029635700189344815,"score_gpt":0.40005410824838994,"score_spread":0.37041840805904513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977708183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344796,0.0027281607,0.00049645774,0.00019180351,0.0002009016,0.0019387085,0.00037844802,0.000074515796,0.000542969],"genre_scores_gemma":[0.99149674,0.0021978335,0.001122907,0.0003547741,0.0004447997,0.003021769,0.00046092892,0.00001318822,0.0008870638],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99882156,0.00063157623,0.0001144078,0.0001706545,0.00013043285,0.00013142238],"domain_scores_gemma":[0.99813914,0.0005643074,0.00051216176,0.000192265,0.0001119687,0.00048013811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002073417,0.0012933933,0.0036591128,0.0005417446,0.0005590783,0.00071981695,0.0009965915,0.0023419522,0.0033156183],"category_scores_gemma":[0.0022478697,0.0008288477,0.0018428487,0.00049627357,0.00115751,0.0006602734,0.0003114681,0.0016982332,0.00046594976],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.969785,0.012290156,0.0008399822,0.00042241774,0.0007222902,0.000035313715,0.0000409699,0.00008538249,0.0046429234,0.000030955744,0.00017343026,0.010931242],"study_design_scores_gemma":[0.8732772,0.120703734,0.004406168,0.000017881923,0.0005186252,0.00004323146,0.000011341029,0.00020658947,0.0004993902,0.000043214764,0.00025944787,0.000013229689],"about_ca_topic_score_codex":0.00054414483,"about_ca_topic_score_gemma":0.0009230478,"teacher_disagreement_score":0.0036591128,"about_ca_system_score_codex":0.00043724332,"about_ca_system_score_gemma":0.00094286026,"threshold_uncertainty_score":0.011091888},"labels":[],"label_agreement":null},{"id":"W1979180758","doi":"10.1097/yic.0b013e328314e2cb","title":"Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75–225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study","year":2008,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Center for Advancing Translational Sciences; National Institute of Mental Health","keywords":"Venlafaxine; Placebo; Major depressive disorder; Venlafaxine Hydrochloride; Medicine; Internal medicine; Population; Maintenance therapy; Depression (economics); Randomized controlled trial; Fluoxetine; Antidepressant; Chemotherapy","score_opus":0.07622204376022716,"score_gpt":0.45497734628346664,"score_spread":0.37875530252323947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979180758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956462,0.0029863913,0.00012360352,0.000075287506,0.000044044922,0.00020957601,0.000353752,0.000021116908,0.00054001674],"genre_scores_gemma":[0.9972915,0.00081136334,0.00026567234,0.00012428856,0.00011709661,0.00024279345,0.00077541755,0.0000037550221,0.00036807873],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986833,0.00079348346,0.0001230798,0.00016050949,0.00014063342,0.000098990626],"domain_scores_gemma":[0.9969848,0.0008711929,0.0012363751,0.00029230994,0.000215936,0.0003993624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027939912,0.00058645505,0.0031655652,0.00034835344,0.00030791742,0.0005571579,0.00053961616,0.00087428145,0.0013218403],"category_scores_gemma":[0.0029408657,0.00031852568,0.0021699993,0.0002882072,0.0002711766,0.00044817693,0.00031482012,0.0009568371,0.0002531554],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8473424,0.008485617,0.060935624,0.0011197051,0.0070021907,0.00016449719,0.00016200513,0.0009843569,0.0063284137,0.000082754384,0.00077981094,0.066612616],"study_design_scores_gemma":[0.22038406,0.35545388,0.41035876,0.00014109148,0.0070780194,0.0003322877,0.000117104275,0.002086898,0.0015082955,0.00012447746,0.0023414067,0.00007367644],"about_ca_topic_score_codex":0.0007869956,"about_ca_topic_score_gemma":0.0021032777,"teacher_disagreement_score":0.0031655652,"about_ca_system_score_codex":0.0004011543,"about_ca_system_score_gemma":0.00054543046,"threshold_uncertainty_score":0.01477623},"labels":[],"label_agreement":null},{"id":"W1979879412","doi":"10.1097/00004850-200607000-00034","title":"The Japanese version of the Screen for Cognitive Impairment in Psychiatry: a preliminary study","year":2006,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cognitive impairment; Psychiatry; Medicine; Psychology; Cognition","score_opus":0.02794339153818813,"score_gpt":0.4520431467233027,"score_spread":0.42409975518511456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979879412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617959,0.0029582607,0.0013262285,0.0011383949,0.00042188293,0.002589132,0.013916456,0.000049674152,0.01580403],"genre_scores_gemma":[0.9439806,0.003729787,0.013442371,0.0011217064,0.00037442797,0.004041432,0.016395357,0.00008464771,0.016829716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988514,0.0003078234,0.00029928563,0.00013322658,0.00032598598,0.000082266124],"domain_scores_gemma":[0.99633884,0.0006418424,0.0004919684,0.00025445555,0.0018267934,0.00044610022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023297223,0.00060791255,0.00095875753,0.0018028473,0.0011863484,0.0009137017,0.0007076902,0.00046979013,0.0041235336],"category_scores_gemma":[0.005974222,0.00036586475,0.0008361791,0.0016765408,0.00023523133,0.00055782,0.0007961122,0.0007576816,0.001101205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031432412,0.0015380166,0.87014925,0.0008899074,0.00062361296,0.0008217216,0.0050891936,0.00026566652,0.0022003993,0.00038531687,0.016860545,0.09803306],"study_design_scores_gemma":[0.00026154463,0.00048042633,0.9918023,0.00006759247,0.000304647,0.00045297435,0.0010508111,0.00018664837,0.00020337671,0.00012082801,0.005041958,0.000026840107],"about_ca_topic_score_codex":0.03124438,"about_ca_topic_score_gemma":0.050685782,"teacher_disagreement_score":0.03124438,"about_ca_system_score_codex":0.0006742799,"about_ca_system_score_gemma":0.0014352273,"threshold_uncertainty_score":0.062125027},"labels":[],"label_agreement":null},{"id":"W1979892910","doi":"10.1097/yic.0b013e3282ffdedc","title":"Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials","year":2008,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Escitalopram; Duloxetine; Duloxetine Hydrochloride; Tolerability; Venlafaxine; Internal medicine; Major depressive disorder; Reuptake inhibitor; Randomized controlled trial; Medicine; Psychology; Psychiatry; Adverse effect; Anesthesia; Antidepressant","score_opus":0.089783870356015,"score_gpt":0.4951104557882556,"score_spread":0.4053265854322406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979892910","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040332597,0.95513076,0.0007769034,0.00045655423,0.00048015424,0.000901998,0.0010208942,0.000066171946,0.0008339624],"genre_scores_gemma":[0.5162057,0.47078788,0.0034190328,0.0019882794,0.0009152389,0.0032841268,0.0021793372,0.000058255213,0.0011621768],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9895069,0.0059897085,0.002294737,0.00094207213,0.0009255894,0.00034098641],"domain_scores_gemma":[0.990886,0.004767087,0.002983925,0.0003567874,0.0007328878,0.00027339463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009772288,0.0021467826,0.012992523,0.0029042235,0.0003379572,0.0028474622,0.00093254977,0.0025120692,0.002947439],"category_scores_gemma":[0.017762037,0.0011247204,0.018248878,0.0037253224,0.0006199347,0.0010511796,0.001125771,0.0014278425,0.0002938916],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11310679,0.00014899689,0.0038740009,0.12839143,0.7136042,0.00019712148,0.000102466394,0.0007479352,0.00088303204,0.00015214321,0.0016295135,0.037162356],"study_design_scores_gemma":[0.076378055,0.0029777493,0.013641864,0.010007402,0.89228153,0.0002447628,0.00009728651,0.00045081563,0.00034289196,0.00031095213,0.003200987,0.00006571908],"about_ca_topic_score_codex":0.0030561585,"about_ca_topic_score_gemma":0.0064894003,"teacher_disagreement_score":0.012992523,"about_ca_system_score_codex":0.0018665937,"about_ca_system_score_gemma":0.0018096839,"threshold_uncertainty_score":0.0516814},"labels":[],"label_agreement":null},{"id":"W1985243621","doi":"10.1097/01.yic.0000080803.87368.01","title":"Migraine headache prophylaxis and treatment with low-dose mirtazapine","year":2003,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Mirtazapine; Migraine; Medicine; Migraine Disorders; Anesthesia; Psychiatry; Antidepressant","score_opus":0.053906987452666984,"score_gpt":0.436928140555989,"score_spread":0.383021153103322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985243621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90339977,0.04767892,0.0017797359,0.005060911,0.00051558885,0.00045771565,0.00034021382,0.00015483382,0.04061223],"genre_scores_gemma":[0.9883586,0.005428307,0.00089658774,0.0016810131,0.00048155952,0.00007928032,0.000288935,0.000011664542,0.0027740446],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995135,0.00015001338,0.00007707938,0.000047174504,0.00014521558,0.000067014356],"domain_scores_gemma":[0.9992137,0.00021318911,0.00027895035,0.0000707923,0.00006235917,0.00016095168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037793705,0.00027059342,0.0005780937,0.00046189965,0.0005903423,0.00027920696,0.0003845407,0.0012189599,0.00158139],"category_scores_gemma":[0.0040314593,0.00012526117,0.00046892132,0.00039788202,0.00029631736,0.00028944056,0.00024905792,0.0013430491,0.00032032974],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020579448,0.004210081,0.2133019,0.0021950614,0.0010145941,0.058997978,0.00075318647,0.000383309,0.07335734,0.0036710822,0.0081597,0.6133764],"study_design_scores_gemma":[0.0022798548,0.014705075,0.8093414,0.00037705567,0.00065227144,0.11575547,0.00021364052,0.00063328334,0.011109727,0.0016605955,0.04319826,0.000073455805],"about_ca_topic_score_codex":0.0011415303,"about_ca_topic_score_gemma":0.002327489,"teacher_disagreement_score":0.00158139,"about_ca_system_score_codex":0.0005656659,"about_ca_system_score_gemma":0.0005789144,"threshold_uncertainty_score":0.0052903295},"labels":[],"label_agreement":null},{"id":"W1986626492","doi":"10.1097/yic.0b013e32834309fc","title":"A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder","year":2010,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); Centre Hospitalier de l’Université de Montréal; University Health Network; Hôpital Saint-Luc; University of Toronto","funders":"","keywords":"Sildenafil; Erectile dysfunction; Placebo; Depression (economics); Multicenter study; Medicine; Internal medicine; Depressive symptoms; Double blind; Psychiatry; Randomized controlled trial; Anxiety; Pathology","score_opus":0.030563976504769157,"score_gpt":0.3953721313042803,"score_spread":0.3648081547995111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986626492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98905843,0.0040119584,0.00032564413,0.0006135375,0.0002962796,0.0025290134,0.0010741128,0.000083282765,0.0020076479],"genre_scores_gemma":[0.9859158,0.00334795,0.0018133668,0.0010418057,0.00041003668,0.0019270264,0.0012828527,0.0000138262785,0.004247295],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991697,0.00030151423,0.000045550893,0.00011745181,0.00017294455,0.00019296081],"domain_scores_gemma":[0.998917,0.00013664959,0.00015588009,0.000048142116,0.00017746534,0.000564951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014766494,0.0015124219,0.0024002027,0.0004385877,0.001477174,0.0005641163,0.0009872311,0.0015537589,0.0058436412],"category_scores_gemma":[0.0017033216,0.0008385665,0.0009512474,0.000790807,0.0016616851,0.0004911082,0.00031970275,0.0014585332,0.0005054416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9227397,0.02425145,0.0037892475,0.000934629,0.0010483802,0.00009184937,0.0003065733,0.00019804906,0.0106725255,0.00010608297,0.0018533259,0.034008134],"study_design_scores_gemma":[0.77894825,0.16061036,0.05420071,0.000040773557,0.001267861,0.00008696957,0.00010958039,0.00053850544,0.0013714089,0.00007340031,0.00268738,0.00006481868],"about_ca_topic_score_codex":0.15698388,"about_ca_topic_score_gemma":0.2859002,"teacher_disagreement_score":0.84301615,"about_ca_system_score_codex":0.003394784,"about_ca_system_score_gemma":0.009880107,"threshold_uncertainty_score":0.3121403},"labels":[],"label_agreement":null},{"id":"W1986838837","doi":"10.1097/01.yic.0000139342.22133.77","title":"Evidence based review of escitalopram in treating major depressive disorder in primary care","year":2004,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"H. Lundbeck A/S","keywords":"Escitalopram; Citalopram; Placebo; Venlafaxine; Major depressive disorder; Medicine; Internal medicine; Randomized controlled trial; Depression (economics); Meta-analysis; Psychiatry; Adverse effect; Psychology; Antidepressant","score_opus":0.11029778439425995,"score_gpt":0.5137643946306977,"score_spread":0.4034666102364377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986838837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045004746,0.99870455,0.000052303443,0.00018554679,0.00008839596,0.00015501432,0.00010630463,0.000003723515,0.00025411474],"genre_scores_gemma":[0.0067624,0.99174225,0.00049919385,0.00048171234,0.000088514855,0.00021272668,0.00012147033,0.0000021761,0.00008960873],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.995436,0.0017537659,0.0016684624,0.00024024678,0.0007959933,0.00010552119],"domain_scores_gemma":[0.9881605,0.007792953,0.0023468917,0.00011382097,0.001350024,0.00023571572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051346496,0.0011934208,0.006885101,0.0072077233,0.0005320911,0.0024537467,0.0019678702,0.0019355501,0.0059939628],"category_scores_gemma":[0.016867269,0.0007506501,0.0046319976,0.008626988,0.0005186121,0.0011879213,0.00088351045,0.001079177,0.00041009937],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005469605,0.00004898856,0.00030572218,0.92045087,0.008305483,0.00011459674,0.00008861812,0.00010348165,0.00019787515,0.00017200022,0.0019982036,0.06766738],"study_design_scores_gemma":[0.0011886188,0.0009148912,0.0048337243,0.8612212,0.09027119,0.0005193005,0.0001947351,0.00017565189,0.00026924413,0.00029995048,0.04007469,0.00003671635],"about_ca_topic_score_codex":0.0060639535,"about_ca_topic_score_gemma":0.02071957,"teacher_disagreement_score":0.0072077233,"about_ca_system_score_codex":0.0028211651,"about_ca_system_score_gemma":0.006273968,"threshold_uncertainty_score":0.027154982},"labels":[],"label_agreement":null},{"id":"W1988500223","doi":"10.1097/00004850-200307000-00005","title":"Risperidone in acute and continuation treatment of mania","year":2003,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of British Columbia; McGill University","funders":"","keywords":"Young Mania Rating Scale; Risperidone; Mania; Mood stabilizer; Internal medicine; Bipolar disorder; Bipolar I disorder; Psychology; Randomized controlled trial; Psychiatry; Mood; Medicine; Hamilton Rating Scale for Depression; Antipsychotic; Extrapyramidal symptoms; Brief Psychiatric Rating Scale; Psychosis; Schizophrenia (object-oriented programming); Major depressive disorder","score_opus":0.0442284188970842,"score_gpt":0.45578171978774457,"score_spread":0.4115533008906604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988500223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968779,0.0024852306,0.00007449193,0.00003376041,0.000018931698,0.0000840814,0.000065520515,0.000013920513,0.0003461155],"genre_scores_gemma":[0.998103,0.00084908755,0.00032620277,0.00010410607,0.00005525368,0.000081905484,0.00022650119,0.0000033460021,0.00025060592],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99919075,0.0003668513,0.000084790336,0.00009427903,0.00016793338,0.00009534106],"domain_scores_gemma":[0.997881,0.00049154717,0.0008140315,0.000143813,0.00013506245,0.00053454627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016239733,0.00042283363,0.001129507,0.00030106265,0.0003949156,0.0007899156,0.00038487554,0.00064724096,0.0010704206],"category_scores_gemma":[0.0029380834,0.00037553953,0.0008216121,0.00029822532,0.00026237988,0.0004162486,0.00025219805,0.0011232948,0.00028352387],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19821641,0.030294904,0.48183486,0.0009077053,0.0027532384,0.0013347367,0.0010204845,0.000504411,0.018321862,0.00016464287,0.00078099006,0.2638658],"study_design_scores_gemma":[0.026903367,0.27990752,0.68257564,0.00017934297,0.00132718,0.0021772806,0.00029615662,0.0012586176,0.0023356217,0.00012139317,0.0028569486,0.0000609712],"about_ca_topic_score_codex":0.00065526273,"about_ca_topic_score_gemma":0.0017950048,"teacher_disagreement_score":0.0016239733,"about_ca_system_score_codex":0.00041884303,"about_ca_system_score_gemma":0.00046937747,"threshold_uncertainty_score":0.008588493},"labels":[],"label_agreement":null},{"id":"W1991193159","doi":"10.1097/01.yic.0000224782.83287.3c","title":"Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?","year":2006,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Duloxetine; Fibromyalgia; Antidepressant; Analgesic; Placebo; Medicine; Major depressive disorder; Anesthesia; Neuropathic pain; Chronic pain; Duloxetine Hydrochloride; Psychology; Internal medicine; Psychiatry; Anxiety; Mood","score_opus":0.08980493269877934,"score_gpt":0.5331173373544522,"score_spread":0.4433124046556729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991193159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016287358,0.99844295,0.000037455673,0.00046603428,0.00014959583,0.0000042519227,0.000009741643,0.0000030054302,0.00072406424],"genre_scores_gemma":[0.0023819313,0.9959294,0.00013205223,0.00074642035,0.00033441855,0.00001039338,0.000014275138,0.0000011413496,0.0004498111],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99967384,0.00006924048,0.000063221545,0.00004785621,0.000121283716,0.000024476525],"domain_scores_gemma":[0.9995741,0.00026158197,0.00008202534,0.000010070999,0.000053804975,0.000018418048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062759046,0.0007199473,0.0033342582,0.0013257476,0.0002720952,0.0010430923,0.000951668,0.0017881553,0.0039322777],"category_scores_gemma":[0.0011090979,0.00026957886,0.000586074,0.0016968732,0.0008050132,0.0011917555,0.00033617773,0.0011636224,0.0009820047],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026097143,0.000048907208,0.00030135873,0.04832756,0.00029871057,0.00049480953,0.00013895055,0.00009058134,0.0021574777,0.0033460506,0.01742769,0.9271069],"study_design_scores_gemma":[0.0005268317,0.00085602497,0.010022564,0.055582445,0.0018720223,0.010458139,0.0007229103,0.00028200238,0.0022645132,0.007637148,0.9096889,0.00008653341],"about_ca_topic_score_codex":0.0018319888,"about_ca_topic_score_gemma":0.0044688066,"teacher_disagreement_score":0.0039322777,"about_ca_system_score_codex":0.00066746713,"about_ca_system_score_gemma":0.0008753325,"threshold_uncertainty_score":0.013154745},"labels":[],"label_agreement":null},{"id":"W1991997150","doi":"10.1097/00004850-200211000-00009","title":"Dysphoric mania induced by high-dose mirtazapine: a case for ???norepinephrine syndrome????","year":2002,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Mirtazapine; Mania; Norepinephrine; Serotonin syndrome; Medicine; Anesthesia; Bipolar disorder; Internal medicine; Psychiatry; Serotonin; Antidepressant; Receptor; Dopamine; Serotonergic; Anxiety; Lithium (medication)","score_opus":0.06827330872237859,"score_gpt":0.4393751703315637,"score_spread":0.3711018616091851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991997150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871106,0.0021977401,0.0011396001,0.000867347,0.00010798163,0.00007592474,0.000050733634,0.00007879744,0.0067709484],"genre_scores_gemma":[0.99807644,0.00051549345,0.00034822035,0.0004711913,0.00010916197,0.000006950834,0.000022870074,0.000004835736,0.00044490618],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99977225,0.000043258948,0.000039697436,0.00002733063,0.000043589505,0.00007387079],"domain_scores_gemma":[0.9995461,0.00012659651,0.00015599834,0.00003827117,0.000029758326,0.000103280334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017876511,0.0007261515,0.0005560004,0.0011794419,0.0008882521,0.00041094568,0.00038010333,0.0013938752,0.0014396809],"category_scores_gemma":[0.0015380409,0.000453606,0.00046150864,0.0006264467,0.0007590475,0.00058740244,0.00047523918,0.00082604744,0.00040056126],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013531299,0.000047605077,0.030969888,0.00006516095,0.00003078646,0.9583597,0.00033761017,0.000029770019,0.0050176536,0.00023490775,0.00024536738,0.0045261756],"study_design_scores_gemma":[0.000020073041,0.00015311386,0.03507029,0.000013530257,0.000023829916,0.9631084,0.00015576446,0.00012362131,0.0007045682,0.00012607384,0.00049085997,0.000009853043],"about_ca_topic_score_codex":0.0012048543,"about_ca_topic_score_gemma":0.002610881,"teacher_disagreement_score":0.0014396809,"about_ca_system_score_codex":0.00037205787,"about_ca_system_score_gemma":0.00028356686,"threshold_uncertainty_score":0.004816234},"labels":[],"label_agreement":null},{"id":"W1992547531","doi":"10.1097/01.yic.0000277959.60604.d1","title":"High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder","year":2007,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"VGH and UBC Hospital Foundation","keywords":"Depression (economics); Medicine; Psychosocial; Quality of life (healthcare); Internal medicine; Sexual dysfunction; Psychology; Psychiatry","score_opus":0.08221312398091613,"score_gpt":0.47471126675328484,"score_spread":0.3924981427723687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992547531","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031030618,0.99875,0.00005406442,0.00019292261,0.000057045167,0.000004361681,0.00000748197,0.0000059095996,0.00061791315],"genre_scores_gemma":[0.00236909,0.9966821,0.00021482553,0.0001943276,0.000089122346,0.000008797813,0.000021411915,0.0000011296244,0.00041913718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998852,0.000037029597,0.000019716525,0.000015264604,0.00003283517,0.000010098065],"domain_scores_gemma":[0.9998627,0.000069012385,0.000031288313,0.0000035239457,0.000020236597,0.000013144341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004656849,0.00054196926,0.0012286935,0.0009880983,0.0001802647,0.00054450566,0.000721119,0.0008292142,0.0025527864],"category_scores_gemma":[0.00055356533,0.00017079542,0.00048345124,0.001034279,0.00021950922,0.00057381403,0.00031522108,0.0008419509,0.000904529],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022630909,0.00009483127,0.00025601705,0.01855094,0.00018316932,0.00027129106,0.000049696915,0.00012818734,0.0010943984,0.0007989833,0.0112816105,0.9670647],"study_design_scores_gemma":[0.00055932783,0.00082702487,0.010903223,0.015501573,0.00094044296,0.007810596,0.00023015971,0.00034208898,0.0011057337,0.002332872,0.95939827,0.00004866381],"about_ca_topic_score_codex":0.0007916851,"about_ca_topic_score_gemma":0.0032316644,"teacher_disagreement_score":0.0025527864,"about_ca_system_score_codex":0.0003002715,"about_ca_system_score_gemma":0.00045476848,"threshold_uncertainty_score":0.008539915},"labels":[],"label_agreement":null},{"id":"W1993305638","doi":"10.1097/yic.0b013e328013f89d","title":"Lamotrigine in the treatment of recurrent brief depression","year":2007,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Lamotrigine; Venlafaxine; Depression (economics); Suicidal ideation; Antidepressant; Anticonvulsant; Psychiatry; Bipolar disorder; Psychology; Medicine; Reuptake inhibitor; Fluoxetine; Psychotic depression; Internal medicine; Epilepsy; Poison control; Psychosis; Suicide prevention; Lithium (medication); Serotonin","score_opus":0.06425131639068486,"score_gpt":0.492688439523282,"score_spread":0.42843712313259713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993305638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5161875,0.45029894,0.0040895403,0.009841646,0.0009398723,0.00031938672,0.0002436005,0.0002613999,0.01781813],"genre_scores_gemma":[0.9228113,0.06812581,0.0018621141,0.0022875294,0.00055245403,0.00009130347,0.00025070735,0.00002042896,0.0039982847],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99984896,0.00004454422,0.000028031063,0.000012658048,0.000026778795,0.00003898652],"domain_scores_gemma":[0.99985147,0.000042629486,0.000037813694,0.000009190174,0.000012801464,0.000046136436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028648702,0.00028589275,0.0005929894,0.0003416103,0.00025131088,0.0002184817,0.00044452018,0.0009700643,0.0011955212],"category_scores_gemma":[0.00069823605,0.000078570396,0.00046778555,0.00033473046,0.00017362193,0.00018467766,0.00024014778,0.001221784,0.00032002234],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005530264,0.0010560233,0.011799501,0.002195071,0.0005710637,0.07664617,0.0006645561,0.00088566885,0.046543106,0.0026388788,0.009294707,0.842175],"study_design_scores_gemma":[0.0101160025,0.023780873,0.15328535,0.0015298094,0.0014716166,0.4680818,0.00088464055,0.0023462188,0.039301313,0.0034704627,0.29554507,0.00018691324],"about_ca_topic_score_codex":0.0012034395,"about_ca_topic_score_gemma":0.0028894353,"teacher_disagreement_score":0.0012034395,"about_ca_system_score_codex":0.00062771223,"about_ca_system_score_gemma":0.00032681224,"threshold_uncertainty_score":0.004554391},"labels":[],"label_agreement":null},{"id":"W1993810555","doi":"10.1097/yic.0b013e32833e34d9","title":"Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder","year":2010,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"START Clinic","funders":"National Institutes of Health; National Institute of Mental Health; AstraZeneca","keywords":"Quetiapine; Quetiapine Fumarate; Placebo; Tolerability; Anxiety; Internal medicine; Atypical antipsychotic; Hamilton Anxiety Rating Scale; Medicine; Psychology; Somnolence; Psychiatry; Anesthesia; Adverse effect; Antipsychotic; Schizophrenia (object-oriented programming)","score_opus":0.05208654081187643,"score_gpt":0.4759349710285205,"score_spread":0.4238484302166441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993810555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953695,0.0038345184,0.00021794111,0.00005223,0.000031412223,0.000120842255,0.00006961665,0.00002762291,0.000276342],"genre_scores_gemma":[0.99719536,0.0018006889,0.00036194507,0.000076944176,0.00007611262,0.00006678813,0.000120289056,0.0000030093076,0.0002988681],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997192,0.00013682104,0.000028842858,0.000036229736,0.00004835478,0.000030529452],"domain_scores_gemma":[0.99962056,0.00011061898,0.00012908813,0.000028482656,0.00002110419,0.00009016488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076853717,0.0003811678,0.0013196579,0.0002352605,0.00014984712,0.00029054147,0.00039004107,0.00029657426,0.001343477],"category_scores_gemma":[0.00073844794,0.00018051428,0.00061681547,0.00019026849,0.00022124145,0.00028243824,0.00013036492,0.00054825837,0.00018276404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5644518,0.015816843,0.022849523,0.0013305335,0.0031817064,0.0005480904,0.00025410153,0.00096603885,0.07222891,0.00018105621,0.0010390498,0.31715232],"study_design_scores_gemma":[0.29672325,0.5562094,0.13315736,0.00009465048,0.002298335,0.0012123907,0.00012388859,0.0019952662,0.005456266,0.0001246851,0.0025611846,0.00004334713],"about_ca_topic_score_codex":0.0007186672,"about_ca_topic_score_gemma":0.002790047,"teacher_disagreement_score":0.001343477,"about_ca_system_score_codex":0.00031642604,"about_ca_system_score_gemma":0.0002828028,"threshold_uncertainty_score":0.0044944286},"labels":[],"label_agreement":null},{"id":"W1994418013","doi":"10.1097/00004850-200511000-00002","title":"Effect of valproate on plasma levels of interleukin-6 in healthy male humans","year":2005,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; University of British Columbia","funders":"","keywords":"Valproic Acid; Evening; Blood sampling; Epilepsy; Medicine; Morning; Internal medicine; Endocrinology; Anticonvulsant; Cytokine; Plasma levels; Interleukin 6; Immune system; Interleukin; Immunology; Psychiatry","score_opus":0.08186881126748956,"score_gpt":0.5092163322183121,"score_spread":0.4273475209508225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994418013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962604,0.0027503823,0.00015017953,0.000045930286,0.000030243891,0.000018296954,0.00012013319,0.000008776329,0.00061568693],"genre_scores_gemma":[0.99798465,0.00081722956,0.00022562215,0.00012088483,0.000036840796,0.000025218083,0.00016344037,0.0000027797346,0.00062330795],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998741,0.00004458725,0.000009704775,0.000027588176,0.000028712018,0.000015365855],"domain_scores_gemma":[0.9998178,0.000041596082,0.000049237977,0.00001667399,0.00001799645,0.000056707275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001352137,0.00021160109,0.00035491108,0.00019311186,0.00014190249,0.00018303485,0.00004805381,0.00025579124,0.0009442974],"category_scores_gemma":[0.00027104243,0.0001266806,0.00014172426,0.000088076275,0.0001430547,0.00010761984,0.00009579399,0.00027836623,0.00021727121],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06397573,0.003031211,0.20567712,0.00035196636,0.00037332583,0.0016488663,0.0005639808,0.00024975342,0.6431246,0.00012160209,0.0009915144,0.079890385],"study_design_scores_gemma":[0.0005929328,0.043267313,0.9218488,0.000017481263,0.00017214582,0.0015388728,0.0001881041,0.00032606316,0.02845659,0.000097393364,0.0034735186,0.000020869244],"about_ca_topic_score_codex":0.0002740392,"about_ca_topic_score_gemma":0.00044676062,"teacher_disagreement_score":0.0009442974,"about_ca_system_score_codex":0.000071373266,"about_ca_system_score_gemma":0.00008960095,"threshold_uncertainty_score":0.003158927},"labels":[],"label_agreement":null},{"id":"W1995880596","doi":"10.1097/00004850-200207000-00007","title":"Do triglycerides modulate the effectiveness of clozapine?","year":2002,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Riverview Hospital","funders":"","keywords":"Clozapine; Triglyceride; Plasma levels; Internal medicine; Endocrinology; Blood lipids; Medicine; Pharmacology; Cholesterol; Schizophrenia (object-oriented programming); Psychiatry","score_opus":0.08566928400029161,"score_gpt":0.47022307356801757,"score_spread":0.38455378956772596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995880596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809201,0.005122504,0.00087363593,0.0037420897,0.00008700403,0.000031403673,0.00009148778,0.00006675902,0.009065052],"genre_scores_gemma":[0.99714476,0.0013099839,0.00032924715,0.00043962526,0.00007822551,0.000005568753,0.000021691738,0.000009396514,0.0006614746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99972767,0.00008486746,0.000035967063,0.00003318608,0.00007232576,0.000045974455],"domain_scores_gemma":[0.99938774,0.0001811173,0.00026440795,0.000044128592,0.00005313587,0.000069462825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035454112,0.00027079036,0.00035387994,0.00041977793,0.00019850154,0.00065609044,0.00020153748,0.0010145961,0.0013374883],"category_scores_gemma":[0.0021682747,0.00015737428,0.00023606897,0.000265752,0.0004195001,0.0005224412,0.0001740139,0.0005877334,0.0004189526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00916879,0.0006754529,0.45148343,0.0004511302,0.0005367473,0.07884759,0.0016434188,0.00086042535,0.24639773,0.0045547006,0.0019457503,0.20343488],"study_design_scores_gemma":[0.0005695594,0.0033059986,0.79195166,0.000115213756,0.0009632435,0.09453857,0.0016980843,0.0035813488,0.08088031,0.004902813,0.017351381,0.00014180456],"about_ca_topic_score_codex":0.0010074261,"about_ca_topic_score_gemma":0.002195137,"teacher_disagreement_score":0.0013374883,"about_ca_system_score_codex":0.0004862318,"about_ca_system_score_gemma":0.00022559588,"threshold_uncertainty_score":0.0044744015},"labels":[],"label_agreement":null},{"id":"W2000541904","doi":"10.1097/00004850-200015050-00003","title":"A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression","year":2000,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada East Spine Centre","funders":"","keywords":"Sertraline; Clomipramine; Tolerability; Clinical Global Impression; Psychology; Serotonin reuptake inhibitor; Internal medicine; Medicine; Anesthesia; Adverse effect; Antidepressant; Placebo","score_opus":0.048852164935280065,"score_gpt":0.4310610305031207,"score_spread":0.38220886556784067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000541904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946175,0.002475345,0.0005003206,0.00021387408,0.00019791536,0.001016103,0.00022892926,0.00006780165,0.0006822537],"genre_scores_gemma":[0.99325824,0.0015492485,0.0015468658,0.00062101195,0.0005773312,0.0011835266,0.00047170056,0.000013131271,0.00077904155],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987332,0.00083626795,0.00012619319,0.00010654376,0.00012010723,0.00007758789],"domain_scores_gemma":[0.99766254,0.0009449935,0.00044376357,0.00016654725,0.00014032323,0.0006418939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001649732,0.0008323039,0.002354961,0.00035272937,0.00042254815,0.00036562205,0.00047986687,0.0011701115,0.0022405153],"category_scores_gemma":[0.003445495,0.0004888992,0.00072081364,0.0002931134,0.0006989604,0.000520516,0.00025606307,0.001211817,0.00043051504],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91106844,0.02009391,0.0030107333,0.000680934,0.0010410821,0.00010144333,0.00016038679,0.00020289006,0.014895692,0.00006603864,0.0005538151,0.048124645],"study_design_scores_gemma":[0.6008613,0.37803045,0.01801023,0.00003184115,0.0004448337,0.00013347264,0.00003854301,0.0005344461,0.0009822818,0.0000896605,0.000819137,0.000023725355],"about_ca_topic_score_codex":0.00041586903,"about_ca_topic_score_gemma":0.0008270071,"teacher_disagreement_score":0.002354961,"about_ca_system_score_codex":0.0002901196,"about_ca_system_score_gemma":0.00058679725,"threshold_uncertainty_score":0.008724749},"labels":[],"label_agreement":null},{"id":"W2003131209","doi":"10.1097/yic.0b013e32831daf6c","title":"Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study","year":2008,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Montreal Neurological Institute and Hospital; Hôpital Louis-H Lafontaine","funders":"","keywords":"Quetiapine; Voxel-based morphometry; Anterior cingulate cortex; Grey matter; Psychology; Clinical Global Impression; Prefrontal cortex; Positive and Negative Syndrome Scale; Orbitofrontal cortex; Schizophrenia (object-oriented programming); Cingulate cortex; Scale for the Assessment of Negative Symptoms; Internal medicine; Audiology; Psychiatry; Medicine; Psychosis; Brief Psychiatric Rating Scale; Magnetic resonance imaging; Cognition; White matter; Pathology; Central nervous system","score_opus":0.024532997260244938,"score_gpt":0.36655062608064015,"score_spread":0.3420176288203952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003131209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996482,0.00009251945,0.00008986726,0.000012821462,0.000001123706,0.0000045884317,0.000043078257,0.0000061381916,0.0001016107],"genre_scores_gemma":[0.99971503,0.000039424438,0.000106988744,0.0000067694004,0.0000023589648,0.0000024505503,0.000052478586,0.0000018512831,0.00007256099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999453,0.000011347229,0.0000055100036,0.00001072653,0.000015185355,0.000011990207],"domain_scores_gemma":[0.9998485,0.000033801905,0.00006617681,0.000012888351,0.000014339926,0.000024333787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001671713,0.00016880897,0.00023338116,0.0006438746,0.0001604676,0.00024919046,0.00014884515,0.00026589772,0.00082668447],"category_scores_gemma":[0.00047053996,0.00014420266,0.00029324196,0.00026451537,0.00025719983,0.00014114474,0.000128312,0.00013946921,0.00008722607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005520029,0.00028261222,0.8287747,0.000114101786,0.0006696842,0.0030473564,0.0010570766,0.0007981569,0.13700631,0.0001432558,0.0002498764,0.022336861],"study_design_scores_gemma":[0.000022283904,0.00013975873,0.9978835,0.0000016720534,0.000039237613,0.0006719268,0.00006231851,0.00040860765,0.0006731583,0.000025616691,0.000068014946,0.000003886632],"about_ca_topic_score_codex":0.0054103606,"about_ca_topic_score_gemma":0.0054696198,"teacher_disagreement_score":0.0054103606,"about_ca_system_score_codex":0.00034045338,"about_ca_system_score_gemma":0.00014340502,"threshold_uncertainty_score":0.010757744},"labels":[],"label_agreement":null},{"id":"W2006347666","doi":"10.1097/yic.0b013e3282f424d6","title":"Weight gain during olanzapine treatment for psychotic depression: effects of dose and age","year":2008,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Rehabilitation Institute; Toronto General Hospital; University Health Network","funders":"National Center for Advancing Translational Sciences; National Institute of Mental Health; Pfizer Canada; Forest Laboratories; Pfizer; Eli Lilly and Company; American Psychiatric Institute for Research and Education; U.S. Public Health Service; AstraZeneca","keywords":"Olanzapine; Weight gain; Medicine; Body mass index; Depression (economics); Confounding; Confidence interval; Placebo; Sertraline; Internal medicine; Schizophrenia (object-oriented programming); Psychology; Psychiatry; Body weight; Antidepressant","score_opus":0.06542924480534483,"score_gpt":0.4606878485556022,"score_spread":0.39525860375025734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006347666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99060327,0.007322505,0.00028167732,0.00015100629,0.000031285097,0.000049224516,0.00021893227,0.000018225148,0.001323902],"genre_scores_gemma":[0.9979249,0.0011616899,0.00023089384,0.000091896145,0.00003096847,0.000025512454,0.00016941,0.0000082531615,0.00035645734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859256,0.00066864653,0.00015279416,0.00013906986,0.00036068985,0.000086166016],"domain_scores_gemma":[0.99335855,0.0024566941,0.0032886572,0.0002874937,0.00021103771,0.00039757605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019935064,0.00031345204,0.00066181854,0.0003268138,0.00015751614,0.00054075534,0.00024793917,0.00037984236,0.0011576186],"category_scores_gemma":[0.008894735,0.00023084763,0.0009964069,0.00042969544,0.00020320325,0.0003996727,0.00029416013,0.0005941766,0.00018676119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070918925,0.0012277524,0.7902421,0.00061696867,0.004408959,0.00036722582,0.00030748744,0.0013785015,0.009460966,0.00012763841,0.00064498594,0.12029844],"study_design_scores_gemma":[0.0002308437,0.0028549929,0.9946188,0.00003850368,0.00050856307,0.0002324872,0.00004028407,0.00055446225,0.0004770171,0.00007627816,0.0003553523,0.000012421455],"about_ca_topic_score_codex":0.0010771875,"about_ca_topic_score_gemma":0.003474205,"teacher_disagreement_score":0.0019935064,"about_ca_system_score_codex":0.0004931697,"about_ca_system_score_gemma":0.0002404211,"threshold_uncertainty_score":0.01054281},"labels":[],"label_agreement":null},{"id":"W2007245256","doi":"10.1097/yic.0b013e3282eff7e0","title":"Which antidepressants have demonstrated superior efficacy? A review of the evidence","year":2007,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Ottawa","funders":"H. Lundbeck A/S","keywords":"Escitalopram; Venlafaxine; Mirtazapine; Duloxetine; Clomipramine; Milnacipran; Antidepressant; Major depressive disorder; Randomized controlled trial; MEDLINE; Psychiatry; Psychology; Medicine; Clinical psychology; Internal medicine; Alternative medicine; Anxiety; Mood","score_opus":0.256882085168053,"score_gpt":0.5804082420169554,"score_spread":0.3235261568489024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007245256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016224849,0.9993449,0.000022922997,0.00020843292,0.000085207124,0.000020617825,0.000029303417,0.0000017393643,0.00012467412],"genre_scores_gemma":[0.0026374308,0.996609,0.00018675797,0.00036122673,0.000088967376,0.000032896027,0.000030775464,0.000001271997,0.00005169446],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9957046,0.0014227926,0.0015624048,0.0003536349,0.0008481505,0.000108429886],"domain_scores_gemma":[0.9881462,0.008456193,0.0020791313,0.00018656215,0.0010057985,0.0001261837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007079984,0.0014354577,0.008169657,0.0063066888,0.00041145607,0.0026156674,0.0017293872,0.0020713944,0.004408629],"category_scores_gemma":[0.022375662,0.00096997933,0.0040589864,0.0079205595,0.0007782547,0.0027006562,0.00080454495,0.0010593821,0.00050096074],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058151,0.00003210973,0.0006824219,0.7611955,0.007474007,0.0002654513,0.0001518113,0.000117941556,0.0003728248,0.00071342743,0.006199828,0.22221322],"study_design_scores_gemma":[0.0007222487,0.00070499117,0.008375866,0.80579555,0.06462261,0.0015860244,0.00046013,0.00016239542,0.00059864984,0.0018696019,0.11503646,0.00006554832],"about_ca_topic_score_codex":0.003533085,"about_ca_topic_score_gemma":0.011469267,"teacher_disagreement_score":0.008169657,"about_ca_system_score_codex":0.0030053202,"about_ca_system_score_gemma":0.0042706872,"threshold_uncertainty_score":0.037442982},"labels":[],"label_agreement":null},{"id":"W2009607401","doi":"10.1097/yic.0000000000000017","title":"Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia","year":2013,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier; Les Laboratories Pierre Fabre; Eli Lilly and Company","keywords":"Quetiapine; Risperidone; Quetiapine Fumarate; Schizoaffective disorder; Population; Olanzapine; Atypical antipsychotic; Psychology; Psychiatry; Schizophrenia (object-oriented programming); Internal medicine; Medicine; Psychosis; Antipsychotic","score_opus":0.021367465840897257,"score_gpt":0.3842384638397511,"score_spread":0.3628709979988538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009607401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957203,0.00249304,0.00023243904,0.00014057635,0.000095200754,0.0004911747,0.00020012289,0.000044846398,0.0005823403],"genre_scores_gemma":[0.9977169,0.0009030363,0.00042642077,0.000151957,0.000061007348,0.00017891786,0.0001292859,0.000004566031,0.00042788158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992755,0.00045600574,0.000074162665,0.00007336361,0.00006829051,0.000052610623],"domain_scores_gemma":[0.99934715,0.0002188043,0.00022835564,0.000039513012,0.000031297335,0.00013480747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013822793,0.0006272469,0.00152784,0.00029219766,0.00017704454,0.00055814866,0.00050945365,0.00061001326,0.001717633],"category_scores_gemma":[0.0021815794,0.00036196498,0.0012247686,0.00024708087,0.00040022496,0.00048337542,0.00024366133,0.0011163551,0.0002059587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9236676,0.004396484,0.0031518976,0.0004934791,0.0017552826,0.00007167534,0.000096497,0.00040608805,0.0060002557,0.00008935994,0.00055575493,0.059315603],"study_design_scores_gemma":[0.7590467,0.20626485,0.028579088,0.000071756804,0.001460805,0.00015770405,0.00007005487,0.0014812989,0.0015640121,0.00021509218,0.0010536936,0.00003494497],"about_ca_topic_score_codex":0.0017815771,"about_ca_topic_score_gemma":0.0073447656,"teacher_disagreement_score":0.0017815771,"about_ca_system_score_codex":0.0007487176,"about_ca_system_score_gemma":0.0005829203,"threshold_uncertainty_score":0.0073102713},"labels":[],"label_agreement":null},{"id":"W2009666409","doi":"10.1097/yic.0b013e3283430a0e","title":"Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders","year":2011,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Louis-H Lafontaine; Université de Montréal","funders":"","keywords":"Quetiapine; Tolerability; Atypical antipsychotic; Placebo; Mania; Bipolar disorder; Psychiatry; Medicine; Quetiapine Fumarate; Antipsychotic; Schizophrenia (object-oriented programming); Generalized anxiety disorder; Psychology; Internal medicine; Anxiety; Adverse effect; Lithium (medication)","score_opus":0.1720207555705169,"score_gpt":0.5424592692725886,"score_spread":0.3704385137020717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009666409","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053621802,0.9435722,0.000404911,0.0001620441,0.00010459351,0.00031060397,0.0007094292,0.000009777219,0.0011045717],"genre_scores_gemma":[0.6005728,0.3944618,0.0015635606,0.0006144775,0.000406735,0.00045982472,0.0015657854,0.000023773131,0.00033110488],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9848225,0.006399863,0.005677269,0.0011818635,0.0017720709,0.00014646519],"domain_scores_gemma":[0.9702177,0.019300546,0.0075946725,0.00073626835,0.0019368944,0.00021386119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011677959,0.00059167366,0.004562842,0.004624579,0.0001877437,0.0013881194,0.0007635218,0.0008590586,0.0019010179],"category_scores_gemma":[0.027562767,0.0003877424,0.006270782,0.0034548957,0.00051245815,0.001366367,0.0005484144,0.00066961715,0.00016068733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08013123,0.00058849266,0.026927695,0.33211923,0.28496873,0.00067218544,0.00078983454,0.0010287733,0.009414462,0.0007694688,0.0010752307,0.26151466],"study_design_scores_gemma":[0.027616443,0.035118695,0.22091547,0.057502493,0.622877,0.003303158,0.0013078965,0.0008315633,0.007237823,0.0020626544,0.020954726,0.00027216005],"about_ca_topic_score_codex":0.00061460165,"about_ca_topic_score_gemma":0.0017084089,"teacher_disagreement_score":0.011677959,"about_ca_system_score_codex":0.00088575337,"about_ca_system_score_gemma":0.0004935831,"threshold_uncertainty_score":0.06175971},"labels":[],"label_agreement":null},{"id":"W2015979089","doi":"10.1097/00004850-200507000-00007","title":"Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo","year":2005,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Venlafaxine; Paroxetine; Fluoxetine; Placebo; Reuptake inhibitor; Venlafaxine Hydrochloride; Internal medicine; Psychology; Major depressive disorder; Hamilton Rating Scale for Depression; Anesthesia; Medicine; Psychiatry; Antidepressant; Serotonin; Mood; Anxiety","score_opus":0.08536644269240524,"score_gpt":0.5003743618899092,"score_spread":0.415007919197504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015979089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8681933,0.1276317,0.00092822744,0.00020175877,0.000073409756,0.0001269772,0.00045929474,0.000083555366,0.0023018918],"genre_scores_gemma":[0.9901072,0.007895319,0.0005853381,0.00014543446,0.00009436915,0.000049701455,0.0005370527,0.000012848942,0.000572632],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9958454,0.002541948,0.0006630385,0.0003856262,0.00042885842,0.00013514077],"domain_scores_gemma":[0.9936132,0.0033310128,0.0022213573,0.00036190642,0.00030715315,0.00016543744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003911069,0.00033180235,0.002125128,0.00066682114,0.00011187636,0.00058693654,0.00023695991,0.0006131475,0.001676102],"category_scores_gemma":[0.0054254355,0.0002405353,0.0012545437,0.0005183912,0.00017778581,0.00029109739,0.00022521568,0.00040444869,0.00026106284],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18117683,0.0013785433,0.1599244,0.012840575,0.074303605,0.000594676,0.0012108216,0.0010918959,0.065746374,0.0002538356,0.0022723223,0.49920613],"study_design_scores_gemma":[0.017350325,0.073605575,0.8649058,0.00082091696,0.022519054,0.0023228412,0.0003050142,0.0007261486,0.008946507,0.0002520883,0.0081532365,0.00009249097],"about_ca_topic_score_codex":0.00029350127,"about_ca_topic_score_gemma":0.0006061271,"teacher_disagreement_score":0.003911069,"about_ca_system_score_codex":0.00016177117,"about_ca_system_score_gemma":0.00011356224,"threshold_uncertainty_score":0.020683944},"labels":[],"label_agreement":null},{"id":"W2022871996","doi":"10.1097/00004850-200405000-00001","title":"A review of acute treatments for bipolar depression","year":2004,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"","keywords":"Lamotrigine; Bipolar disorder; Mood stabilizer; Bupropion; Lithium (medication); Antidepressant; Carbamazepine; Olanzapine; Electroconvulsive therapy; Mania; Psychiatry; Quetiapine; Psychology; Divalproex; Medicine; Atypical antipsychotic; Antipsychotic; Epilepsy; Schizophrenia (object-oriented programming); Anxiety","score_opus":0.11384981653883985,"score_gpt":0.5568993853070621,"score_spread":0.4430495687682222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022871996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070689704,0.9984623,0.00005594192,0.00024093903,0.00025995134,0.000025033165,0.000058893314,0.000005968378,0.00082038366],"genre_scores_gemma":[0.00036827353,0.9982938,0.00022830519,0.0004318318,0.0002219482,0.000030458954,0.00008926085,0.000001930286,0.00033411125],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9990501,0.0002427248,0.00032289146,0.000092929884,0.00025521926,0.000036205347],"domain_scores_gemma":[0.9986889,0.0007770645,0.00025196886,0.00002422524,0.00021071646,0.00004718542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009474448,0.0010444133,0.0021648316,0.0036146166,0.00039594,0.0011786176,0.0012471331,0.001195639,0.013040692],"category_scores_gemma":[0.0025176206,0.00043210867,0.0017117107,0.0035359063,0.0003289306,0.0012565079,0.00072919787,0.0014909855,0.0024168452],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014453326,0.000070005524,0.00015143893,0.16176835,0.0003396877,0.00020515182,0.000110087414,0.00014051113,0.0004270096,0.0011212763,0.051654957,0.78386706],"study_design_scores_gemma":[0.000100236764,0.00021775387,0.0019142102,0.103048876,0.0011827308,0.0017225248,0.00010363395,0.0000616377,0.00013223357,0.0009216191,0.89056677,0.000027839498],"about_ca_topic_score_codex":0.0018848968,"about_ca_topic_score_gemma":0.0040984186,"teacher_disagreement_score":0.013040692,"about_ca_system_score_codex":0.00090188836,"about_ca_system_score_gemma":0.0019642923,"threshold_uncertainty_score":0.043625474},"labels":[],"label_agreement":null},{"id":"W2026016551","doi":"10.1097/01.yic.0000166403.03732.72","title":"Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials","year":2005,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Child and Adolescent Psychosocial and Emotional Development","field":"Psychology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Risperidone; Placebo; Aggression; Psychology; Conduct disorder; Psychiatry; Randomized controlled trial; Crying; Intelligence quotient; Clinical psychology; Medicine; Internal medicine; Schizophrenia (object-oriented programming); Cognition","score_opus":0.04852347797344033,"score_gpt":0.45601085038314365,"score_spread":0.40748737240970334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026016551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9093254,0.07299676,0.0026428828,0.00073958683,0.0010725639,0.009945199,0.0010501437,0.0003539802,0.0018735947],"genre_scores_gemma":[0.9623588,0.022348786,0.0035426146,0.00067949045,0.0007445305,0.008456094,0.0006558333,0.00004331237,0.0011704729],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99187064,0.005614061,0.000983492,0.0006367664,0.0005387953,0.00035623612],"domain_scores_gemma":[0.9925648,0.0039640767,0.0018021158,0.0004989769,0.0005315438,0.0006385245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008233033,0.0020015133,0.008309367,0.0012948391,0.00053421705,0.0018702192,0.0013859102,0.0030446895,0.0033845296],"category_scores_gemma":[0.011884297,0.0012563594,0.0057230275,0.0011463817,0.0014912466,0.0011372074,0.00060321565,0.0021808562,0.00036088115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9541284,0.0034206645,0.00093157304,0.0036715947,0.009669277,0.00008333904,0.00009793327,0.00032440494,0.0025426887,0.00008860048,0.0003263834,0.024715243],"study_design_scores_gemma":[0.9440023,0.045132123,0.0033238635,0.00015371639,0.0057714963,0.00006227833,0.000039605016,0.000347143,0.0004291964,0.000101272395,0.0006086725,0.000028326842],"about_ca_topic_score_codex":0.0010358059,"about_ca_topic_score_gemma":0.0024189223,"teacher_disagreement_score":0.008309367,"about_ca_system_score_codex":0.0013125894,"about_ca_system_score_gemma":0.0014389984,"threshold_uncertainty_score":0.043540895},"labels":[],"label_agreement":null},{"id":"W2027478291","doi":"10.1097/01.yic.0000170263.46008.54","title":"Major depressive episode with psychotic features induced by pegylated interferon-α-2b and ribavirin treatment","year":2005,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Ribavirin; Pegylated interferon; Alpha interferon; Medicine; Psychosis; Depression (economics); Hepatitis C; Chronic hepatitis; Interferon; Psychiatry; Immunology; Virology; Pharmacology; Internal medicine; Gastroenterology; Virus","score_opus":0.05643365514573141,"score_gpt":0.4710022976697225,"score_spread":0.4145686425239911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027478291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809692,0.0021239973,0.0013627617,0.001609406,0.00028694578,0.00039961786,0.00025773514,0.00008043991,0.012909932],"genre_scores_gemma":[0.99686,0.00048160946,0.00023155083,0.0011292751,0.00012401838,0.000029652922,0.000112292764,0.0000049335977,0.0010266197],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994623,0.00010095148,0.000066198205,0.00005892852,0.00013172759,0.0001797555],"domain_scores_gemma":[0.9993395,0.00012348058,0.00018915161,0.00003590133,0.00007199008,0.00023992115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034180918,0.0006577468,0.000697123,0.0005110655,0.0011757789,0.00044633454,0.000495361,0.0013951077,0.0009700643],"category_scores_gemma":[0.0022627607,0.00044885973,0.00077461224,0.00043348002,0.00046872604,0.00026530717,0.0006469018,0.0015595737,0.0003670321],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001201407,0.000714235,0.1352329,0.0002478733,0.0002270842,0.83131045,0.0012674518,0.0003883456,0.012614604,0.0008899095,0.0022628703,0.013642916],"study_design_scores_gemma":[0.00027462945,0.0014693639,0.2366677,0.00007125027,0.000113855545,0.7548978,0.00037014953,0.0010537341,0.0014526802,0.0004814779,0.0030997577,0.000047680496],"about_ca_topic_score_codex":0.0043779155,"about_ca_topic_score_gemma":0.007243478,"teacher_disagreement_score":0.0043779155,"about_ca_system_score_codex":0.001161468,"about_ca_system_score_gemma":0.0007334624,"threshold_uncertainty_score":0.008704841},"labels":[],"label_agreement":null},{"id":"W2028794531","doi":"10.1097/00004850-200309000-00007","title":"Increased use of antibiotics in clozapine-treated patients","year":2003,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institut universitaire en santé mentale de Montréal","funders":"","keywords":"Clozapine; Schizoaffective disorder; Medicine; Antibiotics; Medical prescription; Schizophrenia (object-oriented programming); Retrospective cohort study; Psychosis; Pediatrics; Internal medicine; Psychiatry; Pharmacology","score_opus":0.08360990557208188,"score_gpt":0.4579341082284898,"score_spread":0.3743242026564079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028794531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876297,0.00052497356,0.0000338479,0.00003244704,0.0000057555953,0.000008035534,0.00025268013,0.0000062635613,0.00037303125],"genre_scores_gemma":[0.9992899,0.00025004064,0.00007906094,0.00003843753,0.00001105914,0.000007506962,0.00025999916,0.0000022178835,0.00006181531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911803,0.00023170137,0.00015482375,0.00013158606,0.00025131667,0.00011254014],"domain_scores_gemma":[0.9959298,0.00080298685,0.0025440624,0.00013626329,0.00023900862,0.00034791935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031434835,0.00018516324,0.00039455382,0.0013253822,0.000522668,0.0006125812,0.00022400527,0.00038611548,0.00096270733],"category_scores_gemma":[0.0034432365,0.00027316948,0.00036881637,0.0013053673,0.00023934545,0.00032782205,0.00021395099,0.00059986225,0.000119994744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020528778,0.00003768684,0.9968072,0.000018773691,0.000047438476,0.00048701267,0.00012995745,0.000021443131,0.0005322724,0.000010615362,0.00008544905,0.0016168029],"study_design_scores_gemma":[0.000010999547,0.00013829186,0.99709034,0.0000119766055,0.00003475455,0.0020037072,0.00015202735,0.00009047218,0.00022301398,0.0000075323087,0.00023075091,0.0000061976093],"about_ca_topic_score_codex":0.0066211456,"about_ca_topic_score_gemma":0.01069242,"teacher_disagreement_score":0.0066211456,"about_ca_system_score_codex":0.0006259149,"about_ca_system_score_gemma":0.0004555347,"threshold_uncertainty_score":0.0131652355},"labels":[],"label_agreement":null},{"id":"W2029612948","doi":"10.1097/00004850-200211000-00002","title":"Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine","year":2002,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Venlafaxine; Hamilton Rating Scale for Depression; Psychology; Placebo; Reuptake inhibitor; Paroxetine; Major depressive disorder; Venlafaxine Hydrochloride; Fluoxetine; Mood; Psychiatry; Anxiety disorder; Anxiety; Internal medicine; Antidepressant; Serotonin; Medicine","score_opus":0.037448981268113225,"score_gpt":0.3871625853630552,"score_spread":0.34971360409494195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029612948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916294,0.0074173408,0.00024350996,0.00006308699,0.000046505545,0.00006629328,0.00015893107,0.000005805683,0.00036922074],"genre_scores_gemma":[0.9977252,0.0012830482,0.00038944377,0.000037974827,0.00005776796,0.000043574324,0.00031665145,0.000001649666,0.00014467555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975204,0.0015566297,0.00029355905,0.00017714775,0.0003690063,0.00008327625],"domain_scores_gemma":[0.99486035,0.002981147,0.0014891478,0.00013632198,0.00017620878,0.00035686142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031420994,0.00041919114,0.0013468958,0.0006148486,0.00015270017,0.0004268356,0.0004088298,0.0005468026,0.0008184868],"category_scores_gemma":[0.005070618,0.00033758525,0.0006920914,0.00034491878,0.0002513166,0.000375277,0.00023454092,0.00051048707,0.00013647588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18498828,0.0021677238,0.665509,0.00094832614,0.0067885756,0.00014246185,0.0002409146,0.0005574129,0.00653567,0.000104187464,0.0004124152,0.13160509],"study_design_scores_gemma":[0.0118247,0.02899427,0.9527784,0.00010344677,0.0017010404,0.00045805724,0.00013867508,0.0022313423,0.000880841,0.00010234304,0.00075433345,0.00003251132],"about_ca_topic_score_codex":0.00043608822,"about_ca_topic_score_gemma":0.0014511566,"teacher_disagreement_score":0.0031420994,"about_ca_system_score_codex":0.00020186383,"about_ca_system_score_gemma":0.00014992758,"threshold_uncertainty_score":0.016617239},"labels":[],"label_agreement":null},{"id":"W2029648794","doi":"10.1097/yic.0b013e32801182e6","title":"Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin","year":2007,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Diet and metabolism studies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Douglas Mental Health University Institute; McGill University","funders":"","keywords":"Internal medicine; Metformin; Endocrinology; Insulin resistance; Medicine; Olanzapine; Placebo; Insulin; Leptin; Glucagon; Schizophrenia (object-oriented programming); Obesity","score_opus":0.021051681698661773,"score_gpt":0.38129224064773604,"score_spread":0.36024055894907425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029648794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975079,0.0020918553,0.00008612826,0.00004492288,0.00001962567,0.000012420774,0.000025644125,0.0000035942364,0.00020787664],"genre_scores_gemma":[0.9987147,0.00075768534,0.00021045079,0.00005816856,0.000021999353,0.000013069411,0.000047957434,0.000002199678,0.00017379444],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997943,0.00007862126,0.000022773162,0.00002369525,0.00005135889,0.000029237079],"domain_scores_gemma":[0.9995196,0.00011370129,0.00019842549,0.000025244179,0.000044813616,0.000098248165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038519345,0.00039170744,0.0006954531,0.00018630923,0.00019885598,0.0002868896,0.000114172675,0.00028509958,0.0005714676],"category_scores_gemma":[0.00091073185,0.0001449851,0.00042700573,0.00021725672,0.0001470827,0.00020781334,0.00012128578,0.00056991825,0.00007119584],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20143013,0.003347081,0.34644094,0.0009068583,0.0015116468,0.0033057842,0.00092758774,0.0006723426,0.20775898,0.00012957561,0.0004038188,0.2331653],"study_design_scores_gemma":[0.0012689779,0.033405695,0.9476038,0.000054043103,0.0006321887,0.0010114175,0.00034832492,0.0005091589,0.013808198,0.000069522684,0.0012556636,0.00003285792],"about_ca_topic_score_codex":0.00095581304,"about_ca_topic_score_gemma":0.0017433986,"teacher_disagreement_score":0.00095581304,"about_ca_system_score_codex":0.0003535832,"about_ca_system_score_gemma":0.00028400222,"threshold_uncertainty_score":0.0025655031},"labels":[],"label_agreement":null},{"id":"W2029931114","doi":"10.1097/01.yic.0000063501.97247.38","title":"Clozapine, quetiapine and olanzapine among addicted schizophrenic patients","year":2003,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Louis-H Lafontaine","funders":"","keywords":"Olanzapine; Quetiapine; Clozapine; Medicine; Psychiatry; Psychology; Schizophrenia (object-oriented programming)","score_opus":0.07605975851459768,"score_gpt":0.4851785600373764,"score_spread":0.40911880152277874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029931114","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981521,0.0011373278,0.000023030758,0.00010117137,0.0000072495063,0.000010786848,0.00005696124,0.0000035088567,0.0005078433],"genre_scores_gemma":[0.99852055,0.0010394526,0.000052327876,0.00007494866,0.000017001988,0.000005930642,0.00006731206,0.0000013685417,0.00022112363],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997899,0.00005545828,0.00003327143,0.000028625174,0.000049072158,0.000043715085],"domain_scores_gemma":[0.9997141,0.000057301473,0.00012907288,0.000008639035,0.00001837289,0.00007250089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018532733,0.0002577001,0.00031350466,0.00086844177,0.00048450605,0.0005242464,0.0001618997,0.0004522495,0.00089694024],"category_scores_gemma":[0.0009881458,0.00021744156,0.00037393786,0.00068793213,0.00021755956,0.00027294483,0.00031894015,0.00033145017,0.0001384034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012070021,0.00016150401,0.97831124,0.00007624262,0.00011151437,0.0047306702,0.00053857476,0.000072816605,0.0026089104,0.00007303226,0.00018301082,0.011925511],"study_design_scores_gemma":[0.000056198412,0.00035694113,0.9936621,0.000028078566,0.00013842374,0.004141214,0.0006179595,0.0001720984,0.00020293216,0.000051497187,0.00056003913,0.000012484028],"about_ca_topic_score_codex":0.009165798,"about_ca_topic_score_gemma":0.018088974,"teacher_disagreement_score":0.009165798,"about_ca_system_score_codex":0.0005593115,"about_ca_system_score_gemma":0.00056270807,"threshold_uncertainty_score":0.018224895},"labels":[],"label_agreement":null},{"id":"W2032636178","doi":"10.1097/yic.0000000000000014","title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","year":2013,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Mental Health & Substance Use Services","funders":"Natural Sciences and Engineering Research Council of Canada; U.S. Food and Drug Administration; Rush University; Centre for Addiction and Mental Health; Provincial Health Services Authority; AstraZeneca","keywords":"Dyslipidemia; Antipsychotic; Medicine; Pharmacology; Schizophrenia (object-oriented programming); Psychiatry; Endocrinology; Diabetes mellitus","score_opus":0.29403028821381527,"score_gpt":0.5581999677391798,"score_spread":0.2641696795253645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032636178","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019385929,0.9993718,0.000021723543,0.000046787547,0.000036467867,0.0000096777785,0.000013971306,0.0000020207353,0.00030362472],"genre_scores_gemma":[0.0014872539,0.9981939,0.0000937372,0.00006986768,0.00002762684,0.000011145297,0.000016742324,5.046861e-7,0.000099259014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99950933,0.00011828502,0.000145791,0.000048032405,0.00015130256,0.000027145166],"domain_scores_gemma":[0.9993981,0.00033802632,0.00015578541,0.000013162087,0.00007674995,0.000018120081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006430789,0.00073202467,0.001967533,0.0027674234,0.00029509832,0.00078934303,0.00068137044,0.0008353525,0.003821498],"category_scores_gemma":[0.0016080162,0.0002704299,0.0015553797,0.0023924718,0.0002767388,0.0005425582,0.00045739615,0.00074050634,0.00046298033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018030385,0.000089388996,0.00044191998,0.31205347,0.0014261808,0.00032009007,0.0001028502,0.00016350884,0.0010439049,0.00078347465,0.008217321,0.6751776],"study_design_scores_gemma":[0.0005219371,0.00066733884,0.014158887,0.31365028,0.01488272,0.008664584,0.0004928324,0.00029981617,0.0020784084,0.0020325715,0.64248276,0.00006783413],"about_ca_topic_score_codex":0.0020293554,"about_ca_topic_score_gemma":0.005051215,"teacher_disagreement_score":0.003821498,"about_ca_system_score_codex":0.0005706507,"about_ca_system_score_gemma":0.0014005536,"threshold_uncertainty_score":0.012784183},"labels":[],"label_agreement":null},{"id":"W2032780198","doi":"10.1097/yic.0b013e32833948d8","title":"Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis","year":2010,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Escitalopram; Duloxetine; Tolerability; Venlafaxine; Major depressive disorder; Antidepressant; Internal medicine; Duloxetine Hydrochloride; Montgomery–Åsberg Depression Rating Scale; Medicine; Reuptake inhibitor; Psychology; Psychiatry; Adverse effect","score_opus":0.022148748943425202,"score_gpt":0.40104834020650554,"score_spread":0.3788995912630803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032780198","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2050754,0.78357416,0.0036975842,0.00043955087,0.0009319031,0.0012791891,0.0032760312,0.00017035981,0.0015559255],"genre_scores_gemma":[0.87850684,0.11184847,0.002966742,0.0010891908,0.00080161454,0.0013468694,0.0025092084,0.00005131492,0.0008797546],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9927361,0.0045395014,0.0013037667,0.00065508013,0.0005563014,0.0002091806],"domain_scores_gemma":[0.9945451,0.0029208923,0.0015316718,0.0003568555,0.00048142677,0.00016404844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010207488,0.0020402253,0.011621765,0.0021596085,0.0001762924,0.0020228685,0.00069137383,0.001451932,0.0022934536],"category_scores_gemma":[0.009933041,0.0008030718,0.022816954,0.0022804074,0.00030714396,0.0008411522,0.0009300417,0.00092133536,0.00028686775],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11057711,0.00013348059,0.005402063,0.035095144,0.8199359,0.00010736109,0.00005393839,0.0008228737,0.0012252046,0.00008171769,0.000645945,0.025919195],"study_design_scores_gemma":[0.036734935,0.0066529345,0.017570578,0.0018516344,0.9338451,0.00013818138,0.00006591558,0.0009362888,0.00038017405,0.00016826387,0.0016079264,0.00004806572],"about_ca_topic_score_codex":0.0014453648,"about_ca_topic_score_gemma":0.0037640883,"teacher_disagreement_score":0.011621765,"about_ca_system_score_codex":0.00076055643,"about_ca_system_score_gemma":0.00076473824,"threshold_uncertainty_score":0.053983033},"labels":[],"label_agreement":null},{"id":"W2036480935","doi":"10.1097/yic.0b013e32836508e6","title":"The social and economic burden of treatment-resistant schizophrenia","year":2013,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Mental Health; National Institutes of Health","keywords":"Schizophrenia (object-oriented programming); Medicine; Quality of life (healthcare); Psychiatry; Adverse effect; Suicidal ideation; Substance abuse; Incidence (geometry); Alcohol abuse; Antipsychotic; Indirect costs; Internal medicine; Poison control; Injury prevention; Environmental health","score_opus":0.13352015733015024,"score_gpt":0.5192197666543232,"score_spread":0.385699609324173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036480935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004374255,0.9990595,0.000016721371,0.00018613832,0.000033854467,0.0000065860295,0.000030820964,0.0000010898505,0.0002279023],"genre_scores_gemma":[0.0037370247,0.99596196,0.00006602698,0.00009913222,0.00004862835,0.000008481198,0.000036475143,6.3593274e-7,0.000041730396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819106,0.0006481902,0.00046499475,0.000093621595,0.00052875443,0.00007328693],"domain_scores_gemma":[0.9974892,0.0013518885,0.0007736038,0.000039038172,0.00027397263,0.00007220203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023598212,0.00083125016,0.0020216971,0.0072212787,0.00034583398,0.0017121988,0.0005320546,0.0007692259,0.0022336375],"category_scores_gemma":[0.0051081213,0.00039192764,0.0014220529,0.0073129437,0.00038953294,0.0011090281,0.0009040802,0.000626478,0.00023653962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016131104,0.00004017724,0.0031653338,0.19148171,0.0041371924,0.00044008525,0.00027089153,0.00032473193,0.0004123058,0.0014839215,0.013718228,0.7843641],"study_design_scores_gemma":[0.0002697354,0.0004989559,0.05824859,0.33809087,0.019893829,0.0077648843,0.0017948395,0.00032552998,0.00083266676,0.004127105,0.56799906,0.00015404557],"about_ca_topic_score_codex":0.0044339104,"about_ca_topic_score_gemma":0.010888945,"teacher_disagreement_score":0.0072212787,"about_ca_system_score_codex":0.0015950043,"about_ca_system_score_gemma":0.0035655792,"threshold_uncertainty_score":0.01248008},"labels":[],"label_agreement":null},{"id":"W2050562005","doi":"10.1097/00004850-200109000-00007","title":"A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics","year":2001,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Riverview Hospital","funders":"","keywords":"Clozapine; Antipsychotic; Schizophrenia (object-oriented programming); Medicine; Depot; Internal medicine; Anesthesia; Psychiatry; Pediatrics","score_opus":0.09978535542722063,"score_gpt":0.4838204559414711,"score_spread":0.3840351005142505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050562005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996767,0.000107787746,0.000010852353,0.000009429488,0.0000019478027,0.000004146975,0.000022819982,8.7570163e-7,0.00016538106],"genre_scores_gemma":[0.99966836,0.00008840788,0.0000306118,0.000034748904,0.0000049987266,0.0000053944336,0.00009370393,7.6751735e-7,0.00007304402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999652,0.00008897457,0.000048645878,0.000053121847,0.00008344673,0.000073809664],"domain_scores_gemma":[0.9991386,0.00024793542,0.0002722594,0.00003184199,0.00007750643,0.00023175741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027321532,0.00020129685,0.00046990885,0.0009172042,0.0004260072,0.0006420127,0.00017006851,0.00062910083,0.0010363903],"category_scores_gemma":[0.001972944,0.00025376945,0.00033698062,0.0005309132,0.0002821032,0.00026820935,0.00027147718,0.00039624795,0.00020519072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011352908,0.00019467794,0.9935766,0.000015272484,0.000098275596,0.0002373406,0.00040017592,0.000018651413,0.0012663895,0.000014839986,0.000043155178,0.0029993611],"study_design_scores_gemma":[0.000036539626,0.00047359694,0.9986547,0.0000039734846,0.000033427328,0.00033190753,0.00027956613,0.000059706705,0.000058109737,0.000008458929,0.00005639068,0.0000035631138],"about_ca_topic_score_codex":0.00885892,"about_ca_topic_score_gemma":0.011864016,"teacher_disagreement_score":0.00885892,"about_ca_system_score_codex":0.00046757355,"about_ca_system_score_gemma":0.0003272088,"threshold_uncertainty_score":0.017614722},"labels":[],"label_agreement":null},{"id":"W2051467860","doi":"10.1097/yic.0b013e3283372977","title":"Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone","year":2010,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Humber River Regional Hospital","funders":"","keywords":"Risperidone; Medicine; Paliperidone; Randomized controlled trial; Positive and Negative Syndrome Scale; Clinical endpoint; Population; Somnolence; Schizophrenia (object-oriented programming); Adverse effect; Internal medicine; Patient satisfaction; Physical therapy; Psychiatry; Psychosis; Surgery","score_opus":0.04001636160128261,"score_gpt":0.4453616468816156,"score_spread":0.405345285280333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051467860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99841344,0.00030008995,0.00020869791,0.000059915623,0.000035790665,0.0006892728,0.00010739805,0.000017400938,0.00016789607],"genre_scores_gemma":[0.9968136,0.00030722847,0.00086080085,0.00017225149,0.0001443611,0.0011809095,0.00023256267,0.000005921769,0.00028236271],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966144,0.0021181626,0.00032359664,0.0003004539,0.00030546953,0.0003378838],"domain_scores_gemma":[0.99372816,0.0017126275,0.002045923,0.000681296,0.0004016462,0.0014302526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005872324,0.0014714431,0.003393676,0.00045354056,0.0006438519,0.0010107437,0.0007914064,0.001674373,0.0023025353],"category_scores_gemma":[0.0058256243,0.0008895124,0.0027113366,0.00043646002,0.0011859749,0.0010046584,0.0008353819,0.002203066,0.0004775337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94662666,0.029716438,0.0049404283,0.00017437014,0.0005953176,0.000036150854,0.0001462689,0.0002276266,0.0027270878,0.000025977644,0.0001377005,0.01464607],"study_design_scores_gemma":[0.5206435,0.46546808,0.011877831,0.000019109466,0.00042387794,0.000038942246,0.000051111736,0.00063794997,0.0006133888,0.00006025278,0.00013528772,0.000030620064],"about_ca_topic_score_codex":0.0010451961,"about_ca_topic_score_gemma":0.0016459713,"teacher_disagreement_score":0.005872324,"about_ca_system_score_codex":0.0010885866,"about_ca_system_score_gemma":0.0021730587,"threshold_uncertainty_score":0.031056166},"labels":[],"label_agreement":null},{"id":"W2053608340","doi":"10.1097/yic.0b013e3282f2d42c","title":"Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia","year":2008,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital","funders":"","keywords":"Quetiapine; Quetiapine Fumarate; Tolerability; Population; Adverse effect; Atypical antipsychotic; Medicine; Internal medicine; Positive and Negative Syndrome Scale; Schizophrenia (object-oriented programming); Psychiatry; Psychology; Anesthesia; Psychosis; Antipsychotic","score_opus":0.11977088058275479,"score_gpt":0.45676853519560195,"score_spread":0.33699765461284714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053608340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988771,0.00032574826,0.00016265379,0.000059099377,0.00003000972,0.00023540472,0.00007242319,0.000020643403,0.00021695414],"genre_scores_gemma":[0.99869066,0.0003009828,0.0004475037,0.00007754435,0.00005626851,0.00015506629,0.00008963035,0.0000047071053,0.00017756106],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99869967,0.0008169915,0.0001051718,0.00014239339,0.0001429788,0.00009282007],"domain_scores_gemma":[0.9978746,0.0011337233,0.0004591763,0.00015433082,0.000086226995,0.0002918925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018952712,0.0006047831,0.0016125928,0.0002489931,0.00019429633,0.00044178872,0.00065878313,0.00087414525,0.0024826026],"category_scores_gemma":[0.0049950057,0.00033488817,0.0008590406,0.00017096536,0.0005007011,0.00042626655,0.00020757412,0.0011539387,0.00026601713],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8376839,0.021574747,0.004581996,0.00055502035,0.0011706987,0.00013399789,0.00023581099,0.0009143429,0.021964079,0.00009522502,0.00027832692,0.11081187],"study_design_scores_gemma":[0.40041274,0.5648287,0.027515154,0.00004397002,0.0007590382,0.00016645655,0.00008452656,0.0024884879,0.003074938,0.00014051578,0.00044019718,0.00004524851],"about_ca_topic_score_codex":0.0011638658,"about_ca_topic_score_gemma":0.002188542,"teacher_disagreement_score":0.0024826026,"about_ca_system_score_codex":0.00050519477,"about_ca_system_score_gemma":0.0006331695,"threshold_uncertainty_score":0.010023236},"labels":[],"label_agreement":null},{"id":"W2055658079","doi":"10.1097/yic.0b013e32835b0814","title":"Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Mental Health Research Topics","field":"Psychology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Servier; Sanofi; AstraZeneca","keywords":"Agomelatine; Medicine; Internal medicine; Oncology; Psychology; Antidepressant","score_opus":0.4378777859731027,"score_gpt":0.6243300459637704,"score_spread":0.18645225999066772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055658079","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057216756,0.10285679,0.08184637,0.6789004,0.03524337,0.026958074,0.0014877585,0.00075374794,0.01473677],"genre_scores_gemma":[0.16522142,0.032555416,0.21859083,0.5209848,0.025680197,0.03169826,0.0011900562,0.0005944821,0.0034845483],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7501559,0.20334844,0.022459134,0.0061443057,0.014158539,0.0037335935],"domain_scores_gemma":[0.60546046,0.26353192,0.025642872,0.040539883,0.05231582,0.012508996],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.34561998,0.0020582527,0.009956032,0.003619652,0.0037245278,0.008996352,0.0039367704,0.014542726,0.005267594],"category_scores_gemma":[0.33338287,0.0017927046,0.007355871,0.004870458,0.0064375657,0.015317138,0.008130009,0.019780267,0.0020500205],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05928535,0.003762449,0.022418568,0.028328322,0.009770928,0.0015859932,0.006852105,0.0019347387,0.011093298,0.043344803,0.07740223,0.7342212],"study_design_scores_gemma":[0.120273866,0.04658812,0.052528534,0.03942787,0.008616147,0.0033387619,0.0050493693,0.0026731037,0.004923868,0.13251275,0.58250844,0.0015591631],"about_ca_topic_score_codex":0.0028786424,"about_ca_topic_score_gemma":0.0052746823,"teacher_disagreement_score":0.65438,"about_ca_system_score_codex":0.004604123,"about_ca_system_score_gemma":0.01080435,"threshold_uncertainty_score":0.8069671},"labels":[],"label_agreement":null},{"id":"W2060249700","doi":"10.1097/00004850-200505000-00011","title":"Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia","year":2005,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Hôpital Louis-H Lafontaine; McGill University","funders":"Pfizer; Eli Lilly and Company","keywords":"Akathisia; Antipsychotic; Gabapentin; Parkinsonism; Schizophrenia (object-oriented programming); Psychosis; Medicine; Anesthesia; Extrapyramidal symptoms; Psychology; Psychiatry; Internal medicine","score_opus":0.07039711655451125,"score_gpt":0.45572098112586645,"score_spread":0.3853238645713552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060249700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8288038,0.14666045,0.0012383097,0.0038009172,0.0005428783,0.00017059875,0.000104392886,0.00017766212,0.01850103],"genre_scores_gemma":[0.959382,0.036363926,0.001107676,0.000612586,0.00023149971,0.00004060984,0.00006211555,0.0000091349275,0.002190434],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998946,0.00004579269,0.000018131277,0.0000049491964,0.000019070892,0.000017391409],"domain_scores_gemma":[0.9998901,0.000027473068,0.00003631044,0.0000034777618,0.00001006103,0.000032578966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030163466,0.00025900904,0.00050496584,0.00043355458,0.00031044206,0.00023741084,0.000230463,0.000427335,0.00087583106],"category_scores_gemma":[0.00037114564,0.00011203896,0.0002386525,0.00026493586,0.00023113083,0.00019090688,0.00017789417,0.000720483,0.0002254617],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0154858995,0.002757489,0.010620641,0.0022674052,0.0003146978,0.01766901,0.00068110955,0.0023766872,0.05626284,0.0019509278,0.0066046547,0.88300866],"study_design_scores_gemma":[0.033596594,0.0930605,0.43608338,0.002460093,0.0018325549,0.1339328,0.002139605,0.009571653,0.05432885,0.005842414,0.226785,0.00036654805],"about_ca_topic_score_codex":0.0012047143,"about_ca_topic_score_gemma":0.0051926905,"teacher_disagreement_score":0.0012047143,"about_ca_system_score_codex":0.0004012155,"about_ca_system_score_gemma":0.00035684457,"threshold_uncertainty_score":0.002929926},"labels":[],"label_agreement":null},{"id":"W2060418293","doi":"10.1097/yic.0000000000000053","title":"Treatment of depressive symptoms in patients with schizophrenia","year":2014,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Quetiapine; Risperidone; Somnolence; Quetiapine Fumarate; Internal medicine; Schizophrenia (object-oriented programming); Population; Psychology; Positive and Negative Syndrome Scale; Psychiatry; Atypical antipsychotic; Medicine; Adverse effect; Psychosis; Antipsychotic","score_opus":0.02471278465266374,"score_gpt":0.40402510407600856,"score_spread":0.3793123194233448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060418293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950283,0.0037227275,0.0001040464,0.0001410064,0.000025407175,0.00010946812,0.0002097896,0.000007444393,0.0006517425],"genre_scores_gemma":[0.99807775,0.0010901927,0.00025900186,0.0001848387,0.000019564597,0.000040028954,0.00022302096,8.39108e-7,0.00010476214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994636,0.00024312535,0.000103461185,0.00003988069,0.00009151601,0.000058430767],"domain_scores_gemma":[0.9995103,0.00010837625,0.00020594304,0.000020968719,0.00004997033,0.00010453978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000961011,0.00022456297,0.0007613342,0.00017589377,0.00019357126,0.00032325985,0.00014762323,0.00021354889,0.00060013245],"category_scores_gemma":[0.0014819263,0.00016525693,0.0007678158,0.0002656248,0.00012723895,0.0001675356,0.0001706323,0.00032245493,0.00009342535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09419033,0.0027479436,0.68071514,0.0013481968,0.0035850555,0.0007313785,0.0003610032,0.0012329542,0.01647081,0.0002544591,0.001713482,0.19664912],"study_design_scores_gemma":[0.013547235,0.026575472,0.95246935,0.00017568881,0.0013932389,0.0008527735,0.00021515829,0.0011847415,0.0008726547,0.00017931021,0.002503822,0.000030537125],"about_ca_topic_score_codex":0.0020914108,"about_ca_topic_score_gemma":0.006394362,"teacher_disagreement_score":0.0020914108,"about_ca_system_score_codex":0.00059556117,"about_ca_system_score_gemma":0.000581533,"threshold_uncertainty_score":0.005082369},"labels":[],"label_agreement":null},{"id":"W2067569855","doi":"10.1097/00004850-200303000-00002","title":"Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients","year":2003,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Alliance for Research on Schizophrenia and Depression","keywords":"Lithium (medication); Bipolar disorder; Sodium; Creatine; Mood stabilizer; Internal medicine; Chemistry; Endocrinology; Valproic Acid; Psychology; Medicine; Epilepsy; Psychiatry","score_opus":0.039800843193126365,"score_gpt":0.38992151949332055,"score_spread":0.35012067630019417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067569855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99941874,0.0002802762,0.000013000951,0.000018179253,0.0000032989385,0.000004899398,0.00003219534,0.000004746042,0.0002247504],"genre_scores_gemma":[0.9994357,0.0002027803,0.00004573995,0.000057432066,0.0000051059,0.000006323437,0.000083808256,0.0000014824238,0.000161579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999099,0.000020355705,0.00001975716,0.00001687911,0.000017069835,0.000015996951],"domain_scores_gemma":[0.99984646,0.000016163776,0.00006286071,0.0000075699236,0.000016394302,0.000050505085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009292839,0.0002818513,0.0005129309,0.00042770873,0.00038013086,0.00036799698,0.000114092676,0.00032866668,0.0008544804],"category_scores_gemma":[0.00037187894,0.00022069534,0.00019229074,0.00029252685,0.00022602195,0.00013346938,0.00012893935,0.00028091285,0.00014794663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018605208,0.0013126091,0.7183009,0.00032649972,0.0006268887,0.003961953,0.0013847525,0.00018515425,0.21508099,0.00006417583,0.00079975114,0.039351113],"study_design_scores_gemma":[0.00015055115,0.0017092046,0.9949108,0.000010928794,0.00007422173,0.0012196243,0.0002638858,0.00007292073,0.0013860285,0.000021249476,0.00017501536,0.0000055612177],"about_ca_topic_score_codex":0.004871424,"about_ca_topic_score_gemma":0.011954349,"teacher_disagreement_score":0.004871424,"about_ca_system_score_codex":0.00034274472,"about_ca_system_score_gemma":0.00018858569,"threshold_uncertainty_score":0.009686172},"labels":[],"label_agreement":null},{"id":"W2069559197","doi":"10.1097/yic.0b013e32819f8400","title":"Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender–age interactions","year":2007,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute of Mental Health; National Alliance for Research on Schizophrenia and Depression; GlaxoSmithKline; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Bupropion; Serotonin reuptake inhibitor; Somatization; Hamilton Anxiety Rating Scale; Psychology; Antidepressant; Hamilton Rating Scale for Depression; Major depressive disorder; Reuptake inhibitor; Psychiatry; Anxiety; Fluoxetine; Internal medicine; Serotonin; Medicine; Mood","score_opus":0.09772833094981877,"score_gpt":0.498031774912075,"score_spread":0.40030344396225626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069559197","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7426154,0.25265825,0.00085562817,0.0004882129,0.0002834812,0.0000675023,0.00069494476,0.000037287235,0.0022993712],"genre_scores_gemma":[0.9864443,0.011429772,0.0005396473,0.00030299716,0.00042202848,0.000045807374,0.00033547592,0.000010952057,0.00046890692],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952933,0.0028919098,0.0007411865,0.00029878432,0.0006276819,0.00014713098],"domain_scores_gemma":[0.98723537,0.009557823,0.0019159364,0.0004096775,0.0005818839,0.00029930743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008867109,0.0003723151,0.0017004836,0.0007669529,0.000111611036,0.0006369238,0.00025123157,0.0006189753,0.0015108753],"category_scores_gemma":[0.009365038,0.00033213687,0.0023736106,0.0007300726,0.00021768654,0.00062448514,0.00030623024,0.0003785365,0.00019498539],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16301437,0.00046460176,0.4947116,0.0067949253,0.056658216,0.0009038135,0.00068090076,0.00108141,0.044108283,0.00046803986,0.0011536438,0.22996019],"study_design_scores_gemma":[0.0024779378,0.017613579,0.93930966,0.00029001775,0.032465152,0.0007401818,0.00022916774,0.00056462805,0.0031070274,0.00030615216,0.0028538017,0.000042686825],"about_ca_topic_score_codex":0.00031721682,"about_ca_topic_score_gemma":0.0009879986,"teacher_disagreement_score":0.008867109,"about_ca_system_score_codex":0.00021333275,"about_ca_system_score_gemma":0.00019777608,"threshold_uncertainty_score":0.04689437},"labels":[],"label_agreement":null},{"id":"W2069919941","doi":"10.1097/yic.0b013e32833a5ff9","title":"Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia","year":2010,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research","keywords":"Tardive dyskinesia; Antipsychotic; Schizophrenia (object-oriented programming); Dyskinesia; Medicine; Pharmacology; Internal medicine; Psychiatry","score_opus":0.026781812637581073,"score_gpt":0.3637141882568271,"score_spread":0.33693237561924605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069919941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993876,0.00007619009,0.0001086414,0.000022317878,0.0000053331546,0.0000039316865,0.00013637294,0.0000034989796,0.00025602503],"genre_scores_gemma":[0.9994734,0.000028283399,0.000107769316,0.000019786823,0.000007525567,0.0000035094026,0.00017956321,0.000003899074,0.00017625831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995115,0.00009093747,0.000089075394,0.00014787944,0.00009392889,0.000066664405],"domain_scores_gemma":[0.99905986,0.0002704942,0.00035971342,0.00009371291,0.000060402457,0.00015588335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050798437,0.00042223875,0.00056518003,0.0006054017,0.0005339213,0.0003848031,0.000293981,0.00049870054,0.0047048205],"category_scores_gemma":[0.0021228136,0.00026911867,0.00041667756,0.00053328223,0.00036552447,0.00016677805,0.0002519195,0.00037394676,0.00040742627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017337129,0.000109958724,0.9612987,0.00003937546,0.0004617653,0.0017582484,0.0003128805,0.00009848348,0.029220497,0.00015039068,0.00021047571,0.0046054823],"study_design_scores_gemma":[0.000059911465,0.00026726475,0.99448615,0.000010139355,0.0001602632,0.0032814408,0.000121896235,0.00027125902,0.0009092501,0.00010299326,0.0003215271,0.00000793864],"about_ca_topic_score_codex":0.0025636544,"about_ca_topic_score_gemma":0.0045972555,"teacher_disagreement_score":0.0047048205,"about_ca_system_score_codex":0.00015869779,"about_ca_system_score_gemma":0.00021903464,"threshold_uncertainty_score":0.015739262},"labels":[],"label_agreement":null},{"id":"W2072716458","doi":"10.1097/yic.0b013e32834e3bea","title":"Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder","year":2011,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Riverview Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Pfizer; Servier; GlaxoSmithKline; H. Lundbeck A/S; Eli Lilly and Company","keywords":"Quetiapine; Risperidone; Mood stabilizer; Mood; Atypical antipsychotic; Bipolar disorder; Psychiatry; Psychology; Neuropsychology; Verbal memory; Neuropsychological test; Antipsychotic; Schizophrenia (object-oriented programming); Clinical psychology; Verbal learning; Population; Bipolar I disorder; Randomized controlled trial; Medicine; Internal medicine; Cognition; Mania","score_opus":0.05650657488474105,"score_gpt":0.4350242997825321,"score_spread":0.37851772489779106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072716458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991304,0.00049107836,0.000013254394,0.000017718181,0.0000044271005,0.000007039255,0.000023142742,0.0000023394791,0.00031053217],"genre_scores_gemma":[0.999424,0.0002943544,0.0000648281,0.000036594705,0.000012693894,0.0000067473875,0.00008158576,7.7510674e-7,0.000078369696],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99978334,0.000081603335,0.000036777543,0.000024952256,0.000043223386,0.000029969846],"domain_scores_gemma":[0.99944896,0.00017514026,0.00014249669,0.000024419309,0.000044173616,0.0001647924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031744433,0.00035247323,0.0006664498,0.00028418587,0.00019495028,0.00031419404,0.00015469949,0.0002637229,0.000549924],"category_scores_gemma":[0.0016037754,0.000116494455,0.00033427286,0.00021779035,0.00022352929,0.00016271966,0.00012850619,0.0003285088,0.00009833973],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14814256,0.005457344,0.6455024,0.0004900666,0.0021315294,0.00223913,0.0011458225,0.00082826486,0.03282865,0.000080759,0.00062420743,0.16052924],"study_design_scores_gemma":[0.0027586443,0.026672976,0.96730286,0.000022952456,0.00041155337,0.00074751815,0.00021828228,0.00038294194,0.0011048923,0.00006249295,0.00030122552,0.0000136795],"about_ca_topic_score_codex":0.0023509425,"about_ca_topic_score_gemma":0.0077132583,"teacher_disagreement_score":0.0023509425,"about_ca_system_score_codex":0.00039433007,"about_ca_system_score_gemma":0.00022932429,"threshold_uncertainty_score":0.0046744943},"labels":[],"label_agreement":null},{"id":"W2074253019","doi":"10.1097/yic.0b013e328337910b","title":"Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching","year":2010,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Brand names; Equivalence (formal languages); Medicine; Bioequivalence; Generic drug; Key (lock); Risk analysis (engineering); Business; Advertising; Intensive care medicine; Computer science; Drug; Psychiatry; Pharmacology; Computer security; Mathematics","score_opus":0.11950303845872741,"score_gpt":0.5020726205829491,"score_spread":0.3825695821242217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074253019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92572725,0.009672184,0.011576291,0.028655818,0.0010822046,0.0005921696,0.00018646703,0.00037588,0.02213166],"genre_scores_gemma":[0.98526335,0.0026202458,0.0029023467,0.005351685,0.0009801317,0.00014095353,0.000081429804,0.000045681118,0.0026141645],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9981614,0.0004388175,0.00030483407,0.00020474609,0.00030734917,0.0005828489],"domain_scores_gemma":[0.995044,0.0019837606,0.0014978496,0.00036428962,0.00026621745,0.0008439304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015060698,0.0020541276,0.0010497775,0.0014760435,0.0035149655,0.001906845,0.0019092725,0.010052972,0.0014218646],"category_scores_gemma":[0.010978365,0.00078171573,0.0019647689,0.001521986,0.0031938914,0.0020147255,0.001950498,0.007283718,0.00059747713],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009586542,0.00013672357,0.009088265,0.00005196037,0.000016158308,0.9834841,0.0009732824,0.00018443225,0.00047790573,0.00062745874,0.00084748026,0.004016441],"study_design_scores_gemma":[0.0000149904845,0.00013164336,0.0028568087,0.000027707049,0.000014001401,0.9941202,0.0003862813,0.00032570615,0.00061097986,0.00035458375,0.0011349694,0.00002209858],"about_ca_topic_score_codex":0.0039752405,"about_ca_topic_score_gemma":0.0039657815,"teacher_disagreement_score":0.010052972,"about_ca_system_score_codex":0.0026275371,"about_ca_system_score_gemma":0.0008598837,"threshold_uncertainty_score":0.019064188},"labels":[],"label_agreement":null},{"id":"W2076012649","doi":"10.1097/yic.0b013e32835b09cd","title":"Safety and tolerability of duloxetine in elderly patients with major depressive disorder","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Duloxetine; Duloxetine Hydrochloride; Placebo; Tolerability; Adverse effect; Medicine; Internal medicine; Discontinuation; Nausea; Anesthesia","score_opus":0.020558531167731448,"score_gpt":0.39723884824329436,"score_spread":0.37668031707556293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076012649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800945,0.018334275,0.00027730077,0.00016876389,0.000044435365,0.0001038855,0.00035937957,0.000012522948,0.00060510176],"genre_scores_gemma":[0.99517006,0.0035950372,0.00028291682,0.0003071938,0.0001420269,0.00005666285,0.0003132401,0.0000022708064,0.00013057305],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99902546,0.0005427777,0.00014445932,0.00006753209,0.00017251997,0.00004721582],"domain_scores_gemma":[0.9973521,0.0009985421,0.0011682749,0.0000882808,0.00024032938,0.00015249627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021117558,0.00026044282,0.0011127219,0.0002515458,0.00019288129,0.00035314186,0.00016265063,0.00031672727,0.00055749336],"category_scores_gemma":[0.0035995936,0.00013661571,0.00086141395,0.0002960113,0.00016182208,0.00020792276,0.00014263885,0.00031444334,0.0001008247],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14105707,0.0017187095,0.58723783,0.003391718,0.008838371,0.00089685054,0.00039200124,0.00071042654,0.017380472,0.000071877985,0.0016171477,0.23668753],"study_design_scores_gemma":[0.010225127,0.058228754,0.9215575,0.00017668515,0.0042252652,0.0012213337,0.00023008358,0.00067630416,0.0015330021,0.00007324279,0.0018197005,0.000033003005],"about_ca_topic_score_codex":0.00066211855,"about_ca_topic_score_gemma":0.0017567547,"teacher_disagreement_score":0.0021117558,"about_ca_system_score_codex":0.0002337847,"about_ca_system_score_gemma":0.00032739414,"threshold_uncertainty_score":0.011168182},"labels":[],"label_agreement":null},{"id":"W2079218917","doi":"10.1097/yic.0b013e3282f2b4c5","title":"Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients","year":2008,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Hôtel-Dieu Grace Healthcare","funders":"","keywords":"Risperidone; Bipolar disorder; Medicine; Psychiatry; Concomitant; Treatment of bipolar disorder; Antipsychotic; Mood stabilizer; Pharmacotherapy; Schizophrenia (object-oriented programming); Pediatrics; Atypical antipsychotic; Antipsychotic Agent; Mood; Extrapyramidal symptoms; Refractory (planetary science); Internal medicine; Mania","score_opus":0.04698393468892187,"score_gpt":0.41285942839306433,"score_spread":0.36587549370414246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079218917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991825,0.00034177589,0.000025328445,0.000048607453,0.000011340195,0.000029655219,0.00007099806,0.0000027191404,0.0002871191],"genre_scores_gemma":[0.9982768,0.00042221605,0.00007812253,0.00027001297,0.00004709835,0.000046961824,0.00036244458,0.000002830297,0.0004934571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939954,0.00016789176,0.00005003575,0.000089448986,0.00014664799,0.0001464191],"domain_scores_gemma":[0.9985714,0.00017916453,0.00045947594,0.00005970719,0.00014929452,0.0005810021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012376604,0.0005857914,0.0008960889,0.00052534917,0.001100905,0.0011096881,0.0002650089,0.00091082416,0.0010494476],"category_scores_gemma":[0.002048315,0.00054770714,0.00084491726,0.0006201099,0.0004509565,0.00081562984,0.00039804933,0.0014848666,0.00035852756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010005369,0.008766481,0.96158004,0.00006712576,0.00034603424,0.0011408996,0.0018324878,0.00014304943,0.0011404933,0.00004021211,0.00066298974,0.014274745],"study_design_scores_gemma":[0.001670034,0.022407942,0.9724238,0.000025972267,0.00022389059,0.0008745739,0.00068446086,0.0005132176,0.0001570067,0.00003025199,0.0009480219,0.000040976007],"about_ca_topic_score_codex":0.008074929,"about_ca_topic_score_gemma":0.0076707955,"teacher_disagreement_score":0.008074929,"about_ca_system_score_codex":0.00070714415,"about_ca_system_score_gemma":0.0005942944,"threshold_uncertainty_score":0.016055882},"labels":[],"label_agreement":null},{"id":"W2079449062","doi":"10.1097/yic.0b013e32831d7980","title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial","year":2009,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Hamilton Health Sciences","funders":"GlaxoSmithKline; Pfizer","keywords":"Pregabalin; Placebo; Hamilton Anxiety Rating Scale; Medicine; Generalized anxiety disorder; Anxiety; Anxiolytic; Internal medicine; Clinical endpoint; Adverse effect; Venlafaxine; Randomized controlled trial; Gastroenterology; Anesthesia; Psychiatry; Antidepressant","score_opus":0.0923804960608773,"score_gpt":0.4760551853894529,"score_spread":0.3836746893285756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079449062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904445,0.005840552,0.0004854242,0.00025709628,0.00027631695,0.0012737736,0.00042159526,0.00008569349,0.0009151289],"genre_scores_gemma":[0.98980266,0.0042398316,0.0011360784,0.00044574746,0.00045173225,0.0017688691,0.0005351444,0.000023903152,0.0015960723],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99879587,0.000737057,0.00010989498,0.00014174834,0.000086725246,0.00012877097],"domain_scores_gemma":[0.9985819,0.0005860813,0.00025857284,0.0001411014,0.00009538652,0.00033709654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024049582,0.0013552732,0.0035455464,0.0004159856,0.00039448403,0.0007541141,0.000916325,0.0017813296,0.0035293049],"category_scores_gemma":[0.0021483256,0.00060341106,0.0016471886,0.00037118525,0.0009898253,0.0008140187,0.00028234103,0.0020158035,0.00053207384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97077,0.0063282796,0.00034858804,0.00055326306,0.0007088135,0.000027841868,0.00005069092,0.00016008738,0.0031579118,0.000039098242,0.00019794903,0.017657517],"study_design_scores_gemma":[0.93793845,0.059392564,0.0015930936,0.000023192453,0.0003039065,0.000020508141,0.0000125501565,0.00015664875,0.00033490872,0.000037436133,0.00017618541,0.00001063215],"about_ca_topic_score_codex":0.00062873395,"about_ca_topic_score_gemma":0.0014022045,"teacher_disagreement_score":0.0035455464,"about_ca_system_score_codex":0.000537239,"about_ca_system_score_gemma":0.00067401706,"threshold_uncertainty_score":0.012718797},"labels":[],"label_agreement":null},{"id":"W2083196423","doi":"10.1097/01.yic.0000195658.91524.61","title":"Sleep disturbances and depression: a challenge for antidepressants","year":2006,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Sleep and related disorders","field":"Psychology","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"","keywords":"Depression (economics); Insomnia; Agomelatine; Sedative; Antidepressant; Sleep (system call); Sleep disorder; Medicine; Psychiatry; Sedation; Adverse effect; Psychology; Anesthesia; Internal medicine; Anxiety","score_opus":0.10450793233081816,"score_gpt":0.5136065227362556,"score_spread":0.40909859040543745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083196423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006218634,0.99414366,0.00009196955,0.0043368293,0.0005462918,0.0000028908096,0.000006186246,0.000009854681,0.00080023805],"genre_scores_gemma":[0.00064118,0.99509144,0.0002577897,0.001874884,0.0011676328,0.0000065167665,0.000012678292,0.0000024830692,0.0009454354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995684,0.00011132044,0.00008041704,0.000048784892,0.00015934165,0.0000317549],"domain_scores_gemma":[0.99899775,0.00046753025,0.00009233897,0.00004747594,0.0002969194,0.00009806024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012905471,0.0009887029,0.0026021937,0.001243336,0.00070116104,0.0016191324,0.0011164178,0.0030780975,0.0038837276],"category_scores_gemma":[0.0015874562,0.00037477363,0.00059777533,0.0013095451,0.00091541966,0.0027193166,0.0009733017,0.003548292,0.0030437128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008216394,0.00007518138,0.0002979809,0.0050917985,0.000070812246,0.00043062054,0.0001346161,0.00014946585,0.0006448396,0.0045282813,0.08675782,0.9017364],"study_design_scores_gemma":[0.00005130003,0.00016383384,0.0018197407,0.0063601756,0.00008566308,0.0035526124,0.00031476727,0.000101207595,0.00013723418,0.005920253,0.9814647,0.000028575894],"about_ca_topic_score_codex":0.0027953323,"about_ca_topic_score_gemma":0.005820393,"teacher_disagreement_score":0.0038837276,"about_ca_system_score_codex":0.0011957302,"about_ca_system_score_gemma":0.001843711,"threshold_uncertainty_score":0.012992322},"labels":[],"label_agreement":null},{"id":"W2083219020","doi":"10.1097/00004850-200403000-00008","title":"Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania","year":2004,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Risperidone; Mania; Lithium (medication); Medicine; Psychiatry; Bipolar disorder; Pharmacology; Psychology; Schizophrenia (object-oriented programming)","score_opus":0.05787318869760582,"score_gpt":0.4440735273378229,"score_spread":0.3862003386402171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083219020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949189,0.0035513204,0.00015255588,0.00009569646,0.000027117148,0.00024729953,0.00014489019,0.000033272438,0.0008289191],"genre_scores_gemma":[0.99758136,0.0011314948,0.0003855193,0.000084709485,0.000065455984,0.00018014092,0.0002577578,0.0000050591484,0.00030863227],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997968,0.001344247,0.00019813863,0.000113488844,0.00019341001,0.00018270175],"domain_scores_gemma":[0.9961008,0.0018360738,0.0010542407,0.0001561903,0.00018060254,0.0006720875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026805943,0.0004461397,0.0017698178,0.000566347,0.00021709932,0.00087118224,0.0004557308,0.00056298106,0.0022459347],"category_scores_gemma":[0.0036964302,0.00026227807,0.0018718428,0.00043660315,0.00037350302,0.0004421993,0.00035335388,0.00093218515,0.00035120867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8389835,0.0069714366,0.020242855,0.0006977197,0.00476255,0.00020655141,0.000316125,0.0012188005,0.003977679,0.0001899532,0.00045512553,0.12197776],"study_design_scores_gemma":[0.18001956,0.67191654,0.13129988,0.00033005947,0.005978685,0.00050741574,0.00028442417,0.0045473245,0.002262332,0.0004103451,0.0023719552,0.00007147358],"about_ca_topic_score_codex":0.00054582057,"about_ca_topic_score_gemma":0.0021489647,"teacher_disagreement_score":0.0026805943,"about_ca_system_score_codex":0.00069390034,"about_ca_system_score_gemma":0.00071827444,"threshold_uncertainty_score":0.0141765475},"labels":[],"label_agreement":null},{"id":"W2088919847","doi":"10.1097/00004850-200015040-00005","title":"Divalproex sodium increases plasma GABA levels in healthy volunteers","year":2000,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"","keywords":"Anticonvulsant; Derivatization; Pharmacology; Medicine; Mood; High-performance liquid chromatography; Internal medicine; Chemistry; Psychology; Endocrinology; Psychiatry; Epilepsy; Chromatography","score_opus":0.08271650141297898,"score_gpt":0.484277862468787,"score_spread":0.40156136105580803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088919847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982462,0.0010070839,0.00012421963,0.00003757257,0.00001598908,0.000019065272,0.000066878725,0.000015944679,0.0004671195],"genre_scores_gemma":[0.9985152,0.00049800024,0.00018576389,0.00011311615,0.000024932135,0.000021794423,0.00013701447,0.0000037130194,0.0005005586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987125,0.000049761307,0.000010924021,0.000028875484,0.000022266564,0.000016872213],"domain_scores_gemma":[0.9998311,0.000041838928,0.00004571164,0.000013056249,0.000015229927,0.000052968913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001265694,0.0003437156,0.0003533532,0.00016675514,0.0002151442,0.00022536305,0.00007210312,0.0003609166,0.00094343716],"category_scores_gemma":[0.00045209494,0.00019524456,0.00010563507,0.00009133412,0.00020413344,0.00016601915,0.00013559898,0.0002943262,0.0002540343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09011655,0.003946106,0.25964248,0.0006006295,0.00055087166,0.003486901,0.0009257118,0.00026044028,0.5323905,0.00012866614,0.0015270197,0.10642419],"study_design_scores_gemma":[0.0018123933,0.07051498,0.8826948,0.000035498964,0.00029496622,0.00519681,0.0004110672,0.0004605939,0.03502007,0.00013396353,0.0033994566,0.000025378824],"about_ca_topic_score_codex":0.0005235299,"about_ca_topic_score_gemma":0.0008575035,"teacher_disagreement_score":0.00094343716,"about_ca_system_score_codex":0.00010805935,"about_ca_system_score_gemma":0.00010116176,"threshold_uncertainty_score":0.003156066},"labels":[],"label_agreement":null},{"id":"W2094664948","doi":"10.1097/yic.0b013e328362db99","title":"Absence of evidence that the pro re nata regimen confers benefit","year":2013,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"Dainippon Sumitomo Pharma","keywords":"Pro re nata; Medicine; Risperidone; Olanzapine; Quetiapine; Psychiatry; Lorazepam; Population; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.28183136811909804,"score_gpt":0.5199563019582739,"score_spread":0.23812493383917588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094664948","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0188762,0.96541625,0.00086055865,0.0042845737,0.00062776473,0.00049868977,0.0031606872,0.000026639687,0.0062485505],"genre_scores_gemma":[0.38864955,0.59521085,0.0024384223,0.008167148,0.0017657414,0.00070391106,0.0023665735,0.00004660959,0.00065108394],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.98221534,0.007085167,0.007058322,0.0014040215,0.001836251,0.000400893],"domain_scores_gemma":[0.82829964,0.14295408,0.019863091,0.002934565,0.005000051,0.0009485109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022561166,0.0007274758,0.0050193635,0.0046132496,0.00040121726,0.0028465348,0.0017063421,0.0027852934,0.010975208],"category_scores_gemma":[0.11293839,0.00066345476,0.008111324,0.004715457,0.0015613106,0.0023864168,0.0013974733,0.0016050669,0.0011713571],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007051162,0.000119957294,0.028507251,0.76262164,0.09248868,0.0007365022,0.00026012684,0.00016651435,0.0008583101,0.0010666358,0.0033471016,0.1027761],"study_design_scores_gemma":[0.0043003806,0.004266825,0.10035493,0.4460768,0.39393562,0.0023836952,0.0007980241,0.00024880943,0.0009582351,0.002952501,0.043629892,0.00009433453],"about_ca_topic_score_codex":0.0019081224,"about_ca_topic_score_gemma":0.004632547,"teacher_disagreement_score":0.022561166,"about_ca_system_score_codex":0.0020303058,"about_ca_system_score_gemma":0.0030354343,"threshold_uncertainty_score":0.11931628},"labels":[],"label_agreement":null},{"id":"W2094885305","doi":"10.1097/yic.0b013e328080ca57","title":"A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania","year":2007,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"","keywords":"Divalproex; Quetiapine; Mania; Lithium (medication); Placebo; Bipolar disorder; Young Mania Rating Scale; Tolerability; Psychology; Medicine; Psychiatry; Internal medicine; Adverse effect; Schizophrenia (object-oriented programming)","score_opus":0.10092405127406186,"score_gpt":0.4979474015834935,"score_spread":0.39702335030943164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094885305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840895,0.005884106,0.0006530545,0.0006138171,0.0011437343,0.0043092947,0.0006696266,0.00023865241,0.002398216],"genre_scores_gemma":[0.9826889,0.0038827178,0.002278805,0.0014441641,0.0011762495,0.004657997,0.00083151046,0.00003651123,0.0030031742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990759,0.000540791,0.00007621282,0.00013271702,0.00007617025,0.000098116],"domain_scores_gemma":[0.9987313,0.00047403004,0.00026733827,0.000098591765,0.00007596917,0.00035278458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014571949,0.0013315933,0.0038048972,0.00068083423,0.00051460456,0.00086832885,0.0014233685,0.002317254,0.0062327594],"category_scores_gemma":[0.0024755476,0.0007376485,0.0013593977,0.00045755424,0.0017450135,0.0010743681,0.00038729425,0.002966307,0.00086817663],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98482716,0.004642857,0.0001761806,0.00038069458,0.0003874556,0.000029218736,0.000021442547,0.000062489846,0.0017719686,0.00004742488,0.0002694241,0.0073838294],"study_design_scores_gemma":[0.9588236,0.039707333,0.0006021606,0.00001363299,0.00019416813,0.000018659892,0.000008030817,0.00013834723,0.00023362567,0.000053040967,0.00020069272,0.000006679392],"about_ca_topic_score_codex":0.0010255186,"about_ca_topic_score_gemma":0.0025549447,"teacher_disagreement_score":0.0062327594,"about_ca_system_score_codex":0.00068820524,"about_ca_system_score_gemma":0.00096939405,"threshold_uncertainty_score":0.020850658},"labels":[],"label_agreement":null},{"id":"W2165348295","doi":"10.1097/00004850-200201000-00007","title":"Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication","year":2002,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Riverview Hospital","funders":"","keywords":"Clozapine; Olanzapine; Risperidone; Neurocognitive; Schizophrenia (object-oriented programming); Psychology; Psychopathology; Cognition; Psychosis; Psychiatry; Medicine; Clinical psychology","score_opus":0.07810214116235702,"score_gpt":0.4065204257726802,"score_spread":0.3284182846103232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165348295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99953103,0.0001848203,0.000019927136,0.000021904178,0.0000025690879,0.000003089395,0.000038602142,0.0000019090037,0.00019615436],"genre_scores_gemma":[0.999765,0.000074145224,0.000026582135,0.000017950078,0.000004488603,0.000002074728,0.000064069936,6.5885337e-7,0.000044882323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968874,0.000095357376,0.000060190207,0.000028298857,0.000091782604,0.000035698573],"domain_scores_gemma":[0.9972076,0.00060264,0.0014293663,0.0000940744,0.00017467153,0.0004917075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036967595,0.00028151236,0.00037529707,0.00054867344,0.00022625201,0.00041476722,0.00013826489,0.00030122255,0.0008212083],"category_scores_gemma":[0.0033792309,0.00020175416,0.00030812502,0.00042684135,0.0002691777,0.00024109366,0.00022964834,0.0004715916,0.0001289128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009001949,0.00014288987,0.9949168,0.000022819619,0.00014290787,0.00019665055,0.00013510285,0.000085738226,0.0009095545,0.000009609045,0.000043079006,0.002494713],"study_design_scores_gemma":[0.000022760447,0.00034723995,0.99903035,0.0000032180237,0.000027796805,0.00029513947,0.0000714947,0.00011149877,0.00004703861,0.0000100962,0.000029971647,0.0000035092992],"about_ca_topic_score_codex":0.0015820987,"about_ca_topic_score_gemma":0.0032472273,"teacher_disagreement_score":0.0015820987,"about_ca_system_score_codex":0.00027323645,"about_ca_system_score_gemma":0.00016317054,"threshold_uncertainty_score":0.0031457543},"labels":[],"label_agreement":null},{"id":"W2306562730","doi":"10.1097/yic.0000000000000121","title":"An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder","year":2016,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); York University","funders":"Pfizer Canada; Pfizer","keywords":"Major depressive disorder; Antidepressant; Placebo; Internal medicine; Reuptake inhibitor; Serotonin reuptake inhibitor; Medicine; Population; Psychiatry; Psychology","score_opus":0.06735467632118762,"score_gpt":0.5010312144244039,"score_spread":0.43367653810321627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306562730","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9211524,0.06955191,0.004793609,0.00022536173,0.00007298668,0.0009720857,0.00214937,0.000045302815,0.0010369834],"genre_scores_gemma":[0.98828554,0.00710218,0.0023483466,0.00014068272,0.0000642957,0.00024636395,0.0015013356,0.000009309131,0.0003019542],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99095213,0.005688871,0.0010490175,0.0006685211,0.0013940646,0.00024746303],"domain_scores_gemma":[0.9907991,0.0054303138,0.0021698046,0.00060207513,0.0007980103,0.00020066711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012671379,0.000852886,0.0036882646,0.0014637455,0.00017955486,0.0011109911,0.00049873313,0.00057201093,0.000917654],"category_scores_gemma":[0.01036087,0.00045477372,0.0074451654,0.0014837472,0.00040845058,0.0006240288,0.00068819016,0.0008193213,0.00010906152],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28617793,0.0019835487,0.092786975,0.013808529,0.35596347,0.00043667507,0.0002667481,0.013910415,0.026931817,0.00048546365,0.0007690735,0.20647943],"study_design_scores_gemma":[0.03401698,0.1386085,0.48683074,0.0008885114,0.30979547,0.00076408207,0.00019877679,0.012838205,0.008324359,0.00084388134,0.006714823,0.00017564371],"about_ca_topic_score_codex":0.0007509685,"about_ca_topic_score_gemma":0.0020713657,"teacher_disagreement_score":0.012671379,"about_ca_system_score_codex":0.000756661,"about_ca_system_score_gemma":0.00088355545,"threshold_uncertainty_score":0.06701344},"labels":[],"label_agreement":null},{"id":"W2312753591","doi":"10.1097/yic.0b013e328363aa5a","title":"Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics","year":2013,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Depot; Schizophrenia (object-oriented programming); Psychiatry; Medicine; Political science","score_opus":0.08944316725605528,"score_gpt":0.4812767298087197,"score_spread":0.39183356255266444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312753591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91261935,0.08455763,0.00006719394,0.000098586606,0.000026668375,0.00005241001,0.002179396,0.000004966698,0.00039387812],"genre_scores_gemma":[0.9840389,0.013587875,0.00012116297,0.00006859798,0.000022448643,0.000048531307,0.002030819,0.0000019496233,0.000079787525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765414,0.0006761253,0.00084169477,0.00026277063,0.00044493197,0.00012042097],"domain_scores_gemma":[0.98844343,0.003363599,0.006764124,0.00021727708,0.0008746025,0.0003370588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002763326,0.00021625518,0.0008805282,0.0025707507,0.00031156818,0.0006224025,0.00038544636,0.0004130512,0.00044549647],"category_scores_gemma":[0.0074429135,0.00022469812,0.001672076,0.0022874495,0.00031704357,0.00059462304,0.00048752868,0.0002855476,0.00004817761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017729652,0.00010389142,0.9690057,0.0057603437,0.004157641,0.00039388085,0.0005284831,0.00012047053,0.00033643504,0.00003624412,0.00040512157,0.01737884],"study_design_scores_gemma":[0.0001036823,0.0006634044,0.9933854,0.0014349555,0.0025256686,0.00052659237,0.00038486623,0.00006727769,0.00009711409,0.000027539836,0.0007638771,0.000019586972],"about_ca_topic_score_codex":0.0058827307,"about_ca_topic_score_gemma":0.014488409,"teacher_disagreement_score":0.0058827307,"about_ca_system_score_codex":0.0008066142,"about_ca_system_score_gemma":0.0009783673,"threshold_uncertainty_score":0.014614046},"labels":[],"label_agreement":null},{"id":"W2313477739","doi":"10.1097/yic.0000000000000105","title":"A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan","year":2015,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"Eli Lilly Japan; Meiji Seika Pharma; Shionogi; Pfizer Japan; Abbott Japan; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; AbbVie; Novartis Pharma; Otsuka Pharmaceutical; Eisai; Astellas Pharma; GlaxoSmithKline Japan; Kyowa Hakko Kirin; Pfizer; Dainippon Sumitomo Pharma; Boehringer Ingelheim Japan; Astellas Foundation for Research on Metabolic Disorders; GlaxoSmithKline; FP Pharmaceutical Corporation; Bristol-Myers Squibb; Eli Lilly and Company; MSD K.K.; Asahi Kasei Pharma Corporation","keywords":"Venlafaxine; Placebo; Major depressive disorder; Medicine; Term (time); Randomized controlled trial; Immediate release; Anesthesia; Venlafaxine Hydrochloride; Internal medicine; Psychiatry; Pharmacology; Antidepressant; Anxiety; Physics; Alternative medicine; Mood","score_opus":0.05728496281993833,"score_gpt":0.4471914282007698,"score_spread":0.38990646538083146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313477739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903134,0.003150419,0.0007251473,0.00019228671,0.00034704385,0.0046082796,0.00022314732,0.00004113094,0.00039915903],"genre_scores_gemma":[0.985898,0.0021871827,0.0023672145,0.0007168132,0.0004689135,0.006863268,0.00036692395,0.000008264706,0.0011233025],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99876165,0.00065364223,0.00015760792,0.00021262273,0.0001068433,0.00010769011],"domain_scores_gemma":[0.9988524,0.00022063396,0.00029295727,0.00012724602,0.00013162688,0.0003752011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027228866,0.0010796927,0.003636422,0.00034028594,0.0005161414,0.00052592234,0.0006614078,0.0012633511,0.0021718037],"category_scores_gemma":[0.0015989054,0.0007152154,0.0013970395,0.0002942746,0.0011385113,0.00064276543,0.00031149213,0.001403032,0.00028722078],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9515552,0.018625924,0.0023552314,0.00090956007,0.0013706358,0.00006707961,0.00009842252,0.00016732817,0.0076189917,0.00006824834,0.00030897788,0.016854431],"study_design_scores_gemma":[0.8386265,0.15432844,0.005342464,0.000024107656,0.0006222613,0.000035463378,0.000020666477,0.00020050486,0.00033618184,0.000028801842,0.000419211,0.0000153974],"about_ca_topic_score_codex":0.00061704917,"about_ca_topic_score_gemma":0.0018629166,"teacher_disagreement_score":0.003636422,"about_ca_system_score_codex":0.00048070395,"about_ca_system_score_gemma":0.0013833981,"threshold_uncertainty_score":0.014400184},"labels":[],"label_agreement":null},{"id":"W2314697748","doi":"10.1097/01.yic.0000423366.01355.8a","title":"Recovery is such a huge word","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Becton Dickinson (Canada)","funders":"","keywords":"Word (group theory); Computer science; Natural language processing; Psychology; Philosophy; Linguistics","score_opus":0.06557486367087356,"score_gpt":0.4726603440295946,"score_spread":0.40708548035872105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314697748","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011994407,0.013253524,0.0019056193,0.88060933,0.05228162,0.000026032469,0.00027294896,0.00026104503,0.050190367],"genre_scores_gemma":[0.041803673,0.02530656,0.005280285,0.8001643,0.037786674,0.00015047671,0.00082842226,0.00082043733,0.08785914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99124444,0.0042251884,0.0007122768,0.0005227843,0.0023720448,0.0009232128],"domain_scores_gemma":[0.97270983,0.011549048,0.0014574222,0.002247915,0.0052206926,0.0068150535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010185236,0.0009223831,0.0012981751,0.0011867847,0.0063494667,0.008751694,0.0014238396,0.006084586,0.042314213],"category_scores_gemma":[0.033320196,0.00034005096,0.00080428936,0.0011006618,0.0115111,0.013981364,0.0075561823,0.021093756,0.019494869],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004362511,0.000045438013,0.00026747052,0.00024006354,0.000019214307,0.00018830194,0.0014166804,0.000034186796,0.00012544438,0.026921013,0.91700715,0.053691443],"study_design_scores_gemma":[0.000018394285,0.000044733188,0.00051553844,0.0008314004,0.000014158007,0.0006389096,0.004790131,0.000034544322,0.00008326703,0.02963174,0.9633535,0.000043617052],"about_ca_topic_score_codex":0.0017321109,"about_ca_topic_score_gemma":0.0040285788,"teacher_disagreement_score":0.042314213,"about_ca_system_score_codex":0.002353598,"about_ca_system_score_gemma":0.0067791906,"threshold_uncertainty_score":0.14155513},"labels":[],"label_agreement":null},{"id":"W2315927007","doi":"10.1097/yic.0000000000000031","title":"Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine","year":2014,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); University of British Columbia","funders":"Pfizer","keywords":"Major depressive disorder; Hamilton Rating Scale for Depression; Rating scale; Placebo; Depression (economics); Post-hoc analysis; Internal medicine; Psychology; Psychiatry; Medicine; Physical therapy; Cognition","score_opus":0.01820573840165302,"score_gpt":0.35671394959965935,"score_spread":0.33850821119800634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315927007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982022,0.0007376569,0.00009373189,0.000035624926,0.00001708188,0.0001278262,0.00044462777,0.000005600578,0.00033555177],"genre_scores_gemma":[0.99867827,0.00016973754,0.00011859154,0.000056071858,0.00002382229,0.00012339652,0.00060797844,0.0000013947403,0.0002206967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993255,0.00030212343,0.00010205563,0.000080951526,0.00010439225,0.00008498158],"domain_scores_gemma":[0.99889874,0.00029077716,0.00045438245,0.00007859294,0.00010998914,0.00016744794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001232436,0.0003580485,0.0011713014,0.0003901846,0.00024174993,0.00041941553,0.00028967575,0.00044147126,0.0011852601],"category_scores_gemma":[0.0021326167,0.0002105664,0.0011195254,0.00038739818,0.00017667825,0.00017808595,0.00025849885,0.0005585236,0.00013735137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1505668,0.0033230933,0.8064432,0.0004096358,0.002786752,0.0002712307,0.00013630386,0.00042653797,0.0044382443,0.00006156793,0.00084566476,0.03029088],"study_design_scores_gemma":[0.006339921,0.013180544,0.9782702,0.000018436976,0.00062202883,0.00012123324,0.000033004162,0.0005354063,0.000438129,0.000031791897,0.00039863886,0.000010786569],"about_ca_topic_score_codex":0.00092488504,"about_ca_topic_score_gemma":0.0020556278,"teacher_disagreement_score":0.001232436,"about_ca_system_score_codex":0.00027687894,"about_ca_system_score_gemma":0.0003018291,"threshold_uncertainty_score":0.006517768},"labels":[],"label_agreement":null},{"id":"W2318292225","doi":"10.1097/yic.0000000000000099","title":"Management of aripiprazole-induced tardive Pisa syndrome","year":2015,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Parkinson's Disease and Spinal Disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Aripiprazole; Dystonia; Medicine; Trunk; Side effect (computer science); Anesthesia; Physical medicine and rehabilitation; Pediatrics; Psychology; Schizophrenia (object-oriented programming); Psychiatry; Computer science","score_opus":0.10954743023457313,"score_gpt":0.47933243507801576,"score_spread":0.3697850048434426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318292225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8130881,0.08829261,0.051987953,0.015620504,0.0010835157,0.0013489703,0.00022623266,0.0010613119,0.027290743],"genre_scores_gemma":[0.94922876,0.023139454,0.019438088,0.0035581954,0.0010635799,0.00031980025,0.00024184906,0.000041614043,0.0029687197],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9998323,0.00003407901,0.0000391317,0.000024817962,0.000035579356,0.000034051332],"domain_scores_gemma":[0.9998568,0.000024867804,0.00003488164,0.000004167691,0.000024259147,0.000054816523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002465754,0.00046174802,0.0006304152,0.0005778345,0.0006816059,0.00029544317,0.0005677295,0.000965697,0.00059198675],"category_scores_gemma":[0.0008205801,0.00010476673,0.0003707791,0.00016938087,0.00018617837,0.00042099156,0.0005242517,0.0011797436,0.00022699835],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010330577,0.0017290002,0.05585906,0.0021422105,0.00026744656,0.24893805,0.0011462617,0.0032217712,0.046149034,0.002506965,0.012764867,0.6242423],"study_design_scores_gemma":[0.0014007512,0.009264433,0.1534502,0.0023305344,0.0005237665,0.7034432,0.0015424018,0.017510422,0.020941988,0.007856667,0.08153471,0.00020090914],"about_ca_topic_score_codex":0.000425464,"about_ca_topic_score_gemma":0.0010120971,"teacher_disagreement_score":0.000965697,"about_ca_system_score_codex":0.00030333063,"about_ca_system_score_gemma":0.00053279806,"threshold_uncertainty_score":0.0022007823},"labels":[],"label_agreement":null},{"id":"W2319063634","doi":"10.1097/yic.0b013e328343ba60","title":"Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features","year":2011,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Hôtel-Dieu Grace Healthcare; Western University","funders":"Canadian Institutes of Health Research; AstraZeneca","keywords":"Risperidone; Bipolar disorder; Term (time); Medicine; Psychology; Psychiatry; Schizophrenia (object-oriented programming); Lithium (medication); Physics","score_opus":0.050307854249508566,"score_gpt":0.41442800989747497,"score_spread":0.3641201556479664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319063634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599326,0.0029331418,0.00012109408,0.00005792536,0.000020428137,0.00004684747,0.00003619163,0.000021239837,0.0007698732],"genre_scores_gemma":[0.9983821,0.00089192064,0.00026276833,0.00006548297,0.00003689848,0.000019833418,0.00008802366,0.0000015396713,0.00025147188],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99981946,0.00008833183,0.000019942374,0.000013612103,0.00003690994,0.000021752372],"domain_scores_gemma":[0.9996488,0.00008900195,0.00012890404,0.000018643392,0.00002280205,0.00009179548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005382698,0.00023487903,0.0005770796,0.00014854386,0.00016923783,0.00023175335,0.00020213041,0.0002313136,0.00065885537],"category_scores_gemma":[0.0008708046,0.000125484,0.00032650863,0.00012778465,0.00021300632,0.00018792802,0.00011760153,0.00063592114,0.00017127897],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11354011,0.023244964,0.111426346,0.0010035782,0.0012125401,0.0018263041,0.000751558,0.0019966874,0.06584344,0.00019433128,0.0012102833,0.6777499],"study_design_scores_gemma":[0.019310929,0.4870682,0.47314578,0.00017010597,0.0009874018,0.0025549266,0.00031124518,0.0036491686,0.008870469,0.00023849377,0.00364242,0.000050867366],"about_ca_topic_score_codex":0.0005638476,"about_ca_topic_score_gemma":0.0031953128,"teacher_disagreement_score":0.00065885537,"about_ca_system_score_codex":0.00021603139,"about_ca_system_score_gemma":0.0001889327,"threshold_uncertainty_score":0.0028467178},"labels":[],"label_agreement":null},{"id":"W2319238862","doi":"10.1097/yic.0000000000000100","title":"Use of benzodiazepines in obsessive–compulsive disorder","year":2015,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Richmond Hospital","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Anxiety; Obsessive compulsive; Benzodiazepine; Psychology; Anxiety disorder; Clonazepam; Psychiatry; Clinical psychology; Medicine; Internal medicine","score_opus":0.11439863408449251,"score_gpt":0.4689470046037267,"score_spread":0.35454837051923416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319238862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984332,0.0009680763,0.00003497237,0.000049656483,0.00000393715,0.000007840389,0.00014112532,0.0000020627233,0.00035903745],"genre_scores_gemma":[0.99908304,0.0005116131,0.000084085485,0.000046561243,0.000008206197,0.0000047259605,0.00016402209,9.400035e-7,0.00009684126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996107,0.00008499003,0.00007933221,0.000056317444,0.0001243128,0.00004436963],"domain_scores_gemma":[0.99868304,0.00020740388,0.00082633074,0.0000337656,0.00011275149,0.00013665616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031331312,0.00013613445,0.00033613722,0.0009118749,0.00030381366,0.00047409645,0.000206063,0.00030359882,0.0010543625],"category_scores_gemma":[0.0017966024,0.00018451412,0.00029446036,0.0008100298,0.00018092766,0.0003481111,0.0003554134,0.00038094257,0.00013879949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057036686,0.00003433982,0.9963308,0.000026735028,0.000035777604,0.00012695446,0.00008457297,0.000014967559,0.00021447125,0.000007713549,0.00004135483,0.0030253446],"study_design_scores_gemma":[0.0000041019307,0.000040399635,0.99915254,0.000009301801,0.000012676971,0.00051532185,0.0001027034,0.00003734311,0.00002107603,0.0000061262435,0.00009658301,0.0000017997678],"about_ca_topic_score_codex":0.004808881,"about_ca_topic_score_gemma":0.010139956,"teacher_disagreement_score":0.004808881,"about_ca_system_score_codex":0.00032436318,"about_ca_system_score_gemma":0.0003164888,"threshold_uncertainty_score":0.009561777},"labels":[],"label_agreement":null},{"id":"W2329067297","doi":"10.1097/yic.0b013e328356acad","title":"Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Risperidone; Paliperidone; Neurocognitive; Positive and Negative Syndrome Scale; Schizophrenia (object-oriented programming); Psychology; Randomized controlled trial; Psychiatry; Medicine; Internal medicine; Clinical psychology; Cognition; Psychosis","score_opus":0.056762757058961,"score_gpt":0.43032528274506926,"score_spread":0.37356252568610826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329067297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996931,0.0022159282,0.000072654395,0.00011429301,0.00003989003,0.00008253489,0.000048081514,0.000015142281,0.00048045831],"genre_scores_gemma":[0.9982198,0.00096187036,0.00024435623,0.00013434178,0.00006276155,0.000070338494,0.0000716946,0.0000020637206,0.0002328157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999577,0.00023184739,0.000060701797,0.00004530872,0.00004065629,0.00004453074],"domain_scores_gemma":[0.99935406,0.00024824965,0.00014986805,0.000040148083,0.000033382254,0.00017428209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008731963,0.0004551762,0.0012927159,0.00024489177,0.00021616841,0.00032548734,0.00023533475,0.0004241513,0.0011924044],"category_scores_gemma":[0.0015167219,0.00020144315,0.0006982187,0.00014943318,0.0002690399,0.00044560307,0.00019215913,0.00080033904,0.00020098481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7383285,0.008390583,0.011076584,0.000773691,0.0011349309,0.00029419133,0.000312444,0.00083801476,0.012357324,0.00010484099,0.0004934642,0.22589543],"study_design_scores_gemma":[0.28498358,0.6140153,0.09013545,0.00015821657,0.0018857346,0.00058861583,0.00035931286,0.002414516,0.0028789556,0.0003799344,0.002132041,0.000068304405],"about_ca_topic_score_codex":0.0006381959,"about_ca_topic_score_gemma":0.0021038044,"teacher_disagreement_score":0.0012927159,"about_ca_system_score_codex":0.00029904358,"about_ca_system_score_gemma":0.00039569943,"threshold_uncertainty_score":0.0046179295},"labels":[],"label_agreement":null},{"id":"W2332743496","doi":"10.1097/yic.0b013e32834c2488","title":"Assessing the relationship between functional impairment/recovery and depression severity","year":2011,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Depression (economics); Functional impairment; Psychology; Medicine; Clinical psychology; Economics","score_opus":0.22410403835261347,"score_gpt":0.49022974845831996,"score_spread":0.2661257101057065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332743496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977715,0.0164342,0.0028347604,0.00011633971,0.000028595503,0.00023078581,0.0011906541,0.000022050495,0.0014276353],"genre_scores_gemma":[0.99699414,0.00094920356,0.0006744326,0.000051697327,0.000031891257,0.000098368284,0.0009608625,0.000003169259,0.0002362793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99301434,0.004376402,0.0009832088,0.00057714485,0.00082690077,0.00022201889],"domain_scores_gemma":[0.9837309,0.009211568,0.005242375,0.00077304314,0.00080155453,0.00024045695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015287515,0.00057296664,0.0014306083,0.0013436467,0.0001625686,0.00050507754,0.00036552624,0.00035803465,0.0011287057],"category_scores_gemma":[0.01648813,0.00020286873,0.0010397062,0.0009587196,0.00032263546,0.00047694074,0.00070766185,0.00041691278,0.00013780764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007544922,0.00017266413,0.93461925,0.0005738152,0.006492856,0.00006766824,0.000110258814,0.0009105006,0.00072217465,0.00006562447,0.00018642364,0.04853384],"study_design_scores_gemma":[0.00018746064,0.0025371818,0.9935114,0.00005373409,0.0014433254,0.0002384521,0.00005732213,0.0009097746,0.00027875698,0.00011433193,0.00065308687,0.000015221059],"about_ca_topic_score_codex":0.0006039258,"about_ca_topic_score_gemma":0.0012510611,"teacher_disagreement_score":0.015287515,"about_ca_system_score_codex":0.00019728638,"about_ca_system_score_gemma":0.00025488902,"threshold_uncertainty_score":0.08084911},"labels":[],"label_agreement":null},{"id":"W2333163906","doi":"10.1097/01.yic.0000423254.26080.9f","title":"Lithium use for bipolar disorder - does the LiTMUS trial change anything?","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Litmus; Bipolar disorder; Lithium (medication); Psychology; Medicine; Psychiatry; Chemistry","score_opus":0.1290522916230237,"score_gpt":0.47193055650982085,"score_spread":0.3428782648867972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333163906","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59606105,0.27073005,0.0005527274,0.067457646,0.007303739,0.000979721,0.0043831444,0.00055355526,0.051978305],"genre_scores_gemma":[0.9045598,0.05142841,0.0015173043,0.024529552,0.0032736121,0.0010816915,0.00227979,0.00006079584,0.011269113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999355,0.0003919517,0.00007127764,0.000040105875,0.00007092768,0.00007080704],"domain_scores_gemma":[0.99919325,0.00030674957,0.00016393195,0.000054997538,0.00005998587,0.0002210212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001536681,0.00043391512,0.0018699949,0.00044894856,0.00041771674,0.0010093609,0.00061233685,0.001825061,0.01044937],"category_scores_gemma":[0.0030493203,0.00021229626,0.0016916068,0.00041595628,0.0005679503,0.0010982575,0.00033024244,0.0023518025,0.0011849114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44073567,0.0024533696,0.0087558655,0.009121105,0.0068035326,0.00028311822,0.0002026195,0.00056612113,0.0021169346,0.0034999263,0.066113666,0.45934802],"study_design_scores_gemma":[0.8279196,0.053329345,0.044807386,0.0060985796,0.009732151,0.0006063126,0.0005326288,0.001493212,0.0008571067,0.004986607,0.049485467,0.00015160418],"about_ca_topic_score_codex":0.0015388575,"about_ca_topic_score_gemma":0.008816607,"teacher_disagreement_score":0.01044937,"about_ca_system_score_codex":0.00073112914,"about_ca_system_score_gemma":0.0008757631,"threshold_uncertainty_score":0.034956634},"labels":[],"label_agreement":null},{"id":"W2333649059","doi":"10.1097/yic.0b013e3283528d22","title":"Efficacy and safety of ziprasidone in the treatment of first-episode psychosis","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer Pharmaceuticals","keywords":"Ziprasidone; Positive and Negative Syndrome Scale; Schizoaffective disorder; Clinical Global Impression; Schizophrenia (object-oriented programming); Internal medicine; Adverse effect; Schizophreniform disorder; Medicine; Population; Global Assessment of Functioning; Depression (economics); Psychiatry; Psychology; Psychosis; Antipsychotic; Placebo","score_opus":0.08186127582196423,"score_gpt":0.48189086329520814,"score_spread":0.4000295874732439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333649059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787843,0.0016100071,0.00011535036,0.00004340366,0.000015142107,0.00012626807,0.000039741262,0.000012934647,0.00015872448],"genre_scores_gemma":[0.99869436,0.0006174852,0.0003453161,0.000049824608,0.000048537855,0.000080230646,0.000053185973,0.000002559411,0.00010851066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993699,0.0003690582,0.00006300037,0.000059100686,0.00008696132,0.000051897077],"domain_scores_gemma":[0.9989625,0.0003293055,0.00039978046,0.00005149834,0.00006596418,0.00019091557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013197422,0.0003811028,0.0014178123,0.00022557394,0.00022998556,0.00042191645,0.0003007901,0.0005318715,0.0006511956],"category_scores_gemma":[0.0019707107,0.00022278246,0.00044830277,0.00013082194,0.00034839712,0.0004526568,0.0002157504,0.0009759394,0.00011530738],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5287178,0.025606807,0.035782617,0.0015218955,0.0010406687,0.00045819127,0.0005274889,0.0019211398,0.06942894,0.00014632625,0.0004926974,0.33435547],"study_design_scores_gemma":[0.15950292,0.7200037,0.103079185,0.00009801259,0.00061912736,0.0009607737,0.00013710937,0.0031490058,0.010865206,0.00017579606,0.00134725,0.00006189163],"about_ca_topic_score_codex":0.00025615,"about_ca_topic_score_gemma":0.00057189836,"teacher_disagreement_score":0.0014178123,"about_ca_system_score_codex":0.00032479299,"about_ca_system_score_gemma":0.00039701283,"threshold_uncertainty_score":0.006979525},"labels":[],"label_agreement":null},{"id":"W2333723698","doi":"10.1097/yic.0000000000000125","title":"Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy","year":2016,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Scientific Affairs","keywords":"Risperidone; Antipsychotic; Medicine; Schizophrenia (object-oriented programming); Relapse prevention; Internal medicine; Schizoaffective disorder; Proportional hazards model; Psychiatry; Post-hoc analysis; Psychosis","score_opus":0.14859341014902064,"score_gpt":0.4625397788618425,"score_spread":0.3139463687128219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333723698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99936455,0.00024277503,0.0000460006,0.000067371904,0.0000035467626,0.000010501237,0.000090985435,0.0000029982916,0.00017125037],"genre_scores_gemma":[0.99965775,0.000073317235,0.000057472495,0.000027433673,0.0000048480883,0.0000073813776,0.00010224711,0.000001393921,0.00006810691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898726,0.00038821544,0.0001525422,0.000104089246,0.00023982605,0.00012804808],"domain_scores_gemma":[0.9971836,0.0005120214,0.0016628649,0.00015449038,0.0001605821,0.00032637815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015260115,0.00017961599,0.0004674472,0.00039491768,0.00040601552,0.0005104041,0.00025838922,0.0003491552,0.00092185073],"category_scores_gemma":[0.0040267673,0.00017462092,0.000994983,0.0006083504,0.0002162688,0.0002553395,0.00039650468,0.00086665415,0.00008077068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054082705,0.00009947123,0.994925,0.000018036431,0.0001449193,0.00008074439,0.000099604506,0.00006198939,0.0002943676,0.000017453242,0.00006203215,0.0036554234],"study_design_scores_gemma":[0.00001081206,0.00022021282,0.9992379,0.000008079253,0.000039085953,0.00010279724,0.00010030873,0.00017668815,0.000031848347,0.000020406065,0.000048170306,0.000003793125],"about_ca_topic_score_codex":0.0055618384,"about_ca_topic_score_gemma":0.010497394,"teacher_disagreement_score":0.0055618384,"about_ca_system_score_codex":0.00039958357,"about_ca_system_score_gemma":0.0006165736,"threshold_uncertainty_score":0.011058927},"labels":[],"label_agreement":null},{"id":"W2335391602","doi":"10.1097/01.yic.0000425948.30166.26","title":"Advancing bipolar disorders research via collaborative knowledge translation","year":2012,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Becton Dickinson (Canada)","funders":"","keywords":"Psychopharmacology; Psychology; Medicine; Psychiatry","score_opus":0.12493642474446953,"score_gpt":0.5433096485007194,"score_spread":0.41837322375624986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335391602","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016755387,0.0741243,0.15900645,0.5142626,0.021345727,0.0056303893,0.0021940211,0.0016205617,0.20506054],"genre_scores_gemma":[0.23008707,0.09995152,0.5531943,0.06817689,0.0145011265,0.0076867966,0.0064918054,0.00094947504,0.018961065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9371198,0.04519657,0.0056122793,0.002646366,0.0074851764,0.0019398588],"domain_scores_gemma":[0.70156175,0.19829682,0.008613841,0.034157466,0.04058829,0.016781894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12397133,0.0012488533,0.0021358542,0.0077901166,0.0031474046,0.01253935,0.0042780926,0.004661017,0.03493417],"category_scores_gemma":[0.18574081,0.00086642796,0.0023368774,0.005354111,0.004658237,0.0099364,0.023321405,0.009694999,0.010045191],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025347347,0.0010256829,0.002211517,0.0053483383,0.00030405662,0.000802829,0.014180169,0.0007482564,0.0017447937,0.037530214,0.13412756,0.8017231],"study_design_scores_gemma":[0.00095780817,0.0006284898,0.0053062835,0.027867801,0.0004741781,0.0010856447,0.021514183,0.0018801341,0.0018758044,0.28955668,0.648668,0.00018494096],"about_ca_topic_score_codex":0.004213803,"about_ca_topic_score_gemma":0.0058490154,"teacher_disagreement_score":0.12397133,"about_ca_system_score_codex":0.004367426,"about_ca_system_score_gemma":0.043199915,"threshold_uncertainty_score":0.6556309},"labels":[],"label_agreement":null},{"id":"W2413247405","doi":"10.1097/yic.0000000000000094","title":"Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder","year":2015,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Placebo; Major depressive disorder; Confidence interval; Odds ratio; Internal medicine; Post-hoc analysis; Psychology; Psychiatry; Sexual function; Medicine; Antidepressant; Cognition","score_opus":0.05018944234956795,"score_gpt":0.41088989903616147,"score_spread":0.3607004566865935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413247405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672897,0.011192711,0.00019205576,0.00026716175,0.00019322766,0.00027989928,0.0003265318,0.000032275886,0.00078718894],"genre_scores_gemma":[0.9948689,0.0032850495,0.00043530064,0.00021877918,0.00012605592,0.00025156344,0.00022332987,0.0000039872853,0.0005870563],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987809,0.00077937153,0.00018271182,0.00011425813,0.00006187115,0.00008082651],"domain_scores_gemma":[0.9986713,0.0007856996,0.0002794042,0.000058026304,0.000049314476,0.00015624549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019400324,0.00066851405,0.002615552,0.00038340254,0.00019609007,0.0006065698,0.00040680318,0.0007233277,0.002978279],"category_scores_gemma":[0.0030853637,0.0004227357,0.0024433113,0.0002913895,0.0003889993,0.0005308755,0.00025254837,0.0008959173,0.00021991857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9470311,0.0022115177,0.0021239673,0.0013281469,0.0038206421,0.000051690848,0.00006187445,0.00032348017,0.0052171564,0.00006877697,0.00028504297,0.03747655],"study_design_scores_gemma":[0.5748437,0.36124474,0.050886318,0.00022669816,0.007200503,0.00016360503,0.00017934137,0.001217078,0.0020203374,0.00028439093,0.0016731375,0.000060212416],"about_ca_topic_score_codex":0.0006808044,"about_ca_topic_score_gemma":0.0026382643,"teacher_disagreement_score":0.002978279,"about_ca_system_score_codex":0.0005612524,"about_ca_system_score_gemma":0.00046429492,"threshold_uncertainty_score":0.010259986},"labels":[],"label_agreement":null},{"id":"W2415583435","doi":"10.1097/yic.0000000000000148","title":"Adverse events in children and adolescents treated with quetiapine","year":2016,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"H. Lundbeck A/S; Novo Nordisk; Pfizer; Bristol-Myers Squibb","keywords":"Quetiapine; Medicine; Pediatrics; Adverse effect; Psychiatry; Danish; Quetiapine Fumarate; Psychosis; Atypical antipsychotic; Population; Antipsychotic; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.04784931414317471,"score_gpt":0.4643678070081879,"score_spread":0.4165184928650132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415583435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614792,0.03168213,0.00021489813,0.00037882032,0.000033023054,0.000080539394,0.001304956,0.0000112268945,0.0048151957],"genre_scores_gemma":[0.9822534,0.015964767,0.00032282918,0.00024050922,0.000037730806,0.000025671496,0.0007840034,0.0000035808096,0.00036746796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939525,0.00015394724,0.00015551464,0.00007446177,0.00016471426,0.00005605863],"domain_scores_gemma":[0.9983317,0.00047826776,0.0009701955,0.000032342843,0.000107114116,0.000080346814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041527775,0.00012175661,0.00026451738,0.00091286545,0.00025831137,0.00038585626,0.00012260968,0.00026489343,0.001040703],"category_scores_gemma":[0.0023423634,0.00008099845,0.0004128196,0.0012828576,0.00021485188,0.00024361162,0.00026175895,0.00033878302,0.00010752506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024907905,0.000046152432,0.94099814,0.00091818476,0.00011700482,0.025357148,0.001486724,0.00009715742,0.00066309905,0.00028137304,0.0012324469,0.028553337],"study_design_scores_gemma":[0.000038442595,0.00028302454,0.8598217,0.0011604177,0.00030979165,0.10887103,0.0032535004,0.00013959875,0.0012427537,0.00018237418,0.024672536,0.000024822653],"about_ca_topic_score_codex":0.0038886264,"about_ca_topic_score_gemma":0.0046116663,"teacher_disagreement_score":0.0038886264,"about_ca_system_score_codex":0.0003888851,"about_ca_system_score_gemma":0.00045018617,"threshold_uncertainty_score":0.0077320337},"labels":[],"label_agreement":null},{"id":"W2485425172","doi":"10.1097/yic.0000000000000143","title":"Psychological dependence on antidepressants in patients with panic disorder","year":2016,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"Astellas Pharma","keywords":"Panic disorder; Panic; Psychiatry; Psychology; Clinical psychology; Internal medicine; Medicine; Anxiety","score_opus":0.05361500174004916,"score_gpt":0.4554414760138532,"score_spread":0.401826474273804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485425172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993036,0.0003678855,0.000015291702,0.000034656878,0.0000057643147,0.0000041575936,0.000020585556,7.047054e-7,0.0002473776],"genre_scores_gemma":[0.9995511,0.00025818552,0.000027436474,0.0000552801,0.000017099892,0.000003818705,0.00003886971,3.015003e-7,0.000047928068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99971515,0.00010308081,0.000041370437,0.00003542126,0.00006157103,0.00004332617],"domain_scores_gemma":[0.99933463,0.00013212342,0.00029969128,0.000026618833,0.00006158494,0.00014531524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030284634,0.00014720154,0.00035097005,0.00065763394,0.00045861883,0.00052807655,0.00012787862,0.0003543585,0.0008340866],"category_scores_gemma":[0.0018989777,0.00019579488,0.00026178942,0.0006273985,0.00021551295,0.00030142223,0.00029282822,0.00039078618,0.00010103971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007965275,0.000075006676,0.9969253,0.000019447245,0.000025304214,0.00016435685,0.00022814119,0.0000075389803,0.00014030996,0.000006234455,0.000047909412,0.002280705],"study_design_scores_gemma":[0.000012195297,0.00016948255,0.998495,0.000008882503,0.000025286576,0.00066768145,0.00041550104,0.000039389506,0.000018996943,0.000009476915,0.00013530339,0.0000028240045],"about_ca_topic_score_codex":0.0022734518,"about_ca_topic_score_gemma":0.0036178452,"teacher_disagreement_score":0.0022734518,"about_ca_system_score_codex":0.00019359341,"about_ca_system_score_gemma":0.000236227,"threshold_uncertainty_score":0.0045204163},"labels":[],"label_agreement":null},{"id":"W2549416108","doi":"10.1097/yic.0000000000000157","title":"Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments","year":2016,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Allergan; School of Medicine, Duke University; Genentech; H. Lundbeck A/S; Daiichi-Sankyo; FORUM Pharmaceuticals; Cerecor; Forest Research Institute; Sunovion; F. Hoffmann-La Roche; Indivior; Sanofi; National Institute of Mental Health; Pfizer; Brain and Behavior Research Foundation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Population; Psychosocial; Psychology; Post-hoc analysis; Major depressive disorder; Cognition; Rating scale; Depression (economics); Placebo; Psychiatry; Clinical psychology; Medicine; Internal medicine; Developmental psychology","score_opus":0.013062396005296491,"score_gpt":0.3870389944269966,"score_spread":0.37397659842170006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549416108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998228,0.0008125366,0.000059116872,0.000059525613,0.000013941042,0.000108668304,0.000172214,0.000023118377,0.0005228951],"genre_scores_gemma":[0.9986696,0.0004165266,0.00022800005,0.00007796992,0.000015886766,0.000065207525,0.0002098933,0.0000022393967,0.00031479553],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99967813,0.00016966638,0.00003461763,0.000035692952,0.0000375749,0.000044457847],"domain_scores_gemma":[0.99952006,0.000142909,0.00013009046,0.000032429427,0.000033408785,0.00014113501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008504616,0.00047364255,0.00094312936,0.00019298652,0.00017774006,0.00024627746,0.00029197877,0.00033074024,0.00082350697],"category_scores_gemma":[0.0015263858,0.00019929104,0.00075504504,0.000182107,0.0001803529,0.0002595455,0.00021566977,0.0007341768,0.00013303534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6704746,0.023823632,0.038198788,0.0008019005,0.0041191867,0.00033346436,0.00031511806,0.002783704,0.019232731,0.000088272674,0.001289728,0.23853892],"study_design_scores_gemma":[0.11864973,0.45045418,0.42003345,0.000069572816,0.0020032062,0.0002859027,0.00014351872,0.003060997,0.00340894,0.00013300758,0.0017033723,0.000054148804],"about_ca_topic_score_codex":0.0020344122,"about_ca_topic_score_gemma":0.008247342,"teacher_disagreement_score":0.0020344122,"about_ca_system_score_codex":0.00037705048,"about_ca_system_score_gemma":0.00045591657,"threshold_uncertainty_score":0.0044977665},"labels":[],"label_agreement":null},{"id":"W2605044346","doi":"10.1097/yic.0000000000000174","title":"Antidepressant effect in older depressed patients","year":2017,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Mental Health Research Topics","field":"Psychology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Agomelatine; Placebo; Antidepressant; Placebo response; Depression (economics); Medicine; Clinical trial; Internal medicine; Psychiatry; Clinical psychology; Psychology; Intensive care medicine; Alternative medicine","score_opus":0.09843570535062048,"score_gpt":0.5848377536607898,"score_spread":0.48640204831016937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605044346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945975,0.007261655,0.00007068638,0.00033606187,0.000075099735,0.000029897119,0.00016710488,0.000010027201,0.0025896216],"genre_scores_gemma":[0.9961389,0.002461047,0.00013281386,0.00058809743,0.000105199375,0.000017292457,0.00011542249,0.0000012058395,0.00044003245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998815,0.000051000025,0.000019501396,0.000013634594,0.000022208767,0.000012177771],"domain_scores_gemma":[0.9996922,0.000105629006,0.000087562,0.000017203909,0.000033374155,0.00006407871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000453208,0.00011438888,0.0004926919,0.0001989453,0.00016184815,0.00022479221,0.000059596747,0.00028135593,0.000960438],"category_scores_gemma":[0.0012652839,0.00006723867,0.00025086466,0.00018216744,0.00007103051,0.00010729348,0.00009371587,0.00030582034,0.00015851873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056869633,0.0023238244,0.518054,0.0014520946,0.0016587207,0.0025306703,0.0011897011,0.00027398465,0.05353479,0.00036594764,0.003285802,0.35846078],"study_design_scores_gemma":[0.0026019474,0.019159677,0.9680417,0.000121345984,0.000731284,0.0016863707,0.00018206568,0.0001907175,0.0018924112,0.00013989005,0.005234636,0.000017861565],"about_ca_topic_score_codex":0.00043930468,"about_ca_topic_score_gemma":0.0011254086,"teacher_disagreement_score":0.000960438,"about_ca_system_score_codex":0.00013181302,"about_ca_system_score_gemma":0.00009314487,"threshold_uncertainty_score":0.0032129884},"labels":[],"label_agreement":null},{"id":"W2613043758","doi":"10.1097/yic.0000000000000179","title":"Advanced glycation end products among patients maintained on antipsychotics","year":2017,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Advanced Glycation End Products research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"Qatar National Research Fund; International Business Machines Corporation","keywords":"Medicine; Statistical significance; Schizophrenia (object-oriented programming); Internal medicine; Prospective cohort study; Significant difference; Glycation; Psychiatry; Pediatrics","score_opus":0.03850985625461896,"score_gpt":0.45071914001930474,"score_spread":0.4122092837646858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613043758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99964786,0.0001552158,0.000015006567,0.000011130492,0.0000023614937,0.0000035433925,0.00003547577,7.193513e-7,0.0001285581],"genre_scores_gemma":[0.9996555,0.00009835284,0.000049570128,0.000022288632,0.0000043979967,0.0000034415414,0.00006321611,3.8509756e-7,0.00010295697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997904,0.000037698792,0.000027265727,0.000046821653,0.00005694259,0.00004087629],"domain_scores_gemma":[0.99962115,0.00004754672,0.00020926225,0.000014653195,0.000046904715,0.00006036583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002772784,0.00023383243,0.0003326969,0.00061196374,0.00044117746,0.00044352593,0.00014282709,0.00036500389,0.0009199857],"category_scores_gemma":[0.0008903591,0.00017868262,0.00026895528,0.0005898527,0.0001345802,0.00033399253,0.0002368271,0.0003585795,0.00011785805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026868723,0.00007418207,0.9965778,0.000011668892,0.00002423095,0.0001704653,0.00020361616,0.000011608798,0.00077079056,0.000011692028,0.000033468958,0.0018417154],"study_design_scores_gemma":[0.0000067308715,0.00031354852,0.9987153,0.000006371907,0.000021413975,0.00040651194,0.00029706088,0.000046748875,0.00008174247,0.000014066991,0.00008750589,0.000003026328],"about_ca_topic_score_codex":0.003969473,"about_ca_topic_score_gemma":0.004830359,"teacher_disagreement_score":0.003969473,"about_ca_system_score_codex":0.0002981858,"about_ca_system_score_gemma":0.00017618616,"threshold_uncertainty_score":0.007892728},"labels":[],"label_agreement":null},{"id":"W2623679632","doi":"10.1097/yic.0000000000000183","title":"Long-term function and psychosocial outcomes with venlafaxine extended release 75–225 mg/day versus placebo in the PREVENT study","year":2017,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Venlafaxine; Psychosocial; Placebo; Quality of life (healthcare); Medicine; Post-hoc analysis; Venlafaxine Hydrochloride; Internal medicine; Psychology; Psychiatry; Antidepressant; Anxiety","score_opus":0.07418117069487426,"score_gpt":0.4903316870584873,"score_spread":0.416150516363613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623679632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754375,0.0016341032,0.00008816802,0.00004616544,0.000043527987,0.00013341608,0.00013470299,0.000009726858,0.0003663448],"genre_scores_gemma":[0.9981268,0.000603573,0.00019838403,0.000060466045,0.000072927694,0.00017394045,0.0001760284,0.0000024925016,0.000585325],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99934155,0.00039595418,0.00003602679,0.00006339032,0.000058422127,0.00010473297],"domain_scores_gemma":[0.99928516,0.00029318288,0.00018559376,0.000057822926,0.000030309197,0.00014802061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013482473,0.0004220383,0.0022786527,0.00018460758,0.00016584052,0.00045058632,0.00026844034,0.00039405163,0.0013563618],"category_scores_gemma":[0.0009049407,0.00018544946,0.0016982033,0.00014945057,0.0002659137,0.0002487288,0.00019979409,0.00079524255,0.00015093814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9486318,0.0062169726,0.0075399685,0.00042682624,0.0033013935,0.00007985659,0.000038038543,0.0006482251,0.005745772,0.00007761476,0.00026845324,0.02702498],"study_design_scores_gemma":[0.23340021,0.64895594,0.107253864,0.00006960832,0.004450251,0.0001428255,0.0000920383,0.0012221553,0.0027488137,0.00013411522,0.0014972573,0.000032885535],"about_ca_topic_score_codex":0.00042982853,"about_ca_topic_score_gemma":0.0016065302,"teacher_disagreement_score":0.0022786527,"about_ca_system_score_codex":0.00030401332,"about_ca_system_score_gemma":0.00047069672,"threshold_uncertainty_score":0.0071302652},"labels":[],"label_agreement":null},{"id":"W2626036701","doi":"10.1097/yic.0000000000000185","title":"Placebo response in trichotillomania","year":2017,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"H. Lundbeck A/S; University of Oxford; National Institute on Drug Abuse; TLC Foundation for Body-Focused Repetitive Behaviors; National Institute on Alcohol Abuse and Alcoholism; BrainsWay; American Psychiatric Publishing; International OCD Foundation; National Center for Responsible Gaming; Wellcome Trust","keywords":"Placebo; Placebo response; Internal medicine; Medicine; Clinical trial; Psychiatry; Psychology","score_opus":0.0527838860741489,"score_gpt":0.48714668406830475,"score_spread":0.43436279799415584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626036701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8307357,0.1241232,0.014041873,0.0022272996,0.0027579057,0.011935299,0.00096160313,0.00036718213,0.012849959],"genre_scores_gemma":[0.98339635,0.0057075364,0.0041679502,0.0005879983,0.00066920504,0.003858934,0.00024211171,0.00002399504,0.0013459177],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.979083,0.017489545,0.0016278598,0.0006090428,0.0009433566,0.00024715118],"domain_scores_gemma":[0.98754483,0.008601951,0.0024064232,0.0006758948,0.00050497684,0.00026592953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017311748,0.00083025155,0.0024056712,0.0005643113,0.0003653726,0.0005445004,0.0004935664,0.0015605155,0.0034586769],"category_scores_gemma":[0.020937216,0.0002753752,0.0013430286,0.00064423337,0.0011924839,0.00043697914,0.00041630515,0.0012052085,0.00034098074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6540652,0.0049849767,0.013880368,0.012190977,0.003768268,0.0004742161,0.00059688085,0.00090494857,0.027674865,0.0018656414,0.0028752761,0.27671838],"study_design_scores_gemma":[0.23049234,0.5259756,0.16701886,0.002427007,0.004560707,0.0019916296,0.0005275348,0.005051094,0.025913604,0.007348769,0.028537156,0.00015571524],"about_ca_topic_score_codex":0.00016256163,"about_ca_topic_score_gemma":0.00025551312,"teacher_disagreement_score":0.017311748,"about_ca_system_score_codex":0.000381116,"about_ca_system_score_gemma":0.000430459,"threshold_uncertainty_score":0.0915544},"labels":[],"label_agreement":null},{"id":"W2742484016","doi":"10.1097/yic.0000000000000191","title":"Risk of hair loss with different antidepressants","year":2017,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"University of British Columbia","keywords":"Bupropion; Sertraline; Venlafaxine; Citalopram; Escitalopram; Paroxetine; Fluoxetine; Fluvoxamine; Medicine; Mirtazapine; Internal medicine; Duloxetine; Population; Pharmacology; Psychology; Antidepressant; Serotonin; Smoking cessation","score_opus":0.040435980559892476,"score_gpt":0.4519172755265202,"score_spread":0.4114812949666278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742484016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437827,0.0029091195,0.00036791203,0.00011431476,0.000019806079,0.000043322005,0.0010052589,0.000010480658,0.0011514759],"genre_scores_gemma":[0.99839044,0.0006376977,0.00026641312,0.00006596697,0.000020963991,0.000011067451,0.0003569336,0.0000024381716,0.0002481925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987012,0.00031095813,0.00013465469,0.00031235866,0.00036617852,0.00017457866],"domain_scores_gemma":[0.9965532,0.00053094805,0.0022526458,0.00019083366,0.0002726055,0.00019972777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087662257,0.00025376922,0.0003236527,0.00096154533,0.0003158832,0.00066229806,0.00032407508,0.0004131885,0.0016338667],"category_scores_gemma":[0.0035186303,0.00023082802,0.0011762684,0.00085785694,0.00020062467,0.00039866962,0.00049683446,0.0005668468,0.00017512764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016504408,0.00002551249,0.9952442,0.00002670694,0.00024559925,0.00008182969,0.000023130307,0.000060609935,0.00014743695,0.00003057566,0.000083071405,0.0038663235],"study_design_scores_gemma":[0.000009095924,0.00012815515,0.998362,0.000023927116,0.00012030638,0.00065255864,0.00005629711,0.00022796635,0.000079953534,0.000047465866,0.00028756645,0.0000047047847],"about_ca_topic_score_codex":0.0034161538,"about_ca_topic_score_gemma":0.0042913607,"teacher_disagreement_score":0.0034161538,"about_ca_system_score_codex":0.00032256995,"about_ca_system_score_gemma":0.00021611339,"threshold_uncertainty_score":0.0067925453},"labels":[],"label_agreement":null},{"id":"W2742530754","doi":"10.1097/yic.0000000000000192","title":"The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine","year":2017,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Major depressive disorder; Rating scale; Depression (economics); Psychology; Placebo; Psychiatry; Clinical psychology; Medicine; Physical therapy; Cognition; Developmental psychology","score_opus":0.026386629143611774,"score_gpt":0.40071972993538574,"score_spread":0.37433310079177395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742530754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992374,0.00042162943,0.00002269203,0.00005019571,0.000004263446,0.000015942118,0.00005955973,0.0000012093296,0.0001870219],"genre_scores_gemma":[0.9995814,0.00014388959,0.000041447594,0.000052779622,0.000008448832,0.000013258315,0.00009869338,3.5409667e-7,0.00005967673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99948066,0.0002493054,0.000069294605,0.00004814283,0.00008212169,0.00007052573],"domain_scores_gemma":[0.99940634,0.00018261644,0.00022412218,0.000024559002,0.000049047296,0.00011334317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008014254,0.00022189169,0.0008583921,0.00037553164,0.00035231683,0.00041554528,0.0001721597,0.0003344606,0.0005439306],"category_scores_gemma":[0.0019710765,0.00021100313,0.0007992294,0.00038705193,0.00017157433,0.00019803573,0.00023156649,0.00039167717,0.00007187384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005950117,0.0007762977,0.9740694,0.000114705996,0.0006259478,0.00041563873,0.00026153153,0.0002467197,0.0014109577,0.000025313559,0.00019825752,0.015905065],"study_design_scores_gemma":[0.00024974142,0.0014300792,0.9976526,0.000009844485,0.00008730697,0.00014491053,0.0000704957,0.00018702344,0.00005038999,0.000015333806,0.00009811385,0.000004113682],"about_ca_topic_score_codex":0.002336807,"about_ca_topic_score_gemma":0.0057446333,"teacher_disagreement_score":0.002336807,"about_ca_system_score_codex":0.0004857935,"about_ca_system_score_gemma":0.00028862103,"threshold_uncertainty_score":0.0046464205},"labels":[],"label_agreement":null},{"id":"W2756185629","doi":"10.1097/yic.0000000000000196","title":"Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression","year":2017,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Concordia University; Université de Montréal; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Treatment-resistant depression; Depression (economics); Antidepressant; Hamilton Rating Scale for Depression; Psychology; Antipsychotic; Rating scale; Internal medicine; Psychiatry; Montgomery–Åsberg Depression Rating Scale; Comorbidity; Major depressive disorder; Personality disorders; Medicine; Personality; Schizophrenia (object-oriented programming); Anxiety; Mood","score_opus":0.13592372994369623,"score_gpt":0.48674824274596123,"score_spread":0.350824512802265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756185629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821055,0.0013949338,0.00005271317,0.000032260737,0.000020893915,0.00006109554,0.00006691097,0.0000070703527,0.00015367445],"genre_scores_gemma":[0.9978515,0.0011330425,0.00031610677,0.000084987834,0.00006259449,0.00008820539,0.00025875308,0.0000024279245,0.00020238146],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99926287,0.00043699186,0.00008734363,0.000085630556,0.0000722716,0.000054912478],"domain_scores_gemma":[0.99925214,0.0002159605,0.00017095193,0.00007370228,0.000045736786,0.00024148448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012903584,0.00045511237,0.0019799336,0.00044511104,0.00023252759,0.00041668376,0.00035549572,0.00043137444,0.00086353626],"category_scores_gemma":[0.0012899732,0.00024495763,0.00094618055,0.00039430807,0.00030524033,0.0003625147,0.00026240564,0.0006060081,0.0002626965],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7274214,0.01823189,0.042067677,0.0008792841,0.0029165973,0.00033853645,0.00035165244,0.0013205449,0.03419368,0.00012879955,0.0007943337,0.17135563],"study_design_scores_gemma":[0.1162458,0.6886975,0.18514068,0.00009021393,0.001505151,0.00079381414,0.00013918837,0.0024562082,0.0026133736,0.00023753171,0.002013379,0.00006708985],"about_ca_topic_score_codex":0.00072095206,"about_ca_topic_score_gemma":0.0029482883,"teacher_disagreement_score":0.0019799336,"about_ca_system_score_codex":0.00035222247,"about_ca_system_score_gemma":0.00035285414,"threshold_uncertainty_score":0.006824136},"labels":[],"label_agreement":null},{"id":"W2799604498","doi":"10.1097/yic.0000000000000221","title":"Antipsychotic drug exposure and risk of fracture","year":2018,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Medicine; Confounding; Observational study; Confidence interval; Odds ratio; Relative risk; Hip fracture; Pharmacoepidemiology; Population; Internal medicine; Environmental health; Pharmacology; Osteoporosis","score_opus":0.09991378660356631,"score_gpt":0.5483406798708127,"score_spread":0.4484268932672464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799604498","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21811761,0.75488585,0.0049577462,0.0022199803,0.0005481882,0.0005292079,0.014572885,0.000054183645,0.004114371],"genre_scores_gemma":[0.8906431,0.097567126,0.0042538974,0.00096369034,0.00048621523,0.0004232095,0.004669456,0.000027706823,0.00096559006],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888544,0.0032345098,0.003513449,0.001328907,0.002740531,0.0003282685],"domain_scores_gemma":[0.9682317,0.01353219,0.014215804,0.0011694297,0.0024013717,0.00044968133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007287825,0.0006371314,0.0016674958,0.003042421,0.00027475812,0.0010608672,0.0008552574,0.0016166137,0.0034314934],"category_scores_gemma":[0.03936592,0.00050833187,0.0060050725,0.0042869356,0.0003552743,0.00065671763,0.00080889906,0.001492391,0.00027843312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004636151,0.00017394933,0.7603809,0.05518774,0.09538965,0.00035635,0.0002839378,0.0013779962,0.0005167592,0.0009826203,0.003232173,0.07748181],"study_design_scores_gemma":[0.0008661272,0.0014537799,0.9052364,0.017556619,0.05525649,0.0021897017,0.00025475095,0.0017487142,0.0005563546,0.0031751865,0.0115963705,0.00010945862],"about_ca_topic_score_codex":0.006008159,"about_ca_topic_score_gemma":0.009343753,"teacher_disagreement_score":0.007287825,"about_ca_system_score_codex":0.0007763758,"about_ca_system_score_gemma":0.0010327357,"threshold_uncertainty_score":0.03854221},"labels":[],"label_agreement":null},{"id":"W2799973089","doi":"10.1097/yic.0000000000000223","title":"A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder","year":2018,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Health Canada; Pfizer Canada; Pfizer","keywords":"Tolerability; Methadone; Depression (economics); Methadone maintenance; Medicine; Major depressive disorder; Internal medicine; Randomized controlled trial; Psychiatry; Clinical trial; Opioid use disorder; Opioid; Psychology; Adverse effect; Mood","score_opus":0.23979035206828764,"score_gpt":0.5491802309517423,"score_spread":0.30938987888345465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799973089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951727,0.00022672486,0.00029017447,0.00013150291,0.00005391894,0.0029083316,0.0005634429,0.00003720043,0.0006161813],"genre_scores_gemma":[0.98941666,0.00040217157,0.0018708896,0.00046414408,0.00011464129,0.0045669684,0.0009326091,0.000009473976,0.0022223203],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996112,0.00019111518,0.000025476433,0.00006442228,0.000036458066,0.000071348826],"domain_scores_gemma":[0.99899536,0.00023868054,0.00015417107,0.000088226116,0.00009095087,0.0004325282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00133423,0.0010646132,0.001405199,0.00038358037,0.0005859335,0.0004336379,0.00073386583,0.0009486218,0.004407135],"category_scores_gemma":[0.0011260669,0.00052708364,0.0008238346,0.0002155939,0.000686108,0.00068184984,0.0003213759,0.0019152107,0.0007249995],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7057882,0.2192167,0.0074170344,0.00044734555,0.0006520694,0.00026664004,0.00040053207,0.00056520826,0.02294598,0.000088351066,0.001200472,0.041011572],"study_design_scores_gemma":[0.22108926,0.76090467,0.015992753,0.000013342292,0.00011821794,0.000058666235,0.00006683398,0.00035941746,0.00072665553,0.000049420913,0.0006073586,0.000013341478],"about_ca_topic_score_codex":0.001233939,"about_ca_topic_score_gemma":0.0039338265,"teacher_disagreement_score":0.004407135,"about_ca_system_score_codex":0.00038695047,"about_ca_system_score_gemma":0.0009368187,"threshold_uncertainty_score":0.014743328},"labels":[],"label_agreement":null},{"id":"W2909821273","doi":"10.1097/yic.0000000000000251","title":"Hyoscine for clozapine-induced hypersalivation","year":2019,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"King's College London; National Institute for Health and Care Research; South London and Maudsley NHS Foundation Trust","keywords":"Hypersalivation; Clozapine; Placebo; Schizophrenia (object-oriented programming); Psychology; Medicine; Atypical antipsychotic; Anesthesia; Antipsychotic; Psychiatry","score_opus":0.09722528395156863,"score_gpt":0.507904316988038,"score_spread":0.41067903303646935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909821273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064577,0.007527721,0.0002541144,0.00019698673,0.00009621098,0.00036356336,0.000112159505,0.000022379229,0.0007809543],"genre_scores_gemma":[0.9920684,0.0063745338,0.00052468595,0.00014573826,0.00008330844,0.0002024821,0.00010185256,0.0000033752178,0.00049567944],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997708,0.00011481179,0.000033525383,0.000020633637,0.000035170433,0.000025049818],"domain_scores_gemma":[0.99965036,0.0001278071,0.000108395776,0.000024752562,0.000015450867,0.00007311232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038918864,0.0002831349,0.0007764983,0.0003066679,0.0001937127,0.00021548211,0.0002477206,0.00040124284,0.0021171677],"category_scores_gemma":[0.00077860744,0.00012588839,0.00051467126,0.0002871266,0.00037027043,0.00017003444,0.00015649022,0.0006551104,0.00015697697],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.636892,0.012229517,0.0045068027,0.0035832808,0.0014904588,0.00036902612,0.000198076,0.00043735697,0.09551195,0.00044205855,0.0009311126,0.24340837],"study_design_scores_gemma":[0.38392726,0.50443625,0.06771898,0.00047560342,0.0019457431,0.0010523504,0.00024381834,0.0012551333,0.031694066,0.00045905987,0.006730044,0.000061767154],"about_ca_topic_score_codex":0.0009286617,"about_ca_topic_score_gemma":0.0022323267,"teacher_disagreement_score":0.0021171677,"about_ca_system_score_codex":0.00026308978,"about_ca_system_score_gemma":0.00048673232,"threshold_uncertainty_score":0.0070825815},"labels":[],"label_agreement":null},{"id":"W2936650608","doi":"10.1097/yic.0000000000000264","title":"Concomitant use of alcohol and benzodiazepine hypnotics in psychiatric outpatients","year":2019,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Sleep and related disorders","field":"Psychology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Concomitant; Odds ratio; Medicine; Benzodiazepine; Psychiatry; Logistic regression; Confidence interval; Depression (economics); Insomnia; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.05777006794037953,"score_gpt":0.42966230938811906,"score_spread":0.3718922414477395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936650608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994554,0.00023619828,0.000019200668,0.000032600787,0.0000036342676,0.00000412894,0.00002789586,0.0000017475513,0.0002192138],"genre_scores_gemma":[0.9995894,0.00021361349,0.000054743043,0.000024481971,0.000014014987,0.0000035427797,0.00004913077,7.60855e-7,0.000050325714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935526,0.00018456623,0.00008284233,0.000064619824,0.00021607695,0.0000966543],"domain_scores_gemma":[0.9978326,0.00033525916,0.0012309365,0.00005220483,0.00015036545,0.0003986559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035652934,0.00018955233,0.00037732054,0.0008954041,0.00047298474,0.00041902988,0.00016046409,0.00034645767,0.0015390678],"category_scores_gemma":[0.0028137432,0.00029680083,0.00021479165,0.00062945345,0.00032085695,0.00034223177,0.00041538684,0.00043180352,0.00018585504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007764394,0.000051287956,0.99779093,0.000011835771,0.000011777445,0.0003385728,0.00009836995,0.0000051715133,0.00041062423,0.0000043650466,0.000041071115,0.001158327],"study_design_scores_gemma":[0.0000037916336,0.00011167951,0.9982127,0.0000066874345,0.00000803254,0.001292666,0.00024129402,0.00003301404,0.000034575096,0.0000044399853,0.000049437913,0.0000017793516],"about_ca_topic_score_codex":0.0032210187,"about_ca_topic_score_gemma":0.006097201,"teacher_disagreement_score":0.0032210187,"about_ca_system_score_codex":0.000255566,"about_ca_system_score_gemma":0.00033170273,"threshold_uncertainty_score":0.006404519},"labels":[],"label_agreement":null},{"id":"W2946354012","doi":"10.1097/yic.0000000000000269","title":"Addressing clozapine under-prescribing and barriers to initiation","year":2019,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dr. Georges-L.-Dumont University Hospital Centre; Vitalité Health Network","funders":"","keywords":"Clozapine; Schizophrenia (object-oriented programming); Medicine; Psychiatry; Perception; Antipsychotic; Family medicine; Psychology; Clinical psychology","score_opus":0.14308838852583175,"score_gpt":0.5006738307647532,"score_spread":0.3575854422389215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946354012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163646,0.00077487546,0.00019925954,0.004485172,0.000011277995,0.000033834032,0.000027798913,0.0000070893207,0.0028241924],"genre_scores_gemma":[0.99812216,0.00082116976,0.0003833753,0.0003196754,0.0000123880345,0.000012731723,0.000012538903,0.0000013008234,0.00031466287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984275,0.0006997183,0.00009802782,0.00006429987,0.0003595516,0.00035081885],"domain_scores_gemma":[0.9920507,0.0030275055,0.0024923172,0.00015777162,0.0007209489,0.0015507865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019931744,0.00008926018,0.00017400792,0.00025595273,0.0007517554,0.0008040227,0.00031597476,0.0004708271,0.0018785087],"category_scores_gemma":[0.016091887,0.00012595934,0.00017855421,0.00034986026,0.00035729443,0.0006963053,0.00059130724,0.0006881718,0.00013518715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013878255,0.00060668506,0.79808164,0.00056176365,0.00006228187,0.00048768715,0.015384525,0.00038424775,0.0014555713,0.00056903774,0.0029045246,0.17936327],"study_design_scores_gemma":[0.00002924068,0.00050150015,0.9560589,0.00062098267,0.00006406651,0.0008841723,0.031020595,0.0013905406,0.00081847777,0.00039078516,0.008199431,0.000021375177],"about_ca_topic_score_codex":0.028986704,"about_ca_topic_score_gemma":0.050465126,"teacher_disagreement_score":0.028986704,"about_ca_system_score_codex":0.0012855595,"about_ca_system_score_gemma":0.0067099947,"threshold_uncertainty_score":0.057635963},"labels":[],"label_agreement":null},{"id":"W2957405451","doi":"10.1097/yic.0000000000000276","title":"Effectiveness and safety of long-term benzodiazepine use in anxiety disorders","year":2019,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Discontinuation; Anxiety; Placebo; Randomized controlled trial; Medicine; Meta-analysis; Panic; Adverse effect; Hamilton Anxiety Rating Scale; Psychiatry; Anxiety disorder; Internal medicine","score_opus":0.12152631462371016,"score_gpt":0.5192403396675317,"score_spread":0.39771402504382153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957405451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058371044,0.999204,0.000019149067,0.000041161453,0.000022941414,0.000012921529,0.000034467335,0.0000012138507,0.00008049827],"genre_scores_gemma":[0.0129686035,0.9865595,0.00014596956,0.00011706713,0.000044522832,0.00003674001,0.00006568856,0.000001254063,0.000060680828],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973273,0.000937295,0.00091136177,0.00021574894,0.0005248395,0.00008338179],"domain_scores_gemma":[0.9930466,0.004907339,0.0013975988,0.000076538025,0.0004815907,0.00009039703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004161841,0.0007789373,0.004431406,0.0029755319,0.00027846763,0.0013206424,0.0009792513,0.0012793337,0.0029073157],"category_scores_gemma":[0.010175544,0.00043539228,0.0040331366,0.002667287,0.00044265456,0.00084169785,0.00064545206,0.0007969843,0.00020117749],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009794398,0.000056413952,0.0009642229,0.7946348,0.014577694,0.000086226515,0.00011809325,0.00013649985,0.00037325188,0.00026756967,0.0014449288,0.18636087],"study_design_scores_gemma":[0.0020615316,0.0022766874,0.026868574,0.69989717,0.2000559,0.001706149,0.00045056126,0.00033404518,0.0012335669,0.00082472706,0.064207956,0.00008298074],"about_ca_topic_score_codex":0.0032166876,"about_ca_topic_score_gemma":0.007739133,"teacher_disagreement_score":0.004431406,"about_ca_system_score_codex":0.0014834767,"about_ca_system_score_gemma":0.0024176892,"threshold_uncertainty_score":0.022010148},"labels":[],"label_agreement":null},{"id":"W2988235388","doi":"10.1097/yic.0000000000000295","title":"Ophthalmic adverse effects of lithium","year":2019,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Ottawa","funders":"","keywords":"Medicine; Photophobia; Adverse effect; Lithium (medication); Exophthalmos; Intensive care medicine; Ophthalmology; Surgery; Psychiatry; Internal medicine","score_opus":0.09847464799369035,"score_gpt":0.5218891884449253,"score_spread":0.42341454045123494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988235388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012547949,0.99470705,0.0001476632,0.00033644578,0.00012434453,0.000017743585,0.00008442217,0.000017513703,0.003309993],"genre_scores_gemma":[0.018468164,0.9781447,0.00039202758,0.00079197413,0.00024939093,0.0000239754,0.00012754805,0.0000048191937,0.0017974179],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926823,0.00018449457,0.0001811181,0.00007033962,0.00024285977,0.000052982785],"domain_scores_gemma":[0.9991943,0.00038157008,0.00021506345,0.000020206993,0.00016055502,0.000028215487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005368635,0.000509182,0.00098528,0.001511107,0.00038946886,0.0010114826,0.0004458062,0.00077476504,0.0055094077],"category_scores_gemma":[0.0015127942,0.00015209726,0.0010962213,0.0011074039,0.00034304694,0.00054263114,0.00058081315,0.0009450615,0.0006241136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003383033,0.00009116632,0.0021416775,0.04399495,0.00047332945,0.0017411774,0.0002425345,0.00027292484,0.0024635259,0.0027951153,0.026227534,0.9192177],"study_design_scores_gemma":[0.00018800609,0.00062501396,0.013338438,0.026572496,0.0020089175,0.032307595,0.0005025331,0.0003720466,0.005463208,0.0036792099,0.9148577,0.00008486237],"about_ca_topic_score_codex":0.0021216755,"about_ca_topic_score_gemma":0.0048081735,"teacher_disagreement_score":0.0055094077,"about_ca_system_score_codex":0.00055166485,"about_ca_system_score_gemma":0.0009361735,"threshold_uncertainty_score":0.018430829},"labels":[],"label_agreement":null},{"id":"W3005602333","doi":"10.1097/yic.0000000000000307","title":"Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Akathisia; Placebo; Tolerability; Bipolar I disorder; Internal medicine; Extrapyramidal symptoms; Adverse effect; Nausea; Medicine; Psychology; Bipolar disorder; Psychiatry; Antipsychotic; Mania; Schizophrenia (object-oriented programming)","score_opus":0.14853191189811432,"score_gpt":0.5037474588684917,"score_spread":0.3552155469703774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005602333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96572655,0.0131976865,0.00200015,0.001492946,0.00092047796,0.012011503,0.0014054345,0.0003272576,0.0029178697],"genre_scores_gemma":[0.95992774,0.008450026,0.0050982516,0.0025126825,0.0010337806,0.017648648,0.0015605275,0.00004914927,0.0037191499],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991652,0.00050625874,0.000047608322,0.000119334654,0.00006646333,0.000095186086],"domain_scores_gemma":[0.9992963,0.00025157043,0.00016115437,0.000046159657,0.000055093293,0.0001897885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026440008,0.0019160495,0.0023556803,0.0005484557,0.00040743424,0.0008119096,0.0009915574,0.0025465458,0.004201384],"category_scores_gemma":[0.0021332297,0.000672094,0.0012480709,0.00036192304,0.00086504215,0.00081429095,0.00029203197,0.001939255,0.0007360164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9455204,0.011196519,0.00044250838,0.0014111346,0.0006165405,0.000089245485,0.00008338658,0.0003341025,0.0062214895,0.00023221484,0.0014225385,0.032429952],"study_design_scores_gemma":[0.9585112,0.039794248,0.00059032894,0.000025770532,0.00011164654,0.000028500686,0.0000072091816,0.00022856098,0.00023951317,0.000046135832,0.0004091917,0.0000077031555],"about_ca_topic_score_codex":0.0007004731,"about_ca_topic_score_gemma":0.0015210551,"teacher_disagreement_score":0.004201384,"about_ca_system_score_codex":0.0005441339,"about_ca_system_score_gemma":0.0010098476,"threshold_uncertainty_score":0.014055014},"labels":[],"label_agreement":null},{"id":"W3015341766","doi":"10.1097/yic.0000000000000310","title":"Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis","year":2020,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire en santé mentale de Montréal; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Antipsychotic; Psychosis; Medicine; Medical prescription; Early psychosis; Psychiatry; Intervention (counseling); Schizophrenia (object-oriented programming); Prospective cohort study; Pediatrics; Internal medicine; Pharmacology","score_opus":0.11024883096650032,"score_gpt":0.4710722058285814,"score_spread":0.36082337486208105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015341766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993311,0.00031455405,0.00002021855,0.000063782485,0.0000040206105,0.0000038702506,0.00003947463,0.0000030379451,0.00021988017],"genre_scores_gemma":[0.99969697,0.00010718738,0.000034395758,0.000025817579,0.0000058913893,0.0000023949228,0.00005272862,0.0000010810463,0.000073675976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992186,0.00031872327,0.00006697644,0.000048197908,0.00015785878,0.00018965703],"domain_scores_gemma":[0.9950995,0.0012714368,0.0021887633,0.00016499743,0.00024716614,0.0010281084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092058326,0.00018823825,0.00033513375,0.0004001874,0.00040962698,0.000584918,0.00020497113,0.00044824101,0.001152263],"category_scores_gemma":[0.0076916064,0.0001755396,0.000866059,0.0002958482,0.00021625149,0.0004049371,0.0004851255,0.00094440614,0.00013741909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013103217,0.0006895395,0.9805237,0.000028798677,0.00013322038,0.00028437268,0.00018003723,0.0001446942,0.00042214242,0.000027968485,0.00009193473,0.016163234],"study_design_scores_gemma":[0.000011612996,0.0006036746,0.9986853,0.000013821676,0.000029486831,0.00024028875,0.00012250167,0.00014235279,0.00007252823,0.000018525916,0.000054563236,0.0000053862404],"about_ca_topic_score_codex":0.00586152,"about_ca_topic_score_gemma":0.011461987,"teacher_disagreement_score":0.00586152,"about_ca_system_score_codex":0.0005266698,"about_ca_system_score_gemma":0.0005835991,"threshold_uncertainty_score":0.011654794},"labels":[],"label_agreement":null},{"id":"W3027044460","doi":"10.1097/yic.0000000000000314","title":"Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders","year":2020,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"National Institute of Child Health and Human Development; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Research for Patient Benefit Programme; Servier; The Wellcome Trust DBT India Alliance; Universität Zürich; Purdue University; Wellcome Trust; University of Sydney; Allergan; Teva Pharmaceutical Industries; Department of Health and Social Care; Indian Council of Medical Research; Department of Biotechnology, Ministry of Science and Technology, India; Pfizer; LivaNova; Purdue Pharma; Eli Lilly and Company; U.S. Department of Defense; Western Sydney Local Health District; National Institute for Health and Care Research; BrainsWay; H. Lundbeck A/S; Western Sydney University; European College of Neuropsychopharmacology; Neurocrine Biosciences","keywords":"Position statement; Obsessive compulsive; Neurostimulation; Psychotherapist; Intervention (counseling); Psychology; Position paper; Psychological intervention; Evidence-based practice; Clinical psychology; Psychiatry; Medicine; Alternative medicine; Family medicine; Neuroscience","score_opus":0.03484097919763624,"score_gpt":0.46002517481125993,"score_spread":0.4251841956136237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027044460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053970496,0.9897014,0.000121819874,0.005567959,0.0036162445,0.00001824624,0.000026640088,0.0000073999854,0.0008862741],"genre_scores_gemma":[0.0004182624,0.9933629,0.0004500526,0.0033472641,0.0015902512,0.000025281575,0.000046585774,0.0000027529745,0.0007566379],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993174,0.00013953775,0.00013558129,0.00007238122,0.0002825595,0.000052577718],"domain_scores_gemma":[0.9985815,0.0006257517,0.00024191369,0.000025881758,0.00040213022,0.00012289487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002668082,0.0010519531,0.0014031089,0.0032115912,0.0006624316,0.0019400691,0.0012254776,0.0026029935,0.0029022787],"category_scores_gemma":[0.0021984545,0.00034909265,0.0009482377,0.0030882,0.0008599037,0.002101531,0.0016675513,0.0043659727,0.0016533596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059722006,0.00007184206,0.00020583066,0.023767356,0.0000880067,0.00014205235,0.00013074101,0.0001719091,0.00058778556,0.0037831238,0.17444026,0.7965514],"study_design_scores_gemma":[0.00002954212,0.00007759114,0.0008714959,0.016291007,0.00014299928,0.0006360274,0.00011194445,0.00005889457,0.00011042205,0.0017565449,0.9798952,0.000018447694],"about_ca_topic_score_codex":0.0032705907,"about_ca_topic_score_gemma":0.005980551,"teacher_disagreement_score":0.0032705907,"about_ca_system_score_codex":0.0012544475,"about_ca_system_score_gemma":0.0054919566,"threshold_uncertainty_score":0.014110327},"labels":[],"label_agreement":null},{"id":"W3031969505","doi":"10.1097/yic.0000000000000316","title":"Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology","year":2020,"lang":"en","type":"review","venue":"International Clinical Psychopharmacology","topic":"Neuroscience and Neuropharmacology Research","field":"Neuroscience","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Waypoint Centre for Mental Health Care; Centre for Addiction and Mental Health","funders":"","keywords":"Antidepressant; Benzodiazepine; Anxiety; Monoaminergic; Neuropharmacology; Psychology; Psychiatry; Depression (economics); Medicine; Internal medicine; Serotonin","score_opus":0.3680515959617024,"score_gpt":0.5357258199768008,"score_spread":0.1676742240150984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031969505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006242272,0.9993511,0.000040236042,0.00019375693,0.000068444344,0.0000018417986,0.0000068060467,0.0000017341049,0.00027371966],"genre_scores_gemma":[0.00034406933,0.9992834,0.00006811089,0.000110751054,0.00006465131,0.000002550202,0.000008762788,3.557285e-7,0.00011738264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982065,0.00003951816,0.000032715903,0.000031450243,0.000059950537,0.000015857127],"domain_scores_gemma":[0.99955016,0.00027283793,0.000058251768,0.000009014654,0.00008536813,0.000024432591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006273591,0.00078286376,0.0012419192,0.0017445717,0.00021932702,0.0009180445,0.000691501,0.0010748929,0.0023384676],"category_scores_gemma":[0.00085469405,0.00023466416,0.0006160849,0.0016594627,0.00042456554,0.0012391838,0.0006063519,0.0014904859,0.00081403536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006925579,0.000049567814,0.0002486715,0.037855335,0.00016842122,0.00017515273,0.00009270808,0.00031897106,0.0011083594,0.0028528848,0.015723396,0.94133735],"study_design_scores_gemma":[0.000042363143,0.00025429644,0.0038996344,0.030500459,0.0005323742,0.0026495834,0.00019862488,0.00021565214,0.00045877244,0.0041935993,0.9570165,0.000038047372],"about_ca_topic_score_codex":0.0019092053,"about_ca_topic_score_gemma":0.003430957,"teacher_disagreement_score":0.0023384676,"about_ca_system_score_codex":0.0006560864,"about_ca_system_score_gemma":0.001467664,"threshold_uncertainty_score":0.007822931},"labels":[],"label_agreement":null},{"id":"W3109615028","doi":"10.1097/yic.0000000000000344","title":"Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies","year":2020,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Placebo; Post-hoc analysis; Depression (economics); Bipolar disorder; Internal medicine; Bipolar I disorder; Medicine; Randomized controlled trial; Rating scale; Psychology; Psychiatry; Mania","score_opus":0.03949122080845649,"score_gpt":0.44339924525587093,"score_spread":0.40390802444741447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109615028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75320715,0.21302567,0.011572752,0.00070751953,0.0025880248,0.009678373,0.0051884744,0.00061458786,0.003417431],"genre_scores_gemma":[0.974741,0.013767086,0.0042196,0.00058010285,0.0005997097,0.0035907305,0.0016744335,0.00007920068,0.0007481555],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97508687,0.01735868,0.003488393,0.002154275,0.0012212022,0.0006906077],"domain_scores_gemma":[0.9814461,0.0114833955,0.0039362223,0.0015670416,0.0011694725,0.00039770608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027817143,0.0026438662,0.0111255795,0.0018458359,0.00044877888,0.0021692477,0.00085785944,0.0017314556,0.0030271094],"category_scores_gemma":[0.020754647,0.0010989294,0.020224415,0.0017078593,0.0009656138,0.0014894933,0.0009065817,0.0017509026,0.00026206585],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6686411,0.00062625937,0.0049729855,0.007388547,0.2968605,0.00008610586,0.00007414307,0.0007291758,0.0033724145,0.0000746226,0.0005482225,0.016625976],"study_design_scores_gemma":[0.32705587,0.069989406,0.061385218,0.00083235215,0.5320812,0.00018602671,0.0001623504,0.0021296502,0.0027073375,0.00039639318,0.002924938,0.00014934584],"about_ca_topic_score_codex":0.0009381835,"about_ca_topic_score_gemma":0.0023012857,"teacher_disagreement_score":0.027817143,"about_ca_system_score_codex":0.0009081296,"about_ca_system_score_gemma":0.0010626044,"threshold_uncertainty_score":0.1471129},"labels":[],"label_agreement":null},{"id":"W3110396742","doi":"10.1097/yic.0000000000000342","title":"Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology","year":2020,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Body Image and Dysmorphia Studies","field":"Psychology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"European College of Neuropsychopharmacology; National Institute for Health and Care Research","keywords":"Body dysmorphic disorder; Obsessive compulsive; Psychiatry; Psychology; Medicine","score_opus":0.022743495237674615,"score_gpt":0.3339445960319447,"score_spread":0.3112011007942701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110396742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000375872,0.91926605,0.0017426361,0.056301743,0.013489788,0.000656561,0.00074512215,0.00006801929,0.0073542115],"genre_scores_gemma":[0.0048103402,0.9439173,0.01004604,0.02561613,0.006387996,0.0018645686,0.0020838128,0.00006265241,0.005211173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99286616,0.0016118749,0.0026527655,0.0006299768,0.0018792305,0.00036000242],"domain_scores_gemma":[0.9819983,0.004981625,0.0033947306,0.000540444,0.0077929245,0.0012919705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016079336,0.00118425,0.0038327782,0.006080703,0.0011576506,0.0033919574,0.0048841285,0.004183473,0.008005595],"category_scores_gemma":[0.019174065,0.0007994038,0.0025969294,0.008688762,0.001523235,0.0032302514,0.0034789976,0.006727105,0.0033396692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021051924,0.00012980764,0.0004855169,0.03502678,0.0002373765,0.00011358015,0.00030054257,0.00048673106,0.00060712826,0.0055167563,0.21998538,0.7368999],"study_design_scores_gemma":[0.00020450779,0.00012130408,0.002449096,0.10542807,0.00056149205,0.00040222547,0.00041788572,0.00025300344,0.00019623106,0.0039051361,0.88601685,0.00004429135],"about_ca_topic_score_codex":0.006934657,"about_ca_topic_score_gemma":0.012278756,"teacher_disagreement_score":0.016079336,"about_ca_system_score_codex":0.004758189,"about_ca_system_score_gemma":0.019770108,"threshold_uncertainty_score":0.085036695},"labels":[],"label_agreement":null},{"id":"W3158641115","doi":"10.1097/yic.0000000000000363","title":"Adjunctive music improves the tolerability of intravenous ketamine for bipolar depression","year":2021,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"","keywords":"Ketamine; Tolerability; Dissociative; Bipolar disorder; Distress; Anxiety; Psychology; Dissociation (chemistry); Anesthesia; Music therapy; Psychiatry; Clinical psychology; Psychotherapist; Medicine; Cognition; Adverse effect; Internal medicine","score_opus":0.08303040136712138,"score_gpt":0.4649321585020709,"score_spread":0.38190175713494956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158641115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906551,0.0042613368,0.0005088269,0.00025911594,0.00013443695,0.00008234464,0.000052492,0.00007267609,0.0039736987],"genre_scores_gemma":[0.99705577,0.0014008987,0.00056302565,0.00013244349,0.00009469814,0.000016169854,0.00006301191,0.000008535009,0.00066546135],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999212,0.000019693967,0.000014099337,0.000008716822,0.000020664804,0.000015728048],"domain_scores_gemma":[0.999879,0.000029927987,0.00003497925,0.000010728335,0.000012583886,0.00003273351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001470918,0.00017696149,0.00036825036,0.00011844864,0.00014132481,0.00019720383,0.00016300243,0.00018690761,0.0022620847],"category_scores_gemma":[0.0008136484,0.00005738502,0.00024034546,0.00008057366,0.000083304294,0.00015935741,0.00012399777,0.00041302526,0.0002636608],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043069236,0.007103744,0.013990269,0.00096514437,0.00047164928,0.0032153064,0.00033213943,0.00044805245,0.24422096,0.00018194134,0.0020302965,0.6839714],"study_design_scores_gemma":[0.010383063,0.25067756,0.6166162,0.00042139107,0.0017763556,0.018148875,0.00082313776,0.0033976058,0.07437669,0.0006251687,0.022688335,0.00006567676],"about_ca_topic_score_codex":0.0003147151,"about_ca_topic_score_gemma":0.001071021,"teacher_disagreement_score":0.0022620847,"about_ca_system_score_codex":0.0000866423,"about_ca_system_score_gemma":0.000099185825,"threshold_uncertainty_score":0.0075674057},"labels":[],"label_agreement":null},{"id":"W3165315636","doi":"10.1097/yic.0000000000000360","title":"Case report: asenapine and anticholinergic toxicity","year":2021,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; University Health Network","funders":"","keywords":"Asenapine; Anticholinergic; Medicine; Olanzapine; Pharmacology; Anticholinergic agents; Anesthesia; Schizophrenia (object-oriented programming); Psychiatry","score_opus":0.06594291347588983,"score_gpt":0.4834465997257009,"score_spread":0.4175036862498111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165315636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8857387,0.02323889,0.013243914,0.020971349,0.0027063524,0.00075403525,0.0011011048,0.0006170421,0.05162863],"genre_scores_gemma":[0.98109686,0.003680283,0.0032600698,0.003680262,0.0034991207,0.00007015528,0.00019285703,0.000052503,0.004467921],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9988506,0.000109884866,0.00013686613,0.00035892337,0.00018639745,0.00035745316],"domain_scores_gemma":[0.9980463,0.00054429634,0.0003768649,0.00021636309,0.00015258348,0.00066355744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047584274,0.0032351192,0.0018798448,0.0037278149,0.0040872446,0.0021840285,0.001994891,0.01159552,0.004533301],"category_scores_gemma":[0.003441224,0.0016582119,0.0019036642,0.0025069665,0.002356801,0.004436795,0.0026826833,0.006555579,0.0018278168],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012781076,0.000026292779,0.0012220751,0.000013091334,0.000004127968,0.99764234,0.00007030451,0.000030735035,0.00015773771,0.00011928899,0.00014732008,0.0005539516],"study_design_scores_gemma":[0.000004975958,0.000018416815,0.0005137877,0.000007550407,0.0000040230257,0.9987925,0.000042484593,0.00007676498,0.00009038107,0.00012976416,0.00031463677,0.000004633319],"about_ca_topic_score_codex":0.0035692453,"about_ca_topic_score_gemma":0.0038933186,"teacher_disagreement_score":0.01159552,"about_ca_system_score_codex":0.0019081777,"about_ca_system_score_gemma":0.0017131534,"threshold_uncertainty_score":0.015165389},"labels":[],"label_agreement":null},{"id":"W3183401491","doi":"10.1097/yic.0000000000000376","title":"Vortioxetine improves cognition in mild cognitive impairment","year":2021,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vortioxetine; Digit symbol substitution test; Montreal Cognitive Assessment; Cognition; Clinical Dementia Rating; Adverse effect; Medicine; Dementia; Effects of sleep deprivation on cognitive performance; Cognitive impairment; Internal medicine; Psychology; Audiology; Psychiatry; Major depressive disorder; Disease","score_opus":0.05414265949380021,"score_gpt":0.4880621425768187,"score_spread":0.4339194830830185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183401491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481237,0.004268374,0.00012988748,0.00006007406,0.000024356472,0.00008408381,0.000057676432,0.000020758624,0.00054248696],"genre_scores_gemma":[0.9971745,0.0018535946,0.00021306713,0.00012174773,0.00005378936,0.000046472345,0.00013060107,0.000002022997,0.0004042868],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999306,0.000022971502,0.000007488629,0.0000093613135,0.000014798314,0.00001475674],"domain_scores_gemma":[0.99992204,0.0000200622,0.00002669938,0.0000027074389,0.0000062578492,0.000022234422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002800144,0.00038387688,0.0007622895,0.00012786534,0.000102745355,0.00016578377,0.00014984683,0.00023582486,0.00051180547],"category_scores_gemma":[0.00024381565,0.00010034129,0.00035298974,0.000078478224,0.00012268792,0.00014816559,0.00007718032,0.0003451956,0.000093821654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18045539,0.01855197,0.030722361,0.002037647,0.0020073927,0.000912695,0.000276829,0.0020448477,0.27070078,0.00015229234,0.0020367864,0.490101],"study_design_scores_gemma":[0.089488804,0.5080083,0.371655,0.0001544903,0.00095197104,0.0013776231,0.000106925705,0.0024341922,0.020323448,0.00018981169,0.005269167,0.000040359973],"about_ca_topic_score_codex":0.00045127945,"about_ca_topic_score_gemma":0.001612595,"teacher_disagreement_score":0.0007622895,"about_ca_system_score_codex":0.00014499408,"about_ca_system_score_gemma":0.00014541276,"threshold_uncertainty_score":0.0017121434},"labels":[],"label_agreement":null},{"id":"W4200088445","doi":"10.1097/yic.0000000000000385","title":"Personality profile and therapeutic response to lithium carbonate and sodium valproate in mania with psychotic features","year":2021,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Lithium carbonate; Mania; Lithium (medication); Bipolar disorder; Mood stabilizer; Mood; Psychology; Novelty seeking; Harm avoidance; Psychiatry; Internal medicine; Personality; Medicine; Temperament; Chemistry","score_opus":0.035229706057921556,"score_gpt":0.41421944037646946,"score_spread":0.3789897343185479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200088445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994843,0.00020228467,0.000022571254,0.000023054568,0.000004145892,0.000008435749,0.000019456875,0.0000019971758,0.00023364367],"genre_scores_gemma":[0.9996954,0.00008646988,0.000048969257,0.000026618132,0.0000048471984,0.000004041575,0.000041185078,3.6473028e-7,0.0000921421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997708,0.00009729167,0.000036563375,0.000016425094,0.000053860076,0.000025062984],"domain_scores_gemma":[0.9993912,0.00011577847,0.00024819354,0.000021990836,0.00004569458,0.00017705838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003210396,0.00014485893,0.0003121557,0.00028145386,0.0002347962,0.00024541907,0.00006972075,0.00017512181,0.0006669174],"category_scores_gemma":[0.0013605905,0.00010638595,0.00027012662,0.00021720245,0.00013054941,0.00010111798,0.00013571631,0.00027786533,0.00011543114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047490513,0.000544904,0.969442,0.000057960657,0.00024128106,0.0003087951,0.00022360438,0.00012508855,0.004153785,0.000023436474,0.00013306849,0.01999708],"study_design_scores_gemma":[0.00005425015,0.0018453418,0.997233,0.000006666849,0.000032909655,0.0003553665,0.00008578012,0.0001280023,0.00013919451,0.000016032094,0.00009967403,0.0000037958425],"about_ca_topic_score_codex":0.00071952405,"about_ca_topic_score_gemma":0.0020662348,"teacher_disagreement_score":0.00071952405,"about_ca_system_score_codex":0.00020910488,"about_ca_system_score_gemma":0.00013559034,"threshold_uncertainty_score":0.0022310615},"labels":[],"label_agreement":null},{"id":"W4210390943","doi":"10.1097/yic.0000000000000394","title":"Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial","year":2022,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Oxcarbazepine; Adverse effect; Randomized controlled trial; Mania; Clinical Global Impression; Young Mania Rating Scale; Clinical trial; Anticonvulsant","score_opus":0.16460491679814862,"score_gpt":0.5188471833791097,"score_spread":0.35424226658096114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210390943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593118,0.01630916,0.0017212407,0.0013537335,0.0025200977,0.014514005,0.0010465921,0.00026181224,0.0029615697],"genre_scores_gemma":[0.9557134,0.012491292,0.0037128073,0.0024462559,0.0019527801,0.017861145,0.0008745758,0.000036028272,0.0049117333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99904853,0.000515281,0.000091515,0.00016175903,0.0000767668,0.000106082945],"domain_scores_gemma":[0.9988926,0.00032514526,0.00023838007,0.000081054626,0.00010934943,0.00035346294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021181623,0.0014073618,0.0045272065,0.00063410396,0.00053886446,0.0009860425,0.00095903577,0.0021643508,0.006285549],"category_scores_gemma":[0.0019294966,0.0006733538,0.0016268449,0.0005985247,0.0012951215,0.0010645397,0.0004369446,0.002193049,0.00075110124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9812898,0.0071540824,0.00015289168,0.0009593514,0.00056360615,0.000025362178,0.000026347905,0.000092940136,0.0012244125,0.00007474426,0.00032274637,0.008113746],"study_design_scores_gemma":[0.97533447,0.023609104,0.0003096303,0.000026317868,0.00018717928,0.000009141527,0.000007781454,0.00015370655,0.00010128591,0.00004358634,0.00021231115,0.000005427359],"about_ca_topic_score_codex":0.0007168982,"about_ca_topic_score_gemma":0.0014815835,"teacher_disagreement_score":0.006285549,"about_ca_system_score_codex":0.0005039359,"about_ca_system_score_gemma":0.0013090264,"threshold_uncertainty_score":0.021027267},"labels":[],"label_agreement":null},{"id":"W4252967237","doi":"10.1097/01.yic.0000080801.87368.93","title":"Increased use of antibiotics in clozapine-treated patients","year":2003,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institut universitaire en santé mentale de Montréal","funders":"","keywords":"Clozapine; Schizoaffective disorder; Medicine; Antibiotics; Medical prescription; Schizophrenia (object-oriented programming); Retrospective cohort study; Pediatrics; Psychosis; Internal medicine; Psychiatry; Pharmacology","score_opus":0.08360990557208188,"score_gpt":0.4579341082284898,"score_spread":0.3743242026564079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252967237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876297,0.00052497356,0.0000338479,0.00003244704,0.0000057555953,0.000008035534,0.00025268013,0.0000062635613,0.00037303125],"genre_scores_gemma":[0.9992899,0.00025004064,0.00007906094,0.00003843753,0.00001105914,0.000007506962,0.00025999916,0.0000022178835,0.00006181531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911803,0.00023170137,0.00015482375,0.00013158606,0.00025131667,0.00011254014],"domain_scores_gemma":[0.9959298,0.00080298685,0.0025440624,0.00013626329,0.00023900862,0.00034791935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031434835,0.00018516324,0.00039455382,0.0013253822,0.000522668,0.0006125812,0.00022400527,0.00038611548,0.00096270733],"category_scores_gemma":[0.0034432365,0.00027316948,0.00036881637,0.0013053673,0.00023934545,0.00032782205,0.00021395099,0.00059986225,0.000119994744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020528778,0.00003768684,0.9968072,0.000018773691,0.000047438476,0.00048701267,0.00012995745,0.000021443131,0.0005322724,0.000010615362,0.00008544905,0.0016168029],"study_design_scores_gemma":[0.000010999547,0.00013829186,0.99709034,0.0000119766055,0.00003475455,0.0020037072,0.00015202735,0.00009047218,0.00022301398,0.0000075323087,0.00023075091,0.0000061976093],"about_ca_topic_score_codex":0.0066211456,"about_ca_topic_score_gemma":0.01069242,"teacher_disagreement_score":0.0066211456,"about_ca_system_score_codex":0.0006259149,"about_ca_system_score_gemma":0.0004555347,"threshold_uncertainty_score":0.0131652355},"labels":[],"label_agreement":null},{"id":"W4282549478","doi":"10.1097/yic.0000000000000409","title":"Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series","year":2022,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Université de Montréal; BC Mental Health & Substance Use Services; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Ketamine; Treatment-resistant depression; Dosing; Medicine; Depression (economics); Anesthesia; Major depressive disorder; Electroconvulsive therapy; Clinical endpoint; Clinical trial; Internal medicine","score_opus":0.04585327333616393,"score_gpt":0.43261320368525813,"score_spread":0.38675993034909417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282549478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97600603,0.009191331,0.004526257,0.0025435698,0.00041852193,0.00032413832,0.00012393885,0.00013244303,0.0067336406],"genre_scores_gemma":[0.9948614,0.0021272146,0.0010290422,0.0007328396,0.0005380547,0.000040445855,0.00005759847,0.000015776126,0.000597643],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99911183,0.00014621677,0.00015753346,0.0002104905,0.00014709664,0.00022683089],"domain_scores_gemma":[0.9984162,0.00035817566,0.0005065957,0.000160582,0.00009342505,0.00046501824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040242326,0.0017780461,0.0009892323,0.0012497522,0.0015942863,0.0011313565,0.0014422361,0.003992314,0.0016205998],"category_scores_gemma":[0.0027600375,0.0008965091,0.0011540041,0.0011718336,0.0015637043,0.0011207552,0.0011662163,0.0023798381,0.0010091094],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004721471,0.00014874653,0.011258602,0.00004505255,0.00002383024,0.9841144,0.00026837186,0.00009197103,0.0008016059,0.0000957794,0.00036884545,0.0027355165],"study_design_scores_gemma":[0.000020054682,0.00013677769,0.0054847347,0.000016290633,0.000017007125,0.9933837,0.00011071093,0.00021261432,0.00021193757,0.000050886214,0.00034453737,0.000010704698],"about_ca_topic_score_codex":0.001905772,"about_ca_topic_score_gemma":0.00258325,"teacher_disagreement_score":0.003992314,"about_ca_system_score_codex":0.00085931155,"about_ca_system_score_gemma":0.0006075245,"threshold_uncertainty_score":0.0062347054},"labels":[],"label_agreement":null},{"id":"W4375955590","doi":"10.1097/yic.0000000000000462","title":"Ketamine for depression: a potential role in requests for Medical Aid in Dying?","year":2023,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Université de Montréal; McGill University","funders":"","keywords":"Depression (economics); Psychiatry; Ketamine; Intervention (counseling); Mood; Medicine; Major depressive disorder; Psychotherapist; Psychology","score_opus":0.04771850948401163,"score_gpt":0.49477960000518734,"score_spread":0.4470610905211757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375955590","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.574317,0.09195233,0.0040140417,0.22950993,0.0013584929,0.00017151462,0.000089979956,0.00011042179,0.098476276],"genre_scores_gemma":[0.9645524,0.02056705,0.0013044766,0.009673047,0.0015245802,0.000023125334,0.000021029186,0.000012193425,0.0023221401],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993905,0.00026329924,0.000045448214,0.00004458932,0.000097072945,0.00015915719],"domain_scores_gemma":[0.9981427,0.000743144,0.00061991834,0.00005733288,0.00010563489,0.00033125872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007805088,0.00026290375,0.00024965085,0.00023594136,0.0012930484,0.0015012838,0.0005716104,0.002679558,0.0023395214],"category_scores_gemma":[0.0057861195,0.0001557018,0.0003562273,0.00023038434,0.0019961759,0.0015463207,0.0007636906,0.0019667982,0.00037379013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084294303,0.000371678,0.20031357,0.000940636,0.000088707035,0.47972074,0.007799742,0.00053421635,0.004554696,0.0484128,0.015862934,0.2405574],"study_design_scores_gemma":[0.00014389846,0.00062820147,0.07377702,0.0021138284,0.00015176083,0.79447836,0.014593057,0.0017968148,0.001704035,0.011613136,0.09890648,0.00009337853],"about_ca_topic_score_codex":0.0046878993,"about_ca_topic_score_gemma":0.013226157,"teacher_disagreement_score":0.0046878993,"about_ca_system_score_codex":0.0018109969,"about_ca_system_score_gemma":0.0024669666,"threshold_uncertainty_score":0.013139784},"labels":[],"label_agreement":null},{"id":"W4385664517","doi":"10.1097/yic.0000000000000500","title":"Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis","year":2023,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"H. Lundbeck A/S; Purdue Pharma; Supernus Pharmaceuticals; Allergan; Shionogi; Sage Therapeutics; Canadian Network for Mood and Anxiety Treatments; Canadian Institutes of Health Research; Sunovion; Purdue University; Neos Therapeutics; Teva Pharmaceutical Industries; Sanofi; GlaxoSmithKline; Dainippon Sumitomo Pharma; Pfizer; Shire; AstraZeneca; Eli Lilly and Company","keywords":"Placebo; Post-hoc analysis; Psychology; Anxiety; Internal medicine; Young Mania Rating Scale; Tolerability; Mania; Bipolar I disorder; Bipolar disorder; Psychiatry; Medicine; Adverse effect; Mood","score_opus":0.030664042088499443,"score_gpt":0.40256207978707587,"score_spread":0.37189803769857643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385664517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90645,0.0763191,0.0039228434,0.00039762526,0.0012499008,0.0027416083,0.005858455,0.00028730038,0.0027731583],"genre_scores_gemma":[0.9859686,0.0064003575,0.0019250927,0.00045786836,0.00055503455,0.0013640905,0.002204743,0.00004589405,0.0010783282],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99360955,0.0034354944,0.0010218044,0.0009887267,0.00052823743,0.00041617677],"domain_scores_gemma":[0.99435174,0.0030555627,0.001285351,0.0004985808,0.0005570118,0.00025163754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008281061,0.0022254812,0.009599261,0.0012505602,0.0003073534,0.0013195361,0.00071166357,0.0013492376,0.0031995056],"category_scores_gemma":[0.0071960497,0.0008669317,0.019093491,0.0011551545,0.00055327703,0.0010456244,0.0006764247,0.0014384148,0.000303041],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6869699,0.00071797677,0.010018212,0.0070204493,0.2659086,0.00020521278,0.00010770447,0.00088349084,0.0058270292,0.00007691686,0.001125893,0.021138597],"study_design_scores_gemma":[0.22181037,0.09269704,0.14029661,0.00055506284,0.5332388,0.0003299413,0.00021431562,0.003000508,0.0039112377,0.0003275089,0.0034173084,0.00020127482],"about_ca_topic_score_codex":0.001233368,"about_ca_topic_score_gemma":0.0037249366,"teacher_disagreement_score":0.009599261,"about_ca_system_score_codex":0.0007587044,"about_ca_system_score_gemma":0.0008617284,"threshold_uncertainty_score":0.04379499},"labels":[],"label_agreement":null},{"id":"W4388705647","doi":"10.1097/yic.0000000000000521","title":"The impact of mild behavioral impairment on the prognosis of geriatric depression: preliminary results","year":2023,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute on Aging; Canadian Institutes of Health Research; Neuraxpharm; H. Lundbeck A/S; Fondation Brain Canada; Johns Hopkins University; Biogen; Sanofi; Consortium canadien en neurodégénérescence associée au vieillissement; Alzheimer's Drug Discovery Foundation","keywords":"Depression (economics); Medicine; Psychology; Psychiatry","score_opus":0.10248921758814952,"score_gpt":0.5292276529264274,"score_spread":0.4267384353382778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388705647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991498,0.00047078036,0.000043792254,0.000021419819,0.00000351221,0.000010918961,0.000056467085,0.0000011611413,0.00024217373],"genre_scores_gemma":[0.9996271,0.00014483693,0.00006771953,0.000016634855,0.000011636082,0.000005851704,0.00006974342,3.26145e-7,0.00005604822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99979335,0.00009807546,0.000020381185,0.000020520047,0.000037357866,0.00003035508],"domain_scores_gemma":[0.9993087,0.0002044976,0.00020883944,0.00003705345,0.00006749593,0.00017332281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066607643,0.0002633076,0.00028856902,0.00022998863,0.00019657455,0.00026440568,0.00012307083,0.00022236929,0.0005597955],"category_scores_gemma":[0.0017024509,0.0000733921,0.00024049515,0.00019569857,0.00017413091,0.00016699175,0.0002443495,0.00022146474,0.00011534059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040041935,0.00044344174,0.97444046,0.000051475894,0.00007429967,0.00030487656,0.00016621819,0.00013173328,0.0015148022,0.000010869085,0.00007023953,0.018787296],"study_design_scores_gemma":[0.000027811908,0.0030633798,0.9961777,0.000005767008,0.00004333737,0.00023078387,0.0000669719,0.00010084306,0.00015745913,0.000016453592,0.00010576681,0.0000037366256],"about_ca_topic_score_codex":0.0013783777,"about_ca_topic_score_gemma":0.0027200475,"teacher_disagreement_score":0.0013783777,"about_ca_system_score_codex":0.00016278747,"about_ca_system_score_gemma":0.00014899127,"threshold_uncertainty_score":0.0035226345},"labels":[],"label_agreement":null},{"id":"W4391991450","doi":"10.1097/yic.0000000000000543","title":"Prospective, comparative, pilot study of maintenance treatment in comorbid bipolar disorders with post-traumatic stress disorder","year":2024,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; Brain and Cognition Discovery Foundation; University Health Network","funders":"Center for Clinical and Translational Research; Universidad El Bosque","keywords":"Young Mania Rating Scale; Quetiapine; Psychology; Bipolar disorder; Psychiatry; Bipolar I disorder; Rating scale; Mania; Mood; Clinical psychology; Internal medicine; Medicine; Schizophrenia (object-oriented programming)","score_opus":0.0589141435056021,"score_gpt":0.437330468623192,"score_spread":0.37841632511758994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391991450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764097,0.00064252183,0.00011047775,0.000021947531,0.000026939833,0.0009881891,0.00019049797,0.000011543245,0.00036688554],"genre_scores_gemma":[0.99600524,0.00054917985,0.000737817,0.0001205956,0.00012426387,0.0014851334,0.0006239963,0.0000046472046,0.0003491059],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9978853,0.0011768034,0.00025875962,0.00023558782,0.0002200236,0.00022344926],"domain_scores_gemma":[0.9964735,0.00082565687,0.0009863467,0.00052803854,0.0003818867,0.0008045416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032719278,0.000991292,0.0017158925,0.0007241781,0.0009151044,0.00065678236,0.0006609572,0.0012248462,0.0030634839],"category_scores_gemma":[0.004016654,0.00061739335,0.0011752353,0.00077135564,0.0009627081,0.0008056766,0.0004438535,0.0012365691,0.000610471],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7527573,0.12694205,0.07271562,0.000609824,0.001598456,0.00035564837,0.00069649704,0.00040232227,0.0064010876,0.000116795076,0.00046602066,0.036938358],"study_design_scores_gemma":[0.07473907,0.8511077,0.07205803,0.000023817316,0.0005658598,0.00021922331,0.0001589267,0.00019243287,0.00047530944,0.000038906946,0.00039944687,0.000021242187],"about_ca_topic_score_codex":0.0022780914,"about_ca_topic_score_gemma":0.0029877566,"teacher_disagreement_score":0.0032719278,"about_ca_system_score_codex":0.0006508407,"about_ca_system_score_gemma":0.0011799178,"threshold_uncertainty_score":0.017303765},"labels":[],"label_agreement":null},{"id":"W4391993082","doi":"10.1097/yic.0000000000000538","title":"Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders","year":2024,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Polypharmacy; Schizoaffective disorder; Antipsychotic; Metabolic syndrome; Medicine; Schizophrenia (object-oriented programming); Bipolar disorder; Internal medicine; Olanzapine; Psychiatry; Psychosis; Pediatrics; Obesity","score_opus":0.03241707496823191,"score_gpt":0.4324719068644379,"score_spread":0.400054831896206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391993082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986513,0.0008604405,0.000037544432,0.000077791345,0.0000070748106,0.0000040946447,0.00008900248,0.000001060791,0.0002717809],"genre_scores_gemma":[0.9994286,0.0003385238,0.00007043878,0.000018140083,0.00001301321,0.0000030345955,0.00007340634,6.2725826e-7,0.00005434544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999597,0.00013705909,0.00008386616,0.00004477855,0.00009219473,0.000045082776],"domain_scores_gemma":[0.99866295,0.00025337917,0.0007393933,0.000050053735,0.000075149306,0.0002190402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064457237,0.00017382932,0.00026953156,0.0010346476,0.00037241785,0.00044050842,0.0001717362,0.0003348345,0.0010854334],"category_scores_gemma":[0.002087887,0.00022202989,0.00044281708,0.0011726745,0.00019144699,0.00026751164,0.0003568228,0.00065959105,0.000069077025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011035355,0.000018235123,0.9986582,0.000006750594,0.00003459468,0.00006152001,0.000019993475,0.000018999543,0.00010342258,0.000011246062,0.000016755606,0.00093991566],"study_design_scores_gemma":[0.000002167725,0.000022166152,0.9996202,0.0000049026153,0.00001191901,0.00015616234,0.000045359928,0.00008625987,0.00001150046,0.000015051787,0.000022803726,0.0000014361741],"about_ca_topic_score_codex":0.007603984,"about_ca_topic_score_gemma":0.0152290715,"teacher_disagreement_score":0.007603984,"about_ca_system_score_codex":0.0003269073,"about_ca_system_score_gemma":0.00040595498,"threshold_uncertainty_score":0.015119433},"labels":[],"label_agreement":null},{"id":"W4396798286","doi":"10.1097/yic.0000000000000553","title":"Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system","year":2024,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Neurotransmitter Receptor Influence on Behavior","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Tetrabenazine; Parkinsonism; Adverse Event Reporting System; Odds ratio; Medicine; Adverse effect; Suicidal ideation; Psychiatry; Internal medicine; Pharmacology; Poison control; Suicide prevention; Emergency medicine","score_opus":0.08102644478716838,"score_gpt":0.4408891582959155,"score_spread":0.35986271350874716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396798286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96778286,0.0072288527,0.0015753829,0.0005477505,0.00006690988,0.0002551502,0.015419338,0.00016017343,0.006963608],"genre_scores_gemma":[0.98795277,0.0024574667,0.0013454797,0.0002869527,0.0000841881,0.00008740013,0.007233087,0.000017757326,0.0005349507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960769,0.0010991544,0.00084757525,0.00035294527,0.0014602258,0.00016314365],"domain_scores_gemma":[0.9745234,0.00441803,0.017377129,0.00065417157,0.0025477272,0.00047938738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032561664,0.0002806473,0.00033433532,0.001894412,0.00019122899,0.00063941564,0.0002955556,0.0003153079,0.00089546974],"category_scores_gemma":[0.009707019,0.00019174916,0.00093130046,0.002295224,0.00013826872,0.00038901097,0.00040963208,0.0006362558,0.0002103228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001537663,0.00003602401,0.9909672,0.000068834095,0.00030006657,0.000079511854,0.000029728186,0.00011957676,0.00026296088,0.000030794963,0.00080999586,0.0071413415],"study_design_scores_gemma":[0.000008170555,0.00015045512,0.9968919,0.000034896144,0.00014839583,0.0004661191,0.00004585647,0.0004542974,0.0003605111,0.000018154644,0.001408925,0.000012333677],"about_ca_topic_score_codex":0.0054797474,"about_ca_topic_score_gemma":0.0056220945,"teacher_disagreement_score":0.0054797474,"about_ca_system_score_codex":0.0003626075,"about_ca_system_score_gemma":0.00041634246,"threshold_uncertainty_score":0.017220497},"labels":[],"label_agreement":null},{"id":"W4400411923","doi":"10.1097/yic.0000000000000556","title":"Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry","year":2024,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; McGill Pain Questionnaire; Adverse effect; Brief Pain Inventory; Observational study; Quality of life (healthcare); Physical therapy; Anxiety; Internal medicine; Clinical trial; Chronic pain; Visual analogue scale; Psychiatry","score_opus":0.028858942112115014,"score_gpt":0.4776365398539525,"score_spread":0.44877759774183745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400411923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979539,0.0005047079,0.0001007872,0.000032129916,0.000006742219,0.000043477623,0.0009440213,0.000003326303,0.00041088287],"genre_scores_gemma":[0.9977417,0.00026177836,0.00012379399,0.000023420622,0.000014794449,0.000048131493,0.0016946213,0.0000030506963,0.00008888792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954288,0.0016500773,0.00083265814,0.0004874174,0.0012746602,0.0003263007],"domain_scores_gemma":[0.98617727,0.0025188618,0.008542901,0.0008090273,0.0013370885,0.0006147214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020697538,0.0002663534,0.000756974,0.002652497,0.0004117378,0.000872058,0.0004930882,0.0004716368,0.0012333533],"category_scores_gemma":[0.01118749,0.0002905639,0.0005175479,0.0035074244,0.00037609038,0.0006235101,0.0011032583,0.0004739352,0.00039119823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113438386,0.00001442408,0.99846846,0.000024019246,0.000030312714,0.00009767909,0.000062979394,0.000016524158,0.00008505838,0.000005389217,0.00005607243,0.0010257021],"study_design_scores_gemma":[0.0000077673985,0.000061543615,0.9993462,0.0000091519005,0.000015217491,0.00029066336,0.000078806675,0.000049139057,0.00002310894,0.0000032220325,0.000111554444,0.000003625473],"about_ca_topic_score_codex":0.0055864966,"about_ca_topic_score_gemma":0.005492654,"teacher_disagreement_score":0.0055864966,"about_ca_system_score_codex":0.00042424898,"about_ca_system_score_gemma":0.0005246086,"threshold_uncertainty_score":0.011107981},"labels":[],"label_agreement":null}]}